Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Matrices

Subclass of:

424 - Drug, bio-affecting and body treating compositions

424400000 - PREPARATIONS CHARACTERIZED BY SPECIAL PHYSICAL FORM

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
424486000 Synthetic polymer 299
424488000 Polysaccharides (e.g., cellulose, etc.) 105
424485000 Natural gums, resin or latex 21
Entries
DocumentTitleDate
20100143475TRANSDERMAL THERAPEUTIC SYSTEM WITH TWO-PHASE RELEASE PROFILE - The present invention relates to a transdermal therapeutic system (TTS) consisting of an impermeable coating, a matrix containing an ergoline compound having the formula (I)06-10-2010
20110177170 IMPLANTABLE NEUROENDOPROSTHETIC SYSTEM, A METHOD OF PRODUCTION THEREOF AND A METHOD OF RECONSTRUCTIVE NEUROSURGICAL OPERATION - Intended for the use in neurosurgery and organ tissue engineering to replace defects of nervous tissue of a mammal brain and spinal cord (B&SC) in reconstructive neurosurgical operations, a tissue-replaceable artificial cell-biopolymer neuroendoprosthetic system (ACBP NEPS) for surgical plasty of defects of nervous tissue of B&SC, stimulating regeneration and growth of damaged axons of neural cells, comprises an elastic cell-biopolymer biologically active mass, produced from a heterogeneous collagen-containing matrix for implantation, and a biocomposition of cell preparations of various types of autologous cells of a patient. Also disclosed are a method of producing the ACBP NEPS, which provides for perfusion of the biocomposition of the cell preparations of various types of autologous cells of a patient into a heterogeneous collagen-containing matrix for implantation, and a method of reconstructive neurosurgical operation comprising implantation of the ACBP NEPS into a defect of neural tissue.07-21-2011
20110177169OPHTHALMIC FORMULATIONS OF REVERSED LIQUID CRYSTALLINE PHASE MATERIALS AND METHODS OF USING - The eye is effectively treated by providing it with formulations including uncoated cationically charged microparticles of reversed cubic phase or reversed hexagonal phase material. The treatment methods are effective; for a variety of diseases and conditions including dry eye. The structure, charge and components of the microparticles in dispersion, with or without an active ingredient, provide mucoadhesion, layering, protection and prolonged duration of ophthalmic action.07-21-2011
20080268050SPRAYABLE TOPICAL SKIN BARRIERS - Sprayable topical skin barriers for protecting and promoting healing of skin, and for providing comfort to a patient, comprise (i) a semi-solid hydrocarbon in a range by weight from about 25.0% to about 90.0%, (ii) a water-absorbing compound having a particle size range of about 0.5 microns to 20.0 microns, in a range by weight from about 5.0% to about 75.0%, and (iii) a solvent in a range by weight from about 10.0% to about 70.0%. The sprayable topical skin barriers have properties of effective adhesion to skin, protection from moisture and waste, transparency, sprayability, and smoothness to touch.10-30-2008
20090324720BIOCOMPATIBLE CROSSLINKED HYDROGELS, DRUG-LOADED HYDROGELS AND METHODS OF USING THE SAME - Disclosed are hydrogel compositions formed by the mixture of a tetramethylmethane substituted with one or more polyethylene glycols, and wherein each polyethylene glycol substituent is independently further substituted with one or more electrophilic groups, and a tetramethylmethane substituted with one or more polyethylene glycols, and wherein each polyethylene glycol substituent is independently further substituted with one or more nucleophilic groups. Disclosed are also methods of preparing the above hydrogels. The hydrogel compositions can further comprise pharmaceuticals, such as analgesics or local anesthetics. Disclosed are also methods of sealing a wound, preventing post-surgical adhesion, and reducing post-surgical pain using the disclosed hydrogels.12-31-2009
20090220603USE OF RHAMNOLIPIDS IN WOUND HEALING, TREATING BURN SHOCK, ATHEROSCLEROSIS, ORGAN TRANSPLANTS, DEPRESSION, SCHIZOPHRENIA AND COSMETICS - Various methods are provided, including wound healing with reduced fibrosis, treatment of burn shock, treatment and prevention of atherosclerosis, prevention and treatment of organ transplant rejection, treatment of depression and schizophrenia and treatment of the signs of aging, such as wrinkles, each of which uses administration of a composition containing one or more rhamnolipids as an active ingredient.09-03-2009
20090123545Rapid Onset and Short Term Modafinil Compositions and Methods of Use Thereof - Compositions are described that comprise a modafÊnil component that is a combination of the d- and l-enantiomers of modafinil and wherein the modafÊnil component is greater than 50% by weight d-modafÊnil for use in promoting or enhancing the state of wakefulness, alertness, and/or central nervous system stimulation in an individual.05-14-2009
20100119604Solid drug formulation and device for storage and controlled delivery thereof - Devices and methods are provided for the storage and controlled release of a solid form of a drug. The device comprises a body portion; one or more reservoirs located in and defined by the body portion; a solid matrix which comprises a drug and which is contained in each of the one or more reservoirs; and one or more excipient materials dispersed throughout pores or interstices within the solid matrix and substantially filling any space not otherwise occupied by the solid matrix within each of the one or more reservoirs, wherein the excipient material enhances stability of the drug while stored in the one or more reservoirs or enhances release of the drug from each reservoir. In an alternative embodiment, the device provides for the storage and controlled exposure of a chemical sensor material.05-13-2010
20090196926NANO-STRUCTURED THIXOTROPIC INORGANIC PEELING GELS - A composition, a method, and a kit are provided for chemical skin peeling, based on nano-structured thixotropic inorganic gels, which have a higher potency and are less irritant of the conventional peeling formulations. The gels of the invention can easily be applied on the skin, where they form a stable, uniform layer, that doesn't strain. The kit comprises by a defatting gel, different types of peeling gels and a neutralizing gel. The defatting gel is characterized by a markedly enhanced defatting capacity in comparison to the conventional products, because the sebum solubilized by the solvent is strongly adsorbed on the huge surface of the nano-structured material of the gel. The peeling gels are based on conventional peeling compounds, such as glycolic acid, trichloroacetic acid, pyruvic acid, salicylic acid, Jessner solution, but the presence of nano-structured material strongly increases the peeling effect, allowing the use of lower concentrations of peeling compound, with only minimal skin irritation for the user. The neutralizing gel is characterized by a colour change that allows the operator to verify in real time the neutralization of the peeling agent on the treated skin surface. All the gels of the invention can be easily removed from the skin after the treatment. The thixotropic gels of the invention can be used in chemical skin peeling for the treatment of various cosmetic conditions and dermatological disorders, including dry skin, acne, dandruff, keratoses, age spots, wrinkles and disturbed keratinisation.08-06-2009
20090196927Polypeptide Inhibitors of HSP27 Kinase and Uses Therefor - The present invention provides polypeptide inhibitors of HSP27 kinase, compositions thereof, and methods for using such polypeptides and compositions for various therapeutic uses.08-06-2009
20090035376Stem cells obtained from pulp of deciduous or permanent teeth and of dental germ, able to produce human bone tissue - In this invention is described a method that foresees the isolation of a new subpopulation of stem cells derived form dental pulp, whose differentiation is osteoblasts lead to the subsequent production and employment of a bone tissue, called LAB (Living Autologous Bone). Specifically, the invention describes: 1) the isolation of stem cells from the pulp of deciduous and permanent teeth and of dental germs, obtained from human subjects; 2) the growth of these cells in vitro, under specific conditions that allow the isolation of a cellular sub-population, which, after differentiation in osteoblasts, is able to produce in vitro an extracellular matrix, identical to that detectable in bone tissue; 3) the use of this selected and differentiated cell population in order to produce autologous bone tissue in vitro, containing vital osteoblasts; 4) the preservation of the LAB under conditions which guarantee cellular vitality; 5) the use of the LAB in donor patients to reconstruct bone tissue, as required in the daily practice in dentistry, maxillo-facial surgery and orthopedics.02-05-2009
20080260831Extracellular Matrix-Derived Gels and Related Methods - Provided are methods for preparing gelled, solubilized extracellular matrix (ECM) compositions useful as cell growth scaffolds. Also provided are compositions prepared according to the methods as well as uses for the compositions. In one embodiment a device, such as a prosthesis, is provided which comprises an inorganic matrix into which the gelled, solubilized ECM is dispersed to facilitate in-growth of cells into the ECM and thus adaptation and/or attachment of the device to a patient.10-23-2008
20080260830Growth Factor Mutants With Improved Biological Activitiy - The invention relates to novel biosynthetic growth factor mutants which exhibit improved biological activity.10-23-2008
20100055182USE OF GUANIDINOACETIC ACID (SALTS) COMBINATION WITH BETAINE AND/OR CHOLINE TO PRODUCED AN AGENT THAT IS BENEFICIAL TO HEALTH - The use of guanidinoacetic acid and/or salts thereof in combination with choline and/or betaine to produce an agent for improving brain function, bone growth and the mineralization of bones, for improving cartilage growth, for alleviating aging processes, for strengthening the immune system, as an antioxidative and neuroprotective agent, for lowering the cholesterol and triglyceride value, for preventing inflammatory processes and for lowering the blood sugar level in humans and vertebrates is described.03-04-2010
20110189288DIETHYLSTILBESTROL DOSAGE FORM AND METHODS OF TREATMENT - Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, particularly diethylstilbestrol and pharmaceutically acceptable salts thereof to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract.08-04-2011
20090142399DISPERSANT AGENT FOR SUSTAINED-RELEASE PREPARATIONS - The present invention provides a bilayer dispersing agent for a sustained-release preparation, which contains a non water-soluble solvent and an aqueous solvent, and a sustained-release preparation wherein a microcapsule containing a physiologically active substance is dispersed in the aforementioned dispersing agent. When this preparation is subcutaneously administered, the initial release of a physiologically active substance immediately after administration is strikingly suppressed, a constant amount of a physiologically active substance is released for a long period of time from immediately after administration, superior dispersibility is afforded, and the preparation can readily pass through a needle as an injection.06-04-2009
20100086594WATER SOLUBLE REACTIVE DERIVATIVES OF CARBOXY POLYSACCHARIDES AND FIBRINOGEN CONJUGATES THEREOF - The present invention provides water-soluble reactive esters of carboxy polysaccharides and derivatives thereof. The reactive carboxy polysaccharide derivatives are useful per se in aqueous solutions or specifically for the formation of water-soluble covalent fibrinogen conjugates. A preferred conjugate is a hyaluronic acid-fibrinogen conjugate and fibrin adhesive, clot or matrix derived from it. Methods of preparation and methods of use in tissue repair and regeneration are also disclosed.04-08-2010
20110195123METHODS, COMPOSITIONS AND SYSTEMS FOR LOCAL DELIVERY OF DRUGS - Implantable medical device eluting drug locally and in prolonged period is provided, including several types of such a device, the treatment modes of implementation and methods of implantation. The device comprising of polymeric substrate, such as a matrix for example, that is used as the device body, and drugs, and in some cases additional scaffolding materials, such as metals or additional polymers, and materials to enhance visibility and imaging. The selection of drug is based on the advantageous of releasing drug locally and in prolonged period, where drug is released directly to the extracellular matrix (ECM) of the diseased area such as tumor, inflammation, degeneration or for symptomatic objectives, or to injured smooth muscle cells, or for prevention. One kind of drug is the gene silencing drugs based on RNA interference (RNAi), including but not limited to si RNA, sh RNA, or antisense RNA/DNA, ribozyme and nucleoside analogs. The modes of implantation in some embodiments are existing implantation procedures that are developed and used today for other treatments, including brachytherapy and needle biopsy. In such cases the dimensions of the new implant described in this invention are similar to the original implant. Typically a few devices are implanted during the same treatment procedure.08-11-2011
20090191270STRUCTURE AND METHOD FOR RELEASING SUBSTANCE THEREFROM - A structure comprises at least a porous body holding a substance releasably, comprising a capping member for keeping the substance inside the pore and/or on at least a part of the entire surface of the porous body, and a connecting member for connecting the porous body and the capping member separably, the connecting member comprising a biopolymer compound.07-30-2009
20090191269USE OF GELATIN AND A CROSS-LINKING AGENT FOR PRODUCING A CROSS-LINKING THERAPEUTIC COMPOSITION - A therapeutic composition comprising gelatin and a cross-linking agent, for use in biological regenerative methods, which composition can be administered to a target area of the body while ensuring that the suspended cells and/or the growth factors remain in the target area of the body and at the same time eliminating the need for the patient to maintain the treated body area immobilized for unreasonable periods, is disclosed. A method is also disclosed, wherein (i) the gelatin and the cross-linking agent are mixed with each other to form the cross-linking therapeutic composition which is then administered to the target area; or (ii) the gelatin and the cross-linking agent are made available in separate form and are administered, simultaneously or one after the other, to the target area while forming the cross-linking therapeutic composition.07-30-2009
20090191268ALLERGY VACCINES - The invention provides methods and materials related to vaccines against self polypeptides. For example, the invention provides compositions containing chimeric IgE polypeptides and adjuvants.07-30-2009
20100047350OSTEOGENIC COMPOSITIONS CONTAINING A COLORING AGENT - An osteogenic composition is provided for implantation at or near a target tissue site beneath the skin, the osteogenic composition comprising a growth factor and a coloring agent, wherein the coloring agent imparts color to the growth factor to allow the user to see the growth factor at or near the target tissue site. In some embodiments, a method is provided for accelerating bone repair, the method comprising mixing bone morphogenic protein-2 and a coloring agent to form a mixture; applying the mixture to a surface of a porous collagen matrix, wherein the coloring agent allows the user to see bone morphogenic protein-2 distribution on or in the porous collagen matrix; and implanting the porous collagen matrix at or near a target tissue site in need of bone repair.02-25-2010
20100119605COMPOSITIONS FOR TISSUE STABILIZATION - Collagen crosslinking/stabilization composition optionally in combination with elastin crosslinking composition as treatment of vascular aneurysms, methods of using the compositions, especially with respect to in vivo procedures are described. The treatment is achieved through the delivery of an effective amount of crosslinking/stabilization composition to the site of the aneurysm. The crosslinking/stabilization agent may be embedded in a delivery composition and delivered to the site of aneurysm using a delivery device. The site of the aneurysm may be isolated for treatment using the delivery device. The elastin stabilization agent may be simultaneously or sequentially delivered with the collagen crosslinking/stabilization agent for the treatment of vascular aneurysms in the isolated section of blood vessel.05-13-2010
20120183617COMPOSITION AND METHOD FOR TREATMENT OF DIABETES - The present invention relates to a method of treating an incretin related disease such as diabetes, obesity and the like by delivery of butyric acid, bile acid, long chain fatty acid or glutamine to the colon by bypassing the upper digestive tract. The composition is combined either by the same or different route of administration with a monoamine reuptake inhibitor such as buproprion.07-19-2012
20120183616LONG ACTING INSULIN COMPOSITION - The present invention relates to a pharmaceutical composition comprising an insulin compound in a concentration that is sufficient to maintain a therapeutically effective level of the insulin compound in blood plasma for at least 3 days characterized by having a pharmacokinetic profile in vivo with substantially no burst of the insulin compound. The present invention further relates to the use of an insulin compound for preparing said pharmaceutical composition as well as a kit of parts comprising said pharmaceutical composition.07-19-2012
20100074954ADSORBENT FOR ORAL ADMINISTRATION - An adsorbent for oral administration, characterized by comprising a spherical activated carbon, wherein a diameter is 0.01 to 1 mm, a specific surface area determined by Langmuir's adsorption equation is 1000 m03-25-2010
20100074953Methods for intiating in situ formation of hydrogels - Methods for initiating formation of hydrogels in situ from a gellable composition and an initiator where the initiator is provided as a solid article or is contained in a solution infused to the intended site of formation of the hydrogel.03-25-2010
20120244221EXTENDED-RELEASE FORMULATION FOR REDUCING THE FREQUENCY OF URINATION AND METHOD OF USE THEREOF - Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of a pharmaceutical composition comprising an analgesic agent formulated for extended-release.09-27-2012
20130039985Method for aligning cells and applying homogenous strain throughout deformable engineered tissue constructs - A process creates a homogenous sheet of engineered tissue comprised of encapsulated cells and a deformable engineered tissue construct. In the embodiment consisting of a collagen construct with encapsulated cells capable of contracting the matrix, the collagen fibers and encapsulated cells are aligned during the process. An apparatus can deliver controlled homogenous strain and stress to a thin sheet of engineered tissue. This process allows application of dynamic, uniform tensile loading to deformable engineered tissue constructs and creation of an engineered cell-delivery construct with alignment of both fibers and encapsulated cells.02-14-2013
20080292704Methods and Compositions Involving Polymeric Immunoglobulin Fusion Proteins - The present invention concerns inventive polypeptides. The present invention also concerns compositions and vaccines comprising the inventive polypeptides. In other embodiments of the invention, the inventive polypeptides are provided to a subject, used to vaccinate, or used to induce immunity. Other embodiments include methods for making the inventive polypeptides and nucleic acids used to encode the inventive polypeptides.11-27-2008
20090252795Bioceramic scaffolds for tissue engineering - This invention relates to bioinert microporous bioceramic scaffolding, matrices or spheres comprising a particulate microporous bioinert ceramic material, which is a primary structure, and in the form of scaffolds, matrices or spheres, having interconnected pores. Pores on the surface of the spheres, matrices or scaffolds are connected to pores inside the spheres, matrices or scaffolds via blow-holes and the internal pores are in turn interconnected, so that in addition to a high porosity, the spheres, matrices or scaffolds will provide for a highly permeable, biosupportive environment for organic and/or inorganic substances, gases and/or liquids. The pores on the surface of the spheres, matrices or scaffolds are connected to pores inside the spheres, matrices or scaffolds via blow-holes and the internal interconnected pores within the highly porous microarchitecture or nanostructure(s) of the spheres, matrices or scaffolds will therefore prove conducive too, complimentary or suitable for, hosting such organic and/or inorganic substances, nanotechnologies, nanomaterials, gases or liquid that may be introduced, impregnated, activated, mixed, coated, transmitted or blended; and those various substances may be: resorbable bioceramic, polymers, copolymers, adhesives, hydrogels, collagen based materials, carbon based materials, metals, minerals, alternate corundum based materials, nanotechnologies, various forms of therapeutic energy, as well as various chemicals, chemoattractors and pharmaceutical agents or vaccine materials suitable for tissue treatment, tissue engineering, healing, regeneration/integration or repair of tissues within the body in order to ultimately restore tissue integrity, stability, viability, vitality, volume, mass, density, support, strength, purpose, design and function(s).10-08-2009
20130136795SOLID VALSARTAN COMPOSITION - The present invention relates to stable solid pharmaceutical compositions comprising valsartan as the active pharmaceutical ingredient. Optionally the compositions comprise one or more further active pharmaceutical ingredients. The invention further relates to methods for preparing said compositions and to the use of said compositions in the treatment or prevention of angiotensin receptor mediated disorders, in particular hypertension and related disorders.05-30-2013
20100112062KIDNEY STRUCTURES AND METHODS OF FORMING THE SAME - Provided herein are isolated populations of kidney cells harvested from differentiated cells of the kidney, wherein cells have been expanded in vitro, and methods of use thereof. The cells may be provided in a three dimensional matrix for culturing in vitro and/or implanting in vivo. Methods of seeding cells onto the matrix are also provided.05-06-2010
20100112059Methods, Systems and Devices for Administration of Chlorine Dioxide - Devices, compositions, systems and methods for the non-cytotoxic delivery of chlorine dioxide to a tissue.05-06-2010
20100112058HYDROGEL MASK PACK, METHOD OF PREPARING THE SAME, AND RELATED COMPOSITION - In a hydrogel mask pack having good skin-care effects, the hydrogel mask pack is formed by filling a frame with a composition for the hydrogel mask pack and immersing the frame in any one of an aqueous solution of a metal salt, alcohol or distilled water. The composition for the hydrogel mask pack is prepared by mixing an aqueous solution of fibroin and any one of alginate, cellulose or agar. The hydrogel mask pack may have superior moisturizing effects, skin-regenerative effects, mechanical strength and elasticity, and thus may be good enough to be used for a skin-care mask pack.05-06-2010
20090155364Transdiscal administration of anti-TNFalpha antibodies and growth differentiation factors - The present invention relates to injecting a high specificity cytokine antagonist into a diseased intervertebral disc.06-18-2009
20090155363METHODS FOR ORAL ADMINISTRATION OF ACTIVE DRUGS - The present invention relates to methods that facilitate the oral administration of active drugs to a patient. Specifically, the methods of the present invention may utilize compositions comprising an active drug and a gelling agent that provides an easily consumable gel dosage form and the active drug is homogenously mixed within the gel.06-18-2009
20090155362Method of cross-linking hyaluronic acid with divinulsulfone - The present invention relates to methods of producing a homogenous hydrogel comprising hyaluronic acid, or salt thereof, crosslinked with divinylsulfone (DVS), said method comprising the steps of (a) providing an alkaline solution of hyaluronic acid, or salt thereof; (b) adding DVS to the solution of step (a), whereby the hyaluronic acid, or salt thereof, is crosslinked with the DVS to form a gel; (c) treating the gel of step (b) with a buffer, wherein the gel swells and forms a hydrogel comprising hyaluronic acid, or salt thereof, crosslinked with DVS.06-18-2009
20100104641THERAPEUTIC COMPOSITION, AND USE OF A CELL-FREE SUBSTANCE - The invention relates to a therapeutic composition, a method for producing a therapeutic composition, and the use of a cell-free substance, especially a cell-free bone or cartilage matrix. The disclosed therapeutic composition comprises at least a cell-free substance obtained from stimulated stem cells and/or precursor cells. Immunogenic reactions during in vivo therapeutic use are prevented by the fact that the therapeutic composition is free from cells and contains no typically antigenic cell components. The disclosed composition can therefore be universally used for the therapeutic purposes regardless of the origin of the stem cells and/or precursor cells and utilize the natural regenerative potency thereof in a highly efficient manner for replacing tissue, e.g. for a suitable bone and/or cartilage structure.04-29-2010
20100040689GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR TREATMENT AND PREVENTION OF CNS DISORDERS - The present disclosure is directed to methods and compositions for ameliorating, preventing and treating central nervous system (CNS) disorders. The invention aims to treat subjects suffering from, susceptible to, or diagnosed with CNS disorders, and in particular, to treating patients suffering from those disorders which are associated with neurotransmitter system dysfunction.02-18-2010
20100040686BIOMATERIAL - The present invention provides a biomaterial which releases slowly a biologically active substance acting only on bone cell regeneration, in order to compensate for bone or alveolar bone lost due to surgery, accident or the like. Specifically, the invention relates to a biomaterial containing an osteogenic factor adsorbed on a porous material selected from hydroxyapatite, calcium phosphate, β-TCP (tricalcium phosphate [β-Ca02-18-2010
20100040685COLLAGEN-BASED MATRIX FOR USE AS RESTORATIVE MATERIAL, AND METHOD FOR PREPARING THE SAME - Disclosed herein are a collagen-based matrix for use as a restorative material and a method for the preparation thereof. An atelocollagen dispersion is spread at a predetermined thickness over a plate and freeze-dried to form a porous collagen membrane. An atelocollagen dispersion is separately spread over a plate and pressurized to form a dense collagen membrane. This is overlaid with the porous collagen membrane and immersed in an EDS solution in ethanol to crosslink the two membranes with each other. From the bilayer structure thus constructed, EDS is removed, followed by lyophilization and cutting into an appropriate size.02-18-2010
20100040687Tissue Scaffolds - Tissue scaffolds are described herein. Also described are devices for treating wounds and methods of treating wounds using tissue scaffolds.02-18-2010
20080292705Emulsifier system - The invention relates to an emulsifier system, which comprises a nanoparticle with a positive or negative net charge and a hydrophobic compound of opposite charge to the nanoparticle that will bind to the nanoparticle making it hydrophobic and the use of that system for preparing water-in-oil (WIO) emulsions as well as oil-in-water (O/W) emulsions.11-27-2008
20130045277BIOCOMPATIBLE DEVICE - Disclosed is a biocompatible device surface-coated on the base material thereof with a biocompatible polymer layer having antithrombogenicity and endothelialization activity, and embedded in or attached to a living body for use. The polymer layer comprises a polymer matrix formed by the crosslinking of a cell-adhesive peptide-containing polymer.02-21-2013
20100092559BOLDINE COMPOUNDS FOR PROMOTING BONE GROWTH - The present invention provides a method of promoting bone growth in a subject in need thereof, by administering to the subject a therapeutically effective amount of a compound of Formula I. The present invention also provides methods for the treatment of renal disease and cancer.04-15-2010
20100330182Tendon Stem Cells - The invention relates to tendon stem cell useful for treating a variety of diseases and conditions, including tendon repair and attachment of tendon to bone. The invention is also directed to treatment and/or inhibition of bone formation by use of biglycan and/or fibromodulin.12-30-2010
20130028975HEMOSTATIC SPONGE - The present invention provides a hemostatic porous composite sponge comprising i) a matrix of a biomaterial and ii) one hydrophilic polymeric component comprising reactive groups wherein i) and ii) are associated with each other so that the reactivity of the polymeric component is retained, wherein associated means that—said polymeric component is coated onto a surface of said matrix of a biomaterial, or—said matrix is impregnated with said polymeric material, or—both.01-31-2013
20090181091PRODUCT AND PROCESS TO REGULATE A GENE NETWORK INVOLVED IN CONSTITUTIVE INFLAMMATION AND EARLY CANCER PROGRESSION - A recombinant construct arranged for expression of a specific hairpin microRNA which disrupts crosstalk between the two inflammatory pathways is described for intervening in early cancer progression events. Accordingly, the construct can be used as a molecular therapeutic approach to prevent cancer of epithelial origin in mammals, which include but are by no means limited to cancers of the head and neck, lung, breast, ovarian, and prostate tissues.07-16-2009
20100003323HYDROPHILIC MATRIX CONTAINING POORLY WATER-SOLUBLE COMPOUND AND METHOD FOR PRODUCING THE SAME - It is an object of the present invention to solve the problem of precipitation of a poorly water-soluble compound in a hydrophilic matrix upon inclusion of the poorly water-soluble compound in the hydrophilic matrix. The present invention provides a composition wherein a poorly water-soluble compound is contained in a hydrophilic matrix in a finely-dispersed state.01-07-2010
20090324719EXTRACELLULAR MATRIX COMPOSITION - The invention relates to a process for preparing an extracellular matrix composition comprising cross-linked fibrinogen or a derivative thereof, to an extracellular matrix composition obtained by said process and to the use of said composition in wound healing, tissue regeneration or as a tissue engineering scaffold.12-31-2009
20090317467HYDROCOLLOID COMPOSITION - A therapeutic composition is described comprising a particulate dispersion of a hydrocolloid in a low water activity anti-microbial matrix. The composition may also contain any or all of a sequestrant, excipient, carrier and surfactant. The hydrocolloid may be naturally occurring, semisynthetic or synthetic. The invention extends to a method of producing a therapeutic composition. The composition is prepared by mixing a low water activity anti-microbial matrix with hydrocolloid particles at a temperature that will not cause degradation of the matrix. The method may also include the addition of other components such as excipients, sequestrants, carriers and surfactants and other agents. The invention extends to methods for treating a human or animal subject by applying or administering the composition to the subject subject in a therapeutically effective dose.12-24-2009
20110171304INJECTABLE BETA-HAIRPIN PEPTIDE HYDROGEL THAT KILLS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS - A peptide comprising the sequence VKVKVRVKV07-14-2011
201300590063-DIMENSIONAL CARDIAC FIBROBLAST DERIVED EXTRACELLULAR MATRIX - A bioscaffold made from an isolated cardiac fibroblast-derived 3-dimensional extracellular matrix (ECM) is disclosed. The bioscaffold can be used as an epicardial patch for the delivery of therapeutic cells into myocardial tissue. Methods of making the 3-dimensional extracellular matrix using cultured cardiac fibroblasts are also disclosed.03-07-2013
20110014288MICROCAPSULES COMPRISING A FAT-SOLUBLE ACTIVE SUBSTANCE - The invention relates to microcapsule comprising at least one fat-soluble active substance selected from provitamins, vitamins and esters thereof, monounsaturated fatty acids, polyunsaturated fatty acids (PUFA's), carotenoids and benzoquinones embedded in a matrix comprising a hydrocolloid and optionally one or more other matrix components, wherein the content of active substance(s) is from 30 to 60% of total weight of the microcapsule, and wherein the ratio between said fat-soluble active substance(s) and said hydrocolloid is at least 4:1, as well as a process for preparing such microcapsules.01-20-2011
20110014287Silk Fibroin Hydrogels and Uses Thereof - The present specification provides for methods for purifying fibroins, purified fibroins, methods of conjugating biological and synthetic molecules to fibroins, fibroins conjugated to such molecules, methods of making fibroin hydrogels, fibroin hydrogels and fibroin hydrogel formulations useful for a variety of medical uses, including, without limitation uses as bulking agents, tissue space fillers, templates for tissue reconstruction or regeneration, cell culture scaffolds for tissue engineering and for disease models, surface coating to improve medical device function, or drug delivery devices.01-20-2011
20090297605Composition And Device For In Vivo Cartilage Repair - The composition as described serves for in vivo cartilage repair. It basically consists of a naturally derived osteoinductive and/or chondroinductive mixture of factors (e.g. derived from bone) or of a synthetic mimic of such a mixture combined with a nanosphere delivery system. A preferred mixture of factors is the combination of factors isolated from bone, known as BP and described by Poser and Benedict (WO 95/13767). The nanosphere delivery system consists of nanospheres defined as polymer particles of less than 1000 nm in diameter (whereby the majority of particles preferably ranges between 200-400 nm) in which nanospheres the combination of factors is encapsulated. The nanospheres are loaded with the mixture of factors in a weight ratio of 0.001 to 17% (w/w), preferably of 1 to 4% (w/w) and have a release profile with an initial burst of 10 to 20% of the total load over the first 24 hours and a long time release of at least 0.1 per day during at least seven following days. The nanospheres are composed of e.g. ((D,L)lactic acid/glycolic acid)-copolymer (PLGA). The loaded nanospheres are e.g. made by phase inversion. The composition is advantageously utilized as a device comprising any biodegradable matrix in which the nanospheres loaded with the factor combination is contained.12-03-2009
20090269404Crosslinked Gelatin Gel, Multilayered Structure, Carrier for Bioactive Factor, Preparation for Release of Bioactive Factor, and Their Production Methods - A multi-layer crosslinked gelatin gel structure having a layer structure that plural layers of crosslinked gelatin gel crosslinked by irradiating gelatin or a gelatin derivative with electron beam under an oxygen-containing atmosphere are arranged adjoiningly to each other, a preparation for release of a bioactive factor with the bioactive factor contained in the multi-layer crosslinked gelatin gel structure, and production processes thereof.10-29-2009
20110020449METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN BETA 4 (TB4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES - Pain or irritation of the eyes, caused by injury due to dry eye syndrome, chemical burns or the like can be accompanied by corneal stromal edema. It has been discovered that administration of thymosin β4 and/or oxidized thymosin β4 to cornea in need of treatment of corneal stromal edema is a useful treatment for decreasing such corneal stromal edema.01-27-2011
20090238873EXTENDED RELEASE FORMULATION CONTAINING A WAX - Extended release pharmaceutical formulations are disclosed wherein the formulations contain an extended release portion and an immediate release portion, the extended release portion comprising an active pharmaceutical ingredient and a wax. Methods of making such extended release pharmaceutical formulations are also disclosed.09-24-2009
20090238872Chlorine dioxide releasing composite article - A composite article that includes a ClO09-24-2009
20090047347Compositions for Drug Administration - The present invention provides compositions and methods and for speeding the onset of drug action and reducing the first-pass effect drug metabolism in fast-dispersing drug formulations.02-19-2009
20090011023CHEMOTHERAPEUTIC COMPOSITIONS - The present invention relates to the treatment of gastrointestinal and/or cancer, and a method of weight gain, via the ingestion of polymeric compositions in humans, animals or birds in need of said treatment. The invention provides methods for the treatment of cancer, the treatment and/or prevention of gastrointestinal disease and/or infection and/or diarrhea, and a method for increasing weight gain in humans, animals or birds comprising administering to said humans, animals or birds an effective amount of a pharmaceutical or veterinary composition, or feed additive, comprising an effective amount of a polymer and/or copolymer, having the repeating polymeric unit (I), wherein R is H or alkyl, usually C01-08-2009
20090011021Engineered Extracellular Matrices - The invention relates to engineered matrices comprising collagen fibrils with specific characteristics, including, but not limited to, a specific fibril area fraction (i.e., density) and/or a specific elastic or linear modulus (i.e., stiffness). The invention also relates to methods of preparation and use of the matrices.01-08-2009
20090123544STIMULUS-RESPONSIVE BIODEGRADABLE POLYMERS AND METHODS OF PREPARATION - There is presently provided a stimulus-responsive polymer comprising a biodegradable polymer backbone and a stimulus-responsive pendant group attached to the biodegradable polymer backbone, wherein the biodegradable polymer backbone comprises a poly(amino ester) or a poly(amido amine), the poly(amido amine) optionally comprising a disulfide linkage in the backbone.05-14-2009
20120237603ABUSE-RESISTANT OPIOID DOSAGE FORM - We provide a pharmaceutical dosage form including an opioid antagonist surrounded by a controlled release matrix and an opioid agonist in a surrounding matrix.09-20-2012
20090269405ENZYME MEDIATED DELIVERY SYSTEM - The present invention includes compositions, methods, and systems for the development of a novel delivery vehicle that affects release of an agent upon the degradation of components of said vehicle by one or more enzymes. In one example, the system comprises components designed to degrade upon the presence of desired concentrations of proteinases, specifically matrix metalloproteinases, and subsequent release of the agent.10-29-2009
20110150999Organo-Soluble Chitosan Salts and Chitosan-Derived Biomaterials Prepared Thereof - Organo-soluble chitosan salts, method for preparing organo-soluble salts, chitosan-derived materials prepared with organo-soluble chitosan salts, and methods for preparing chitosan-derived materials are disclosed.06-23-2011
20090220602SUBLIMABLE SUSTAINED RELEASE DELIVERY SYSTEM AND METHOD OF MAKING SAME - The invention relates to compositions suitable for the delivery and/or stabilization of biologically active substances. The compositions comprise a sublimable matrix material and the biologically active agent to be delivered. The compositions can be used as drug delivery systems to treat a wide variety of diseases or as systems for the protection and stabilization of such substances. Also disclosed are methods for preparing compositions of the present invention.09-03-2009
20090011022Use of deuterium oxide for treatment of virus-based diseases of the skin - The present invention relates to the use of deuterium dioxide (D01-08-2009
20110142935CARDIAC DIFFERENTIATION OF HUMAN PLURIPOTENT STEM CELLS UNDER DEFINED CONDITIONS USING MATRIX OVERLAY METHODS - Methods for culturing the pluripotent stem cells to undergo epithelial-to-mesenchymal transition and for generating high-yield, high-purity cardiomyocyte cultures from pluripotent stem cells are described. Pluripotent stem cells are cultured on a support with an overlaid matrix and, optionally, exposed to one or more factors to induce epithelial-to-mesenchymal transition and cardiogenesis.06-16-2011
20100055185COMPOSITION AND METHOD FOR TREATING HEMORRHOIDS AND/OR ANORECTAL DISORDERS - The invention provides an oil-in-water emulsion useful in the treatment of anorectal disorders comprising a local anesthetic, vasoconstrictor, glycerin and water, and method of preparation of the emulsion and a method for treating hemorrhoids using the composition of the invention.03-04-2010
20100260844Oral pharmaceutical dosage forms - Controlled release oral dosage forms suitable for administration of methylphenidate are provided. Abuse-resistant controlled release oral dosage forms suitable for administration of methylphenidate are also provided. Methods of treating ADD and ADHD using the oral dosage forms are also provided.10-14-2010
20110070306Antimicrobial nanoemulsion compositions and methods - The present invention relates to compositions and methods for decreasing the infectivity, morbidity, and rate of mortality associated with a variety of pathogenic organisms and viruses. The present invention also relates to methods and compositions for decontaminating areas colonized or otherwise infected by pathogenic organisms and viruses. Moreover, the present invention relates to methods and compositions for decreasing the infectivity of pathogenic organisms in foodstuffs.03-24-2011
20100285129NOVEL AGENT FOR SALTING OUT ACTIVE PRINCIPLES IN DRESSINGS CONTAINING AT LEAST ONE OF FATTY SUBSTANCE - The present invention relates to the use, as an agent for salting out an active substance in a composition for a dressing, of a copolymer of a salt of 2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulphonic acid and the 2-hydroxyethyl ester of propenoic acid. It also relates to dressings of the type comprising at least one fatty substance and/or an elastomeric matrix and at least one active substance, which incorporate the aforementioned copolymer.11-11-2010
20100189795CALCIUM SEQUESTRATION COMPOSITIONS AND METHODS OF TREATING SKIN PIGMENTATION DISORDERS AND CONDITIONS - The present invention provides compositions containing one or more calcium sequestration agents and methods for topical application of such compositions to the skin to treat skin pigmentation disorders, such as melasma, post-inflammatory hyperpigmentation, pigmentation changes due to skin aging, or any other skin conditions related with normal such as skin of color or abnormal pigmentation such as hypo- or hyper-pigmentation in humans.07-29-2010
20100266689Tissue Augmentation With Active Agent For Wound Healing - The invention relates to a bioactive settable hydrogel matrix having a pore creating material, which may also carry a therapeutic agent, and methods of using the same, for example, use in promoting internal wound healing, tissue repair, tissue regeneration.10-21-2010
20100266688ANTI-BACTERIAL COMPOSITION AND METHOD FOR PRODUCING THE SAME - The invention discloses an anti-bacterial composition and method for producing the same. The anti-bacterial composition of the invention includes an organic siloxane material which comprises an amino group, and a plurality of silver atoms. Particularly, the organic siloxane material has a meshed structure, and the plurality of silver atoms are bonded to the amino group and are well dispersed in the meshed structure.10-21-2010
20090252797TOPICAL APPLICATION OF IVERMECTIN FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS/AFFLICTIONS - Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin.10-08-2009
20110033543HYDROGELS WITH COVALENT AND NONCOVALENT CROSSLINKS - A method for targeted delivery of therapeutic compounds from hydrogels is presented. The method involves administering to a cell a hydrogel in which a therapeutic compound is noncovalently bound to heparin. The hydrogel may contain covalent and non-covalent crosslinks.02-10-2011
20110129533POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF - Drugs, especially low aqueous solubility drugs, are provided in a porous matrix form, preferably microparticles, which enhances dissolution of the drug in aqueous media. The drug matrices preferably are made using a process that includes (i) dissolving a drug, preferably a drug having low aqueous solubility, in a volatile solvent to form a drug solution, (ii) combining at least one pore forming agent with the drug solution to form an emulsion, suspension, or second solution and hydrophilic or hydrophobic excipients that stabilize the drug and inhibit crystallization, and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix of drug. Hydrophobic or hydrophilic excipients may be selected to stabilize the drug in crystalline form by inhibiting crystal growth or to stabilize the drug in amorphous form by preventing crystallization. The pore forming agent can be either a volatile liquid that is immiscible with the drug solvent or a volatile solid compound, preferably a volatile salt. In a preferred embodiment, spray drying is used to remove the solvents and the pore forming agent. The resulting porous matrix has a faster rate of dissolution following administration to a patient, as compared to non-porous matrix forms of the drug. In a preferred embodiment, microparticles of the porous drug matrix are reconstituted with an aqueous medium and administered parenterally, or processed using standard techniques into tablets or capsules for oral administration.06-02-2011
20110086101Dispersinb, 5-Fluorouracil, Deoxyribonuclease I and Proteinase K-Based Antibiofilm Compositions and Uses Thereof - The present invention provides antibiofilm composition comprising two or more agents selected from the group consisting of DispersinB™, 5-Fluorouracil, Deoxyribonuclease I and Proteinase K for preventing growth and proliferation of biofilm-embedded microorganisms in wound care, oral care, and disease-related infections and methods of treatment in mammals. The invention further provides methods for preparing medical devices, and wound care devices using an antibiofilm composition comprising two or more antimicrobial agents selected from the group consisting of DispersinB™, 5-Fluorouracil, Deoxyribonuclease I and Proteinase K.04-14-2011
20120288564Interpenetrating polymer network comprising fibrin - There is provided a method of forming a hydrogel, the method comprising: providing a mixture of a polymer comprising a cross-linkable pendant phenolic group, peroxidase, H11-15-2012
20120288565TAMPER-RESISTANT ORAL OPIOID AGONIST FORMULATIONS - Disclosed is an oral dosage form comprising: (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is not released when the dosage form is administered orally intact.11-15-2012
20080268052Collagen preparation and method of isolation - Collagen compositions, methods for preparing those collagen compositions, and graft compositions formed from those collagen compositions are provided. In particular, methods of isolating collagen that exhibits an enhanced rate of polymerization and enhanced microstructural and mechanical properties upon polymerization, such collagen compositions, and graft compositions formed from such collagen compositions are provided.10-30-2008
20110081416ORDERED MESOPOROUS SILICA MATERIAL - A process for preparing a 2D-hexagonal ordered mesoporous silica material with a substantially uniform pore size in the range of 4 to 30 nm comprising the steps of: preparing an aqueous solution comprising an alkali silicate solution; preparing an aqueous solution comprising a poly(alkylene oxide) triblock copolymer and a buffer with a pH greater than 2 and less than 8, adding said aqueous alkali silicate solution to said aqueous solution giving a pH greater than 2 and less than 8 and allowing a reaction between the components to take place at a temperature in the range of 10 to 100° C., and filtering off, drying and calcinating the reaction product to produce said 2D-hexagonal ordered mesoporous silica material with a substantially uniform pore size. In an alternative procedure both aqueous solutions are fed as liquid streams into an elongated mixing receptacle having a first and a second opening such that the liquid streams of the solutions are each discharged independently into said first opening of said elongated mixing receptacle such that they directly impinge thereby giving a pH in the resulting mixture of greater than 2 and less than 8 and producing a reaction product at a temperature in the range of 10 to 100° C. in said elongated mixing receptacle, which upon emergence from said second opening of said elongated mixing receptacle is filtered off, dried and the surfactant removed.04-07-2011
20100203140METHODS, COMPOSITIONS, AND KITS FOR ORGAN PROTECTION DURING SYSTEMIC ANTICANCER THERAPY - Methods, compositions, and kits are presented for local tissue protection during systemic administration of anticancer therapeutic agents.08-12-2010
20120107403BLADDER RECONSTRUCTION - The invention is directed to methods and devices for the reconstruction, repair, augmentation or replacement of laminarily organized luminal organs or tissue structures in a patient in need of such treatment. The device comprises a biocompatible synthetic or natural polymeric matrix shaped to conform to at least a part of the luminal organ or tissue structure with a first cell population on or in a first area and a second cell population such as a smooth muscle cell population in a second area of the polymeric matrix. The method involves grafting the device to an area in a patient in need of treatment. The polymeric matrix comprises a biocompatible and biodegradable material.05-03-2012
20100151025PREVENTION AND TREATMENT FOR OSTEONECROSIS AND OSTEORADIONECROSIS OF THE JAW - The present invention provides compositions and methods useful for treating, preventing or slowing the progression of ONJ and ORNJ. The invention provides for the use of PDGF in a pharmaceutically acceptable buffer in the preparation of a medicament useful for treating, preventing or slowing the progression of ONJ and ORNJ. The invention provides for the use of PDGF in a pharmaceutically acceptable buffer wherein the PDGF is disposed in a biocompatible matrix in the preparation of a medicament useful for treating, preventing or slowing the progression of ONJ and ORNJ. In one embodiment, a method for treating, preventing or slowing the progression of ONJ or ORNJ comprises providing a composition comprising a PDGF solution disposed in a biocompatible matrix and applying the composition to a desired site in the jaw. In another embodiment, a method for treating, preventing or slowing the progression of ONJ or ORNJ comprises providing a composition comprising a PDGF in a pharmaceutically acceptable buffer and applying the composition to a desired site in the jaw. The present invention also provides kits useful for treating, preventing or slowing the progression of ONJ and ORNJ.06-17-2010
20100255096Compositions And Methods For Transmucosal Delivery Of Domperidone - Compositions of domperidone formulated for transmucosal delivery are provided. Also provided are methods for the treatment of nausea, vomiting, and gastrointestinal motility disorders, and methods for the enhancement of breast milk production. The methods utilize domperidone compositions formulated for transmucosal administration, administered to patients in an amount effective to treat nausea, vomiting, or gastrointestinal motility disorders, or to enhance breast milk production.10-07-2010
20100159007PHARMACEUTICAL COMPOSITIONS FOR TRANSMUCOSAL DELIVERY OF A THERAPEUTICALLY ACTIVE AGENT ON THE BASIS OF SUBMICRON PARTICLES - The present invention relates to improved compositions for transmucosal administration, the compositions enabling rapid and efficient uptake of a therapeutically active agent to provide a rapid, effectively durable, predictable and consistent therapeutic effect. In particular, the compositions are intended for buccal and/or sublingual delivery. The invention is particularly suitable for administering therapeutically active agents which have an effect on the central nervous system and even more particularly where rapid onset of this effect is desired or beneficial. The invention is also particularly suitable for administering active agents in low solubility base or acid forms.06-24-2010
20100203138 Controlled Release Composition Comprising a Recombinant Gelatin - The invention relates to the field of pharmacology. More specific, the invention relates to a controlled release composition. In one of the embodiments, the invention provides a method for preparing a controlled release composition comprising the steps of: 08-12-2010
20090117189Method for the Production of Polymerized Nanoparticles and Microparticles by Ternary Agent Concentration and Temperature Alteration Induced Immiscibility - Polymerized drug delivery devices are described. Additionally, methods are described for producing and for using polymerized particles for use as drug delivery devices.05-07-2009
20090022802CARDIOMYOPATHY THERAPEUTIC AGENT - The present invention provides a cardiomyopathy therapeutic agent that contains hepatocyte growth factor (HGF) and gelatin hydrogel, and gradually releases HGF, which is useful in treating cardiomyopathy.01-22-2009
20090297604METAL OXIDE HYDROGELS AND HYDROSOLS, THEIR PREPARATION AND USE - A process for preparing a hydrosol of one or more metal oxides, e.g. titanium dioxide, comprising preparing a metal alkoxide solution in a water-miscible organic solvent, e.g. an alcohol; providing an aqueous solvent; mixing the metal alkoxide solution with the aqueous solvent in a volume or weight proportion to form a single-phase aqueous sol colloid (hydrosol) of hydrated metal oxide in absence of a non-ionic block polymer surfactant. Also disclosed is a corresponding hydrogel; water-insoluble particles encapsulated in hydrated metal oxide and a process for their encapsulation; uses of the encapsulation products.12-03-2009
20090297606GAMMA-LACTAM COMPOUNDS FOR PROMOTING BONE GROWTH - The present invention provides compounds, compositions and methods for promoting bone growth. Compounds useful in the methods of the present invention include compounds of Formula I, wherein each R12-03-2009
20090181088THERMOSENSITIVE POLYPHOSPHAZENE-BIOACTIVE MOLECULE CONJUGATES, PREPARATION METHOD THEREOF AND USE THEREOF - The present invention relates to a poly(organophosphazene)-bioactive molecule conjugates in which biodegradable and thermosensitive poly(organophosphazene) with a functional group showing the sol-gel phase transition with change of temperature is combined with various bioactive molecules, such as drugs, a preparation method thereof, and a use thereof for delivery of bioactive molecules.07-16-2009
20080241243Drug delivery device for providing local analgesia, local anesthesia or nerve blockade - The invention relates to a drug delivery device for providing local analgesia, local anesthesia or nerve blockade at a site in a human or animal in need thereof, the device comprising a fibrillar collagen matrix; and at least one drug substance selected from the group consisting of amino amide anesthetics, amino ester anesthetics and mixtures thereof, the at least one drug substance being substantially homogeneously dispersed in the collagen matrix, and the at least one drug substance being present in an amount sufficient to provide a duration of local analgesia, local anesthesia or nerve blockade which lasts for at least about one day after administration.10-02-2008
20110142938Nanotubes as Mitochondrial Uncouplers - A method of uncoupling mitochondria in a subject including administering nanotubes to the subject in a therapeutically effective amount, wherein the nanotubes are self-rectifying is provided. A method of decreasing reactive oxygen species and decreasing detrimental loading of Ca06-16-2011
20110142937Methods and Compositions To Treat Hemorrhagic Conditions of The Brain - The described invention provides a nonhuman animal model system for hemorrhagic brain conditions, methods for evaluating a substance for treating the hemorrhagic brain condition in a mammal, methods for treating hematoma expansion or recurrent rebleeding resulting from hemorrhagic brain conditions in a mammal, and pharmaceutical compositions for administration into or at a distance proximal to the hemorrhagic brain condition.06-16-2011
20100034879HYALURONIC ACID PRODUCT AND METHOD FOR TREATING LACERATIONS AND WOUNDS IN A LIVING BODY - A method for texturing the surface of a breast implant includes the step of partially impregnating a silicone outer surface of the implant with particles of a biologically active material such as acellular dermis of human or animal origin and/or hyaluronic acid granules. The biologically active material promotes tissue ingrowth into a plurality of cavities filled with a biologically active material.02-11-2010
20100034880PHARMACEUTICAL COMPOSITIONS BASED ON A MICROEMULSION - The invention provides a transdermal, transmucosal pharmaceutical composition suitable for substantially extra-vascular application of at least one biologically active substance to biological membranes of a mammal, comprising a pharmaceutical or cosmetic composition comprising propylene carbonate at least one oil or source of fatty acid or surfactant; and water; in combination with the at least one biologically active substance wherein the propylene carbonate is adapted to enhance the bioavailability of the at least one biologically active substance.02-11-2010
20110217376POLY(AMIDOAMINE) OLIGOMER HYDROGEL FOR DRUG DELIVERY AND DRUG CARRIER USING THE SAME - Disclosed is a temperature- and pH-sensitive hydrogel composed of a poly(amidoamine) oligomer only. The hydrogel is prepared in a simple manner and is readily released from the body. Further disclosed are a method for preparing the hydrogel and a drug carrier using the hydrogel.09-08-2011
20090098203Mucoadhesive Tetracycline Formulations - Mucositis is treated and/or prevented by administrating to a patient a formulation containing a tetracycline and at least one cationic polymer and/or mucoadhesive material. The tetracycline may be in the form of a pharmaceutically acceptable salt or a base. The formulations may optionally also contain an antifungal agent to prevent fungal overgrowth due to reduction in the normal oral flora by the tetracycline. The formulation can be formed into liquid or solid dosage forms such as mouth rinse or tablet. Such compositions have the advantage of prolonged retention of the tetracycline in the mucosa of the oral cavity.04-16-2009
20110171307METHODS AND PRODUCTS FOR TREATMENT OF DISEASES - The present invention relates to the treatment of diseases and conditions with an effective amount of a steroid having those formulas given in the specification, or a pharmacologically-acceptable salt or ester thereof. The disease or conditions treatable according to the invention include angiogenic diseases and conditions of the eye, angiogenic diseases and conditions of the brain, inflammatory diseases and conditions of the eye, inflammatory diseases and conditions of the brain and neurodegenerative diseases.07-14-2011
20100112057MULTIFUNCTIONAL AND BIOLOGICALLY ACTIVE MATRICES FROM MULTICOMPONENT POLYMERIC SOLUTIONS - The present invention relates to a biologically active functionalized electrospun matrix to permit immobilization and long-term delivery of biologically active agents. In particular the invention relates to a functionalized polymer matrix comprising a matrix polymer, a compatibilizing polymer and a biomolecule or other small functioning molecule. In certain aspects the electrospun polymer fibers comprise at least one biologically active molecule functionalized with low molecular weight heparin. Examples of active molecules that may be used with the multicomponent polymer of the invention include, for example, a drug, a biopolymer, for example a growth factor, a protein, a peptide, a nucleotide, a polysaccharide, a biological macromolecule or the like. The invention is further directed to the formation of functionalized crosslinked matrices, such as hydrogels, that include at least one functionalized compatibilizing polymer capable of assembly.05-06-2010
20090317469COMPOSITE EXTRACELLULAR MATRIX MATERIALS AND MEDICAL PRODUCTS FORMED THEREFROM - Described in certain aspects are composite extracellular matrix material products including expanded collagenous materials in combination with non-expanded collagenous materials. Methods for their preparation and use are also disclosed. Certain expanded collagenous materials can be prepared by treating a first collagenous material with an alkaline substance under conditions effective to expand the first collagenous material, and recovering the expanded material. Expanded materials can exhibit beneficial persistence and tissue generation characteristics when implanted, and can be used in the formation of highly porous medical implant bodies which can be compressed to fractions of their original volume and will thereafter substantially recover their original volume.12-24-2009
20100112060FORMULATIONS OF ENTOMOPATHOGENIC FUNGI FOR INSECT CONTROL - The present invention describes insecticidal compositions comprising spores of entomopathogenic fungi suspended in oil in water emulsions comprising fatty acid salts, polyhydric alcohols, and additional emulsifiers. A method of producing such emulsions is presented. Methods for use of the compositions for preventing and controlling insect infestation in animals and natural areas, particularly tick infestations, are disclosed.05-06-2010
20090148527INTRAOCULAR FORMULATION - Biodegradable therapeutic agent incorporating microspheres formulated in a high viscosity carrier suitable for intraocular administration to treat an ocular condition. The formulation can also be used to treat non-ocular conditions such as articular pathologies.06-11-2009
20080268054DERMAL DERIVED HUMAN STEM CELLS AND COMPOSITIONS AND METHODS THEREOF - This application discloses Dermal Derived Human Stem Cells (DDhSCs) and methods of making and using thereof. More specifically, the invention relates to DDhSCs derived from subsets of dedifferentiated dermal fibroblasts that can give rise to a series of cell lineages. The DDhSCs may be used, for example, in cell therapy and in the search for and development of novel medicaments.10-30-2008
20100119606PROCESSES AND APPARATUS FOR EXTRACTION OF ACTIVE SUBSTANCES AND ENRICHED EXTRACTS FROM NATURAL PRODUCTS - Processes for preparing extracts of natural products such as plant material, and for preparing purified extracts from crude extracts of natural products, by extraction with hot gas. Apparatus suitable for use in preparing extracts of natural products are also described.05-13-2010
20100124569AMNION DERIVED ADHERENT CELLS - Provided herein are novel angiogenic cells from amnion, referred to as amnion derived adherent cells, and populations of, and compositions comprising, such cells. Further provided herein are methods of obtaining such cells and methods of using the cells in the treatment of individuals.05-20-2010
20090311324POLYMER MATRIX, METHOD FOR ITS PRODUCTION, AND ITS USE - The present invention relates to a polymer matrix for specifically tethering surface epitopes or receptors of cells, said polymer matrix having been pretreated by molecular imprinting. The invention also relates to a method of producing such a polymer matrix. The polymer matrices according to the present invention are used in therapeutic and diagnostic applications as well as for isolating cells.12-17-2009
20090311323Autologous somatic cells from peripheral blood and uses thereof - The present invention is directed to developing treatment for spinal cord injury, traumatic brain injury and neural disease using autologous somatic stem cells isolated from peripheral blood. The method identified in the present invention will generate functional neural cells/tissues in order to replace the diseased or damaged neural cells/tissues. In doing so, the cells will not only reverse the motor as well as cognitive dysfunction but will also stabilize the injury site, reduce inflammation and scaring, and halt progressive loss of functional tissue. Further, this method also holds a great promise since it is non-invasive, autologous and can be used acutely.12-17-2009
20100297232ONDANSETRON FILM COMPOSITIONS - The present invention relates to products and methods of making products having a taste masked active component. In particular, the present invention relates to taste-masked film dosage forms including at least one active component and a slow dissolving basic composition.11-25-2010
20100119603NANOPARTICLES COMPRISING A DRUG,ETHYCELLULOSE,AND A BILE SALT - A pharmaceutical composition comprises nanoparticles comprising a poorly water-soluble drug, ethylcellulose, and a bile salt.05-13-2010
20100086595NON-IONIZABLE HYDROPHOBIC GALENICAL SYSTEM - The present invention concerns a novel hydrophobic galenic system allowing improved masking of the taste of the active ingredients it contains, the stability of said active ingredients and, when applicable, sustained release thereof. The galenic system of the invention consists of lipid particles with no surfactants or emulsifiers, comprising a lipid hydrophobic matrix that is non-ionizable at physiological pH in which the active ingredient(s) are dispersed. This system is suitable for the preparation of pharmaceutical or veterinary compositions, in particular for administration via oral route or via injection.04-08-2010
20100080848Recombinant Lubricin Molecules and Uses Thereof - Recombinant lubricin molecules and uses thereof. Novel recombinant lubricin molecules and their uses as lubricants, anti-adhesive agents and/or intra-articular supplements for, e.g., synovial joints, meniscus, tendon, peritoneum, pericardium and pleura, are provided.04-01-2010
20120107402PROCESS FOR ANALYZING AND ESTABLISHING DOSAGE SIZE IN AN INGESTIBLE FILM - The present invention is directed to a method of analyzing and establishing a proper dosage size in ingestible films for providing a more precise dosage delivery of an active ingredient.05-03-2012
20120107401OSTEOCONDUCTIVE MATRICES COMPRISING STATINS AND METHODS OF USING THE SAME - Osteoconductive matrices and methods are provided that have one or more statins disposed therein. The matrices may be injected into a fracture site. The osteoconductive matrices provided allow for sustain release of the statin and facilitate bone formation and repair of the fracture site.05-03-2012
20090263483NANOPARTICLE FORMULATIONS AND USES THEREOF - The present invention provides compositions comprising nanoparticles comprising: 1) a drug, such as a hydrophobic drug derivative; and 2) a carrier protein. Also provided are methods of treating diseases (such as cancer) using the compositions, as well as kits and unit dosages.10-22-2009
20090142396USE OF A REGENERATIVE BIOFUNCTIONAL COLLAGEN BIOMATRIX FOR TREATING VISCERAL OR PARIETAL DEFECTS - Techniques for treating visceral or parietal membrane and tissue defects include the application of a collagen biomatrix to the defect to repair and regenerate a visceral or parietal membrane, for example in patients suffering tissue defects or undergoing visceral or parietal surgical treatment. Such approaches avoid persistent tissue leaks and their consequences such as fluid leaks and air leaks. The use of collagen biomatrix, optionally in conjunction with a fibrin sealant, an anti-adhesive, or both, can minimize tissue leaks or fluid leaks in injured patients suffering tissue defects or subjects undergoing surgery such as visceral or parietal resections and other operations.06-04-2009
20090142398NOVEL PHARMACEUTICAL COMPOSITIONS COMPRISING A DISINTEGRATION MATRIX - The present invention relates to a stable pharmaceutical composition comprising a pharmaceutically active substance having poor water solubility dispersed in a pharmaceutically acceptable disintegration matrix, said disintegration matrix comprising at least one pharmaceutically acceptable disintegrant, a pharmaceutically acceptable basic agent provided in a molar ratio of basic agent to active substance of 1:1 to 10:1, a water-insoluble pharmaceutically acceptable diluent, optionally, if desired or necessary at least one pharmaceutically acceptable excipients and/or pharmaceutically acceptable adjuvants, and optionally a pharmaceutically acceptable surfactant or emulsifier. The present invention also provides a process to make such.06-04-2009
20090142397REDUCTION OF DERMAL SCARRING - Methods and compositions for reducing or inhibiting dermal scarring by expressing p2106-04-2009
20090280179Resorbable Calcium Phosphate Based Biopolymer-Cross-Linked Bone Replacement Material - A resorbable bone replacement material made of calcium phosphate particles of different phases which are embedded in an inventive-specific cross-linked collagen matrix. The goal is to form a non-brittle, bone replacement moulded body having a positive fit, i.e. having a shape which is anatomic and/or corresponds to the defect, which perfectly fills the bone defect and can be resorbed thereby. Said goal is achieved by producing the bone replacement material made of a mixture of calcium phosphate particles which is embedded in an inventive cross-linked collagen matrix. In particular, the collagen cross-linking is achieved by a Laccase-induced peptide cross-linking and suitable bridge molecules. Essentially substituted dihydroxyarmotes and/or substrates of the lignolytic polyphenoloxidases, such as Laccases, are suitable as bridge molecules. Also, monocyclic ortho-dihydroxyaromates, monocyclic para-dihydroxyaromates, bicyclic monohydroxyaromates, polycyclic monohydroxyaromates, bicyclic dihydroxyaromates, polycyclic dihydroxyaromates, bicyclic trihydroxyaromates, polycyclic trihydroxyaromates, or mixtures thereof are used. The inventive hydroxyaromates are not part of a polymer chain as opposed to the known conchal adhesive.11-12-2009
20100129449Cosmetic Neurotoxin Compositions and Methods - Cosmetic compositions include a Clostridial neurotoxin component and a microsphere component. In certain compositions, the composition includes a 05-27-2010
20080317860Use of a Polysaccharide Which is Excreted by the Vibrio Diabolicus Species For the Engineering of Non-Mineralized Connective Tissue - The invention relates to the use of a polysaccharide which is excreted by the 12-25-2008
20110171306METHODS AND PRODUCTS FOR TREATMENT OF DISEASES - The present invention relates to the treatment of diseases and conditions with an effective amount of a steroid having those formulas given in the specification, or a pharmacologically-acceptable salt or ester thereof. The disease or conditions treatable according to the invention include angiogenic diseases and conditions of the eye, angiogenic diseases and conditions of the brain, inflammatory diseases and conditions of the eye, inflammatory diseases and conditions of the brain and neurodegenerative diseases.07-14-2011
20090285892METHODS AND SYSTEMS FOR EXPANDING AC133+ CELLS AND DIRECTING DIFFERENTIATION - The invention provides, among other things, methods and systems for expanding CD133+ cells. The invention further provides methods and systems for increasing the blood flow to an ischemic tissue in a subject in need thereof, such as to ischemic myocardium. The invention further provides methods and systems for directing differentiation of expanded CD133+ cells. The invention further provides methods and systems for treating a subject with differentiated cells in a subject in need thereof.11-19-2009
20090285891Pharmaceutical preparation for oral administration with controlled active ingredient release in the small intestine and method for its production - Any pharmaceutical preparation for oral administration with controlled release of active ingredient in the small bowel, on the basis of active ingredient carriers provided with at least one active ingredient which are provided with an inner layer to control the release of active ingredient and with a gastro-resistant coating layer disposed thereon, which is characterized in that the inner layer is formed from at least two diffusion layers whose permeability for the diffusing active ingredient decreases from the inside to the outside, and a method for the production thereof, are described.11-19-2009
20110171305DEHYDRATED HYDROGEL INCLUSION COMPLEX OF A BIOACTIVE AGENT WITH FLOWABLE DRUG DELIVERY SYSTEM - The invention provides a controlled release biodegradable polymer formulation adapted for administering bioactive agents such as therapeutic proteins to a patient through implantation of a bolus that forms a depot within the patient's body tissues. The formulation includes a dehydrated inclusion complex of the bioactive agent within a hydrogel, wherein the hydrogel can comprise a polymerized polyalkyleneglycolyl diacrylate, and, optionally, polyalkyleneglycolyl monoacrylates, including methacrylates. Alternatively, the hydrogel can comprise hyaluronic acid, chitosan, agarose, polyvinylacetate, polyvinylpyrrolide, or polyvinylalcohol nanoparticles. The bioactive agent can be a macromolecular material, such as a protein. A method of forming the inventive formulation is also provided, as well as a method for using the formulation in the treatment of a malcondition in a patient in need thereof.07-14-2011
20090291140TREATMENT OF DYSMENORRHEA VIA TRANSDERMAL ADMINISTRATION OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS - Methods and compositions are provided for the treatment of a subject suffering from dysmenorrhea, including both primary and second dysmenorrhea. Aspects of the invention include transdermally administering to the subject an effective amount of a nonsteroidal anti-inflammatory agent. Also provided are transdermal NSAID formulations and kits including the same that find use in practicing the subject methods.11-26-2009
20090274761TRANSDERMAL DELIVERY OF (R)-3,3-DIPHENYLPROPYLAMIN-MONOESTERN - The invention relates to a device for transdermally administering a compound of formula (I), wherein A represents hydrogen or deuterium, R represents a group selected among C11-05-2009
20090274758Solid Composition for Intra-Oral Delivery of Insulin - The invention provides a solid composition for intra-oral delivery of insulin, comprising; insulin; a hydrophilic polymer matrix; and a phospholipid, providing insulin bioavailability of at least 5%.11-05-2009
20090280180COLLAGEN-BASED MATRICES WITH STEM CELLS - Collagen based-matrices and methods of their use are described. More particularly, collagen-based matrices for differentiating stem cells and progenitor cells, and for producing and isolating blood vessels and vascularized graft constructs are described.11-12-2009
20090280181DELIVERY OF NUCLEIC ACID COMPLEXES FROM PARTICLES - Embodiments of the invention include particles with nucleic acid complexes, medical devices including the same and related methods. In an embodiment, the invention can include a method of making a medical device. The method can include contacting nucleic acids with cationic carrier agents to form nucleic acid complexes, adsorbing the nucleic acid complexes to porous particles to form nucleic acid complex containing particles, mixing the nucleic acid complex containing particles with a polymer solution to form a coating mixture, and applying the coating mixture to a substrate. In an embodiment, the method can include contacting nucleic acids with cationic carrier agents to form nucleic acid complexes, combining the nucleic acid complexes with a material to form nucleic acid complex containing particles in situ, mixing the nucleic acid complex particles with a polymer solution to form a coating mixture, and applying the coating mixture to a substrate. In an embodiment, the invention can include an implantable medical device including a substrate, an elution control matrix disposed on the substrate; a plurality of particles disposed within the elution control matrix, and a plurality of nucleic acid complexes disposed within the particles, the nucleic acid complexes comprising a nucleic acid and a cationic carrier agent. Other embodiments are included herein.11-12-2009
20090285890ANTIMICROBIAL PEROXIDASE COMPOSITIONS - The present invention discloses a class of compounds which have an enhancing effect on peroxidase based antimicrobial compositions. The invention relates to pharmaceutical compositions for prolonged topical use comprising enhancing agents such as methoxyphenols and substituted benzylaldehydes. Examples hereof are respectively guaiacol and vanillin.11-19-2009
20090285893TREATMENT OF HEART FAILURE IN WOMEN - A method is disclosed utilizing an androgen such as testosterone and/or a selective androgen receptor modulator for treating or delaying the further development of heart failure, and other disorders in females including manifestations of heart failure and concomitant cardiovascular and noncardiovascular disorders.11-19-2009
20110076331Use of Deuterium Oxide as an Elastase Inhibitor - The invention relates to the use of deuterium oxide (D03-31-2011
20110076330USE OF ADIPOSE TISSUE-DERIVED STROMAL CELLS IN SPINAL FUSION - The present invention encompasses methods and compositions for treating a bone condition. The isolated adipose tissue-derived stromal cell of the invention and products related thereto have a plethora of uses, including but not limited to research, diagnostic, and therapeutic applications such as in spinal fusion procedures.03-31-2011
20120269892IMPLANTABLE COMPOSITIONS AND METHODS FOR PREPARING THE SAME - Methods for forming implantable compositions are provided. In some embodiments, the methods include (i) providing a gel base, (ii) adding water and a hydrating agent to the gel base to form a mixture, (iii) reducing the water content of the mixture; and (iv) adding a delivered material before, during, and/or after step (ii) or (iii). The water content is reduced to about 5% or less by weight of the implantable composition.10-25-2012
20110076329GRAFT PROSTHESIS, MATERIAL AND METHODS - A graft prostheses (03-31-2011
20100278915COMPOSITIONS COMPRISING AN ANTIHISTAMINE, ANTITUSSIVE AND DECONGESTANT IN EXTENDED RELEASE FORMULATIONS - The invention provides oral formulations for the treatment of cold and allergy symptoms. Each formulation combines an antihistamine, an antitussive, and/or a decongestant into one extended release composition. The invention further provides for methods of making and using such formulations, as well as for methods for preventing abuse or extraction of a single drug present in an oral extended release composition comprising two or more of an antihistamine, antitussive, and/or decongestant.11-04-2010
20090291139SPARC AND METHODS OF USE THEREOF - The invention provides methods for predicting or determining the response of a mammalian tumor to a chemotherapeutic agent and for treating a mammalian tumor comprising detecting and quantifying the SPARC protein or RNA in a sample isolated from the mammal. The invention further provides kit for predicting the response of a mammalian tumor to a chemotherapeutic agent, comprising a means for the isolation of protein or RNA from the tumor, a SPARC protein or RNA detection and quantification means, control RNAs, and rules for predicting the response of the tumor based on the level of SPARC protein or RNA in tumor.11-26-2009
20100291212PHARMACEUTICAL COMPOSITION COMPRISING FGF18 AND IL-1 ANTAGONIST AND METHOD OF USE - FGF18 is known to stimulate the proliferation of chondrocytes, bone, and nervous tissue, resulting in repair of diseased tissue. When an IL-1 antagonist is administered in addition to FGF18, the effects on the IL-1 mediated disease and also, the effect on cartilage, bone, and nervous cell proliferation, are found to be greater than administration of FGF18 or the IL-1 antagonist alone. The present invention encompasses a pharmaceutical composition that combines FGF18 with IL-1 antagonist and methods of treating IL-1 mediated disease using this pharmaceutical composition.11-18-2010
20100129447NANOPARTICLES COMPRISING A CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR AND ANON-IONIZABLE POLYMER - A pharmaceutical composition comprises nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a poorly aqueous soluble non-ionizable polymer.05-27-2010
20090297603INTERSPINOUS DYNAMIC STABILIZATION SYSTEM WITH ANISOTROPIC HYDROGELS - Disclosed are embodiments of an interspinous dynamic stabilization system that can uniquely address the dynamic stabilization of a spinal segment and facet joint concurrently and that can be useful for drug delivery applications. The interspinous dynamic stabilization system comprises a relatively rigid casing and relies on the anisotropic expansion feature of specially manufactured hydrogels contained in the casing to resist and control the extension of the spine. In a surgical procedure, the casing is attached to adjacent spinous processes laterally or in an anterior-posterior direction. Dehydrated hydrogels are then inserted inside the casing, perhaps one by one in a minimally invasive manner. Upon absorption of fluid, the hydrogels swell axially in the preferred direction, eventually lifting the superior spinous process. As the casing is attached to the spinous processes, the interspinous dynamic stabilization system can also have enhanced stability against torsional and lateral bending.12-03-2009
20110200673OXIDIZED HEPARIN FRACTIONS AND THEIR USE IN INHIBITING ANGIOGENESIS - The present invention relates to a heparin fraction comprising constituents having molecular weights of from about 2,000 to about 4,000 daltons, wherein from about 1% to about 100% of hydroxyl residues of the constituents are oxidized. The present invention also relates to methods of inhibiting angiogenesis and treating an angiogenesis-mediated disorder in a subject by administering a heparin fraction comprising constituents having molecular weights of from about 2,000 to about 30,000 daltons, wherein from about 1% to about 100% of hydroxyl residues of the constituents are oxidized. Another aspect of the present invention relates to compositions including the heparin fractions of the present invention.08-18-2011
20090297602Modified Release Loxoprofen Compositions - The invention relates to a modified release composition comprising loxoprofen or a salt or derivative thereof that in operation delivers the drug in a pulsatile or continuous manner for the treatment of pain and/or inflammation. The composition may comprise a first loxoprofen component and one subsequent loxoprofen component, wherein the first loxoprofen component comprises an immediate release component and the subsequent loxoprofen component comprises a modified release component.12-03-2009
20080213367WATER SOLUBLE CONCENTRIC MULTI-WALL CARBON NANO TUBES - The present invention relates to water soluble carbon nano tubes (WSNT) which have been made function by functionalizing with carboxylic acid groups. The carbon nano tubes are isolated from hydrocarbon wax soot and then functionalized by oxidation treatment with an oxidizing agent. The WSNT can contain a pharmaceutical composition for release by a biological degradation agent of the WSNT for example 09-04-2008
20080213368Method for Stabilizing Anti-Dementia Drug - The present invention provides a method for stabilizing an anti-dementia drug in a pharmaceutical composition containing the anti-dementia drug and a high molecular weight basic substance by adding a high molecular weight acidic substance to said pharmaceutical composition. Further, the present invention provides a pharmaceutical composition containing an anti-dementia drug and a high molecular basic substance in which a high molecular weight acidic substance is contained for stabilizing the anti-dementia drug. Furthermore, the present invention provides a method for manufacturing a pharmaceutical composition which comprises steps wherein a solution or suspension containing a high molecular weight acidic substance is added to a mixture of an anti-dementia drug and a high molecular weight basic substance for the sake of stabilizing the anti-dementia drug.09-04-2008
20090169624Nano-emulsion technology for drug elution - Embodiments of the invention provide to apparatuses and media used in drug elution studies and methods for making and using them. One embodiment of the invention is a drug elution method that can be used for in-vitro studies of a matrix impregnated with a compound such as a drug blended polymer matrix. Such methods and materials can be used for example to assess and control the manufacturing process variability of drug eluting implantable devices such as cardiac leads.07-02-2009
20080241245Drug delivery device for providing local analgesia, local anesthesia or nerve blockage - The invention relates to a drug delivery device for providing local analgesia, local anesthesia or nerve blockade at a site in a human or animal in need thereof, the device comprising a fibrillar collagen matrix; and at least one drug substance selected from the group consisting of amino amide anesthetics, amino ester anesthetics and mixtures thereof, the at least one drug substance being substantially homogeneously dispersed in the collagen matrix, and the at least one drug substance being present in an amount sufficient to provide a duration of local analgesia, local anesthesia or nerve blockade which lasts for at least about one day after administration.10-02-2008
20110206768MEDICAL PREPARATION - A bone matrix, including: a bone matrix material, which has had organic material removed, and a replacement material that has replaced the organic material, the bone matrix characterised in that the bone matrix is formed from a single piece of bone.08-25-2011
20100129448TOPICAL HYDROGEL COMPOSITION - Compositions for topical application to the skin and/or a wound are disclosed. In some embodiments, the compositions include a suspension or dispersion of particles of at least one poorly soluble drug chelated or otherwise complexed with a metal salt. The compositions may further contain at least one stabilizer, at least one excipient, and at least one physiologically acceptable carrier. Methods for making such compositions, pharmaceutical formulations containing such compositions, and methods of treatment utilizing such compositions are also disclosed.05-27-2010
20080274188Oral Vehicle For Systemic Pharmaceuticals - Systemic drug delivery includes boluses of a semi-solid agar gel, each containing active ingredients, packed singly or in co-operating sets in blister packs, or loose in a container. When placed in the mouth the bolus is disrupted, comes apart, and releases the active ingredients. Sialogogues, flavours, and other additives assist in swallowing. Grains of the active ingredients may be encapsulated inside harder gel capsules. Active ingredients include over-the-counter medications and prescription medications. Applications include self-medication particularly in water—free situations such as public transport, medication for children, stroke victims or the aged.11-06-2008
20080274189Organic Compounds Comprising a Glycopyrr Onium Salt - Medicaments comprising (A) an antimuscarinic agent and (B) a corticosteroid for the treatment of inflammatory or obstructive airways diseases.11-06-2008
20080274187Hard capsule composition and method of use - A hard shell capsule composition and method which is gelatin, BSE, plasticizer and preservative free, which is less sensitive to temperature, humidity and climate changes during manufacture and storage while remaining dimensionally and microbially stable.11-06-2008
20080274185Shape and Dimension Maintenance of Soft Tissue Grafts by Stem Cells - Methods and compositions for de novo and in vivo synthesis of soft tissue in predefined shape and dimensions from adult mesenchymal stem cells (MSC11-06-2008
20080274183Thermoplastic articles containing a medicament - A composition suitable for making a fiber or a film includes a biocompatible primary polymer matrix which forms a continuous phase of the composition and an active agent forming a substantially discontinuous phase of the composition. The biocompatible primary polymeric matrix has a glass transition temperature of less than about 100° C. and is impermeable to the active agent. A process for making an article, such as a fiber or a film, includes the steps of providing a polymer blend comprising a polymer matrix having from 99.9 weight % to about 30 weight % of a biocompatible polymeric matrix and from about 0.1 to about 70 weight % of an active agent, wherein the weight % are based on the total weight of the of the polymeric matrix and active agent, and extruding the polymer blend into the article.11-06-2008
20120294943EXTENDED-RELEASE FORMULATION FOR REDUCING THE FREQUENCY OF URINATION AND METHOD OF USE THEREOF - Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of a pharmaceutical composition comprising an analgesic agent formulated for extended-release.11-22-2012
20080279939EXTRACELLULAR MATRIX COMPOSITIONS FOR TISSUE REGENERATION - The invention is compositions of extracellular matrix that comprise mammalian extracellular matrix from two or more tissue sources in a mammal. The invention also includes methods of using these compositions to regenerate tissue or generate new tissue at sites of defects or wounds in mammals.11-13-2008
20080279940Microemulsions of Cannabinoid Receptor Binding Compounds - The present invention relates to a novel spontaneously dispersible pharmaceutical composition, e.g. a microemulsion preconcentrate, in which the active drug substance is a cannabinoid receptor binding compound, in particular a corresponding naphthalene derivative, that is useful, e.g., for the treatment or prevention of chronic pain.11-13-2008
20100003325COMPOSITION AND METHOD FOR TREATMENT OF WARTS - Provided is a composition comprising 5-FU and salicylic acid. This composition is useful as a treatment for warts. As opposed to conventional compositions and methods, this composition need only be applied once a day. Also provided are methods for the preparation and use of the composition for treatment of warts.01-07-2010
20100209508Substituted Phenylphosphates as Mutual Prodrugs of Steroids and -Agonists for the Treatment of Title Pulmonary Inflammation and Bronchoconstriction - A mutual prodrug of a corticosteroid and a substituted phenylphosphate (β-agonist derivative) for formulation for delivery by aerosolization to inhibit pulmonary inflammation and bronchoconstriction is described. The mutual prodrug is preferably formulated in a small volume solution (10-500 μL) dissolved in a quarter normal saline having pH between 5.0 and 7.0 for the treatment of respiratory tract inflammation and bronchoconstriction by an aerosol having mass median average diameter predominantly between 1 to 5μ, produced by nebulization or by dry powder inhaler.08-19-2010
20110008436Silk Fibroin Hydrogels and Uses Thereof - The present specification provides for methods for purifying fibroins, purified fibroins, methods of conjugating biological and synthetic molecules to fibroins, fibroins conjugated to such molecules, methods of making fibroin hydrogels, fibroin hydrogels and fibroin hydrogel formulations useful for a variety of medical uses, including, without limitation uses as bulking agents, tissue space fillers, templates for tissue reconstruction or regeneration, cell culture scaffolds for tissue engineering and for disease models, surface coating to improve medical device function, or drug delivery devices.01-13-2011
20080274184Ecm-Based Graft Material - This invention is directed to graft materials comprising an extracellular matrix (ECM) and therapeutic agents. This invention is also directed to methods of using the graft materials for healing of damaged or diseased tissues on a patient's body.11-06-2008
20080268051HIGH VISCOSITY MACROMOLECULAR COMPOSITIONS FOR TREATING OCULAR CONDITIONS - Anti-angiogenesis compositions, and methods of using such compositions, useful for injection into the vitreous of human eyes are provided. Such compositions include MAAC solutions or particles present in a therapeutically effective amount, a viscosity-inducing component, and an aqueous carrier component. The compositions have viscosities at about 25° C. of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity at 25° C. is in the range of from about 80,000 cps to about 300,000 cps.10-30-2008
20080268053COLLAGEN CARRIER OF THERAPEUTIC GENETIC MATERIAL, AND METHOD - A collagen matrix material is charged with a cell growth-promoting derived nucleic acid sequence. The nucleic acid sequence-charged collagen matrix material may be utilized in a method of promoting regeneration of surface cartilage of a joint. In the method, an area of injury is covered with the nucleic acid sequence-charged collagen matrix material, the collagen matrix material is fixed over the area to be treated, and the area is allowed to heal.10-30-2008
20100143477Methods and Compositions for Stimulating the Proliferation or Differentiation of Stem Cells with Substance Por an Analog Thereof - Compositions and methods are provided for stimulating cell proliferation and differentiation with substance P or a substance P analog. In one embodiment, the methods provide for stimulating or promoting stem cell differentiation by contacting a stem cell with substance P or a substance P analog. In another embodiment, the methods provide for administering to subject an effective amount of substance P or a substance P analog to treat an illness, disease or disorder.06-10-2010
20090181087Use of human cord blood-derived pluripotent cells for the treatment of disease - The present invention features methods of organ tissue regeneration using pluripotent cells derived from umbilical cord blood, compositions of these pluripotent cells, methods for further transforming these cells, and uses for these transformed cells.07-16-2009
20090181089PH-Controlled Pulsatile Delivery System, Methods for Preparation and Use Thereof - The invention relates to delivery systems that allow for the pulsatile release of a substance, such as a drug, in response to a change in pH. More specifically, it relates to drug administration to the GI tract, in particular to site-specific intestinal drug delivery via the oral route. Provided is a pH-controlled pulsatile release system (PPRS) comprising a core surrounded by a coating layer, wherein said core comprises an active substance and wherein said coating layer comprises a pH-sensitive coating material wherein a swellable agent is embedded. Said swellable agent is capable of taking up at least 1.1 times, preferably at least 5 times, more preferably at least 10 times its weight in water. Also provided is a pharmaceutical composition comprising a PPRS, in particular a colon-specific PPRS.07-16-2009
20100143476COMPOSITION FOR STIMULATING FORMATION OF VASCULAR STRUCTURES - Cell based compositions and methods are provided for inducing the formation of vascular structures in a warm blooded vertebrate. In one embodiment the composition comprises purified endothelial progenitor cells and adipose stromal cells and the method of stimulating the formation of vascular structures comprises the steps of implanting the composition in a host organism.06-10-2010
20090181090Protein-Based Carrier System for Overcoming Resistance in Tumour Cells - Nanoparticles, the particle matrix of which is based on at least one protein and has at least one active agent embedded therein and methods of producing the nanoparticles with at least one active agent embedded in the protein matrix are disclosed. The use of the nanoparticles for the treatment of tumours, in particular for the treatment of tumours which are resistant to chemical medicaments is also disclosed.07-16-2009
20110045072PHARMACEUTICAL COMPOSITION, DRESSING AND METHOD FOR TREATING SKIN LESION, INTERMEDIATE COMPOSITION AND PROCESS FOR PREPARING SAID DRESSING, AND USE OF CERIUM SALT ASSOCIATED WITH A COLLAGEN MATRIX - The present invention refers to a pharmaceutical composition for treating skin lesion, comprising a cerium salt on a collagen matrix and a dermatologically acceptable carrier. In addition, the present invention also provides an intermediate composition for preparing a dressing for treating skin lesion and a process for preparing such dressing by lyophilizing said intermediate composition. The present invention also refers to a dressing for treating skin lesion, comprising a cerium salt on a collagen matrix, as well as to the use of a cerium salt associated with collagen in the preparation of the pharmaceutical composition or dressing according to the present invention. Another embodiment of the present invention is a method for treating skin lesion by applying such pharmaceutical composition or dressing on said skin lesion. The composition or dressing of the present invention can be used in topical applications in a variety of lesion types, such as skin lesions involving the release of toxins related to microbial proteins on human or animal organisms, or those so-called HSPs (heat shock proteins); burns which involve burned skin toxin formation or LPC (lipoprotein complex); chronically ulcerate skin lesions in which there is an overproduction of proteinase; skin lesions of difficult resolution, in which control of exudate overproduction is required; and critically infected or colonized skin lesions.02-24-2011
20110217377Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents - The present disclosure is directed in part to a biocompatible nanoparticle composition comprising a plurality of non-colloidal long circulating nanoparticles, each comprising a α-hydroxy polyester-co-polyether and a therapeutic agent, wherein such disclosed compositions provide a therapeutic effect for at least 12 hours.09-08-2011
20090136574COMPOSITIONS COMPRISING AT LEAST ONE AQUEOUS PHASE AND AT LEAST ONE FATTY PHASE WHICH COMPRISES AVERMECTIN COMPOUNDS - Pharmaceutical/dermatological emulsions containing at least one avermectin compound, notably ivermectin, include at least one fatty phase and at least one aqueous phase, the at least one avermectin compound being solubilized in the fatty phase, which emulsions are useful for the treatment of a variety of dermatological conditions/afflictions, in particular rosacea.05-28-2009
20090186089 NON-POROUS FILM FOR CULTURING CELLS - The invention relates to collagenous polypeptide films on which cells are cultivated. In particular the invention relates to such films that are used to treat wounds such as severe burns or physical or chemical injury. The invention also related to methods for producing such films.07-23-2009
20110142936IMPLANTS AND BIODEGRADABLE FIDUCIAL MARKERS - Implantable materials may be used in an iatrogenic site. Applications include radioopaque materials for fiducial marking.06-16-2011
20090162438COMPOSITIONS AND METHODS FOR JOINING NON-CONJOINED LUMENS - Disclosed are compositions, methods, and kits for joining together non-conjoined lumens in a patient's body including vascular lumens. More particularly, in various aspects, this invention provides compositions, methods, and kits for joining such non-conjoined lumens, including small lumens typically requiring microsurgical technique06-25-2009
20090162436Compositions and methods for repair of tissues - Biomaterials providing sustained release of growth factor for repair of tissues such as bone and cartilage are disclosed. The biomaterials comprise a proteoglycan derived from domain I of perlecan and a growth factor, and, optionally, collagen.06-25-2009
20090186088INHALABLE DRUG - A process for preparation of particles of an inhalable drug is described. The process comprises combining a first liquid and a second liquid in a region of high shear, whereby the first liquid and the second liquid interact to form the particles of the drug. One of the first and second liquids comprises the drug or a precursor thereof. In the case where one of the liquids comprises the precursor, the other of the first and second liquids comprises a reagent which reacts with the precursor under high shear conditions to form particles of the drug. In the case where one of the liquids comprises the drug, the other of the first and second liquids comprises a liquid which, when mixed with the liquid containing the drug under high shear, forms particles of the drug.07-23-2009
20090136572EMULSIFIED COMPOSITION FOR DILUTION AND CANCER VACCINE COMPOSITION - Provided is an emulsified composition for diluting a cancer antigen peptide or a dimer thereof. Also provided is a novel cancer vaccine composition or specific CTL inducer that efficiently induces CTL irrespective of the type of cancer antigen peptide when mixing the emulsified composition for dilution and a water phase comprising a cancer antigen peptide or a dimer thereof.05-28-2009
20080279941METHOD OF TREATING JOINTS WITH HYDROGEL IMPLANTS - Implantable biomaterials, particularly hydrogel substrates with porous surfaces, and methods for enhancing the compatibility of biomaterials with living tissue, and for causing physical attachment between biomaterials and living tissues are provided. Also provided are implants suitable for load-bearing surfaces in hard tissue repair, replacement, or augmentation, and to methods of their use. One embodiment of the invention relates to an implantable spinal disc prosthesis.11-13-2008
20090208577Inkjet Printing of Tissues and Cells - Provided herein is an apparatus for printing cells which includes an electrospinning device and an inkjet printing device operatively associated therewith. Methods of making a biodegradable scaffold having cells seeded therein are also provided. Methods of forming microparticles containing one or more cells encapsulated by a substrate are also provided, as are methods of forming an array of said microparticles.08-20-2009
20090022801Compositions and Methods for Promoting the Healing of Tissue of Multicellular Organisms - Methods are provided for promoting the healing of tissue of a multicellular organism. The methods can include administering a therapeutically effective amount of a polysulfonated material in a liquid mixture to reduce one or both of inflammation and cancerous cell growth. The methods may alternatively or additionally include internally administering a therapeutically effective amount of a polysulfonated material associated with a solid material to reduce one or both of inflammation and cancerous cell growth. Compositions for healing the tissue of a multicellular organism are provided that can include a sulfonated material in a liquid mixture, as well as solid particles.01-22-2009
20090053312Methodology and Composition for a Skin Lubricant - One possible embodiment of the invention could be a method of lubricating human skin comprising of the following steps, but not necessarily in the order shown: providing a composition of a gel formed from cross-linking siloxane polyethers, the gel being further micronized in one or more low viscosity, silicone fluids; applying an effective amount of the composition to a portion of the exterior surface of a skin; and moving the portion within at least a part of an elastic and flexible skin contact article.02-26-2009
20090053311Pharmaceutical Compositions for Treating or Preventing Bone Conditions - Provided herein is a pharmaceutical composition for treating, preventing or ameliorating a bone or cartilage condition and methods of making and using the same.02-26-2009
20090081292Oil-containing solid product and process for producing the same - An oil-containing solid in which liquid oil is contained in a large amount and from which oil seepage is slight; and a process for producing the same. The oil-containing solid is produced by impregnating a porous solid with a W/O emulsion. Further, use is made of the W/O emulsion having a water-soluble gellable substance incorporated in the water phase thereof. Consequently, the water-soluble gellable substance is converted to a gel in pores of the porous solid, thereby enhancing the liquid oil leakage preventing effect of the W/O emulsion.03-26-2009
20090202638BMP GENE AND FUSION PROTEIN - This invention relates to BMP fusion genes, BMP fusion proteins, and methods for making BMP fusion genes and BMP fusion proteins. The invention further relates to methods for treatment using BMP fusion genes and BMP fusion proteins. Additionally, the invention relates to BMP fusion gene and BMP fusion protein pharmaceutical compositions. 08-13-2009
20090220601Autologous Oral Grafts - The present invention provides autologous oral grafts that may be used, for example, to treat oral cavity disease characterized by inflamed or damaged oral mucosa tissue, or to treat oral caries characterized by damaged enamel, dentin, or cementum. In certain embodiments, the autologous oral grafts comprise a biocompatible matrix and cultured oral cells (e.g., keratinocytes) from the patient to be treated. In certain embodiments, the cultured oral cells comprise an expression vector comprising a nucleic acid sequence encoding a therapeutic polypeptide configured to at least partially reduce the patient's oral mucosa tissue inflammation or damage. In particular embodiments, the oral disease is characterized by infiltration of the oral mucosa with activated, maturing dendritic cells.09-03-2009
20090220600ANTIMICROBIAL FILMS - A film consisting of a titanium dioxide host matrix comprising silver oxide nanoparticles.09-03-2009
20090117187METHOD OF TREATING OR PREVENTING TISSUE DETERIORATION, INJURY OR DAMAGE DUE TO CONGESTIVE HEART FAILURE - A method of treatment for treating, preventing, inhibiting or reducing tissue deterioration, injury or damage due to congestive heart failure disease, or for restoring tissue adversely affected by said disease, in a subject, includes administering to a subject an effective amount of a composition including a peptide agent including amino acid sequence LKKTET or LKKTNT, a conservative variant thereof, or a peptide agent that stimulates production of an LKKTET or LKKTNT peptide, or a conservative variant thereof, in the tissue.05-07-2009
20100015228CONTROLLED RELEASE ION CHANNEL MODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS - Disclosed herein are compositions and methods for the treatment of otic disorders with ion channel modulators. In these methods, the ion channel modulator compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the ion channel modulator compositions and formulations onto the auris interna target areas, or via perfusion into the auris interna structures.01-21-2010
20120195968CONTROLLED-RELEASE MELATONIN COMPOSITIONS AND RELATED METHODS - This disclosure relates to controlled-release melatonin compositions and related methods. In one embodiment, a controlled-release medicament composition comprises melatonin dispersed in a controlled melatonin release portion comprising a polymer matrix, the polymer matrix adapted to encapsulate the melatonin in a melatonin solubility enhancing pH environment and to maintain the melatonin solubility enhancing pH environment when the composition is located in a melatonin solubility diminishing pH environment for allowing an effective amount of melatonin to be released into the melatonin solubility diminishing pH environment.08-02-2012
20090317468MULTICOMPARTMENT GRANULATE FORMULATIONS FOR ACTIVE SUBSTANCES - The invention relates to molded article that contains active substances and comprises at least two compartments that have a different material composition. Each compartment is independently provided with at least one active substance that is contained in a matrix. Each matrix encompasses at least one filler at a concentration of ≧20 percent by weight to ≦100 percent by weight relative to the total weight of the respective matrix. The invention further relates to a method for producing such molded articles as well as the use thereof.12-24-2009
20100015226BIORESORBABLE HYDROGEL - The invention relates to a water-swellable, hydrophilic, physically-crosslinked hydrogel which can slowly disintegrate in an aqueous medium. The inventive hydrogel essentially consists of albumin blood proteins which are bound in the form of a gel in a basic medium. The invention also relates to the use of said hydrogel as a bioresorbable separation membrane and to a method of preparing same.01-21-2010
20100178343STORAGE-STABLE LAMINATE SEGMENTS - The invention relates to laminate segments equipped or coated with an adhesive matrix, particularly transdermal therapeutic systems having formulations strongly tending to leak adhesive. The inventive laminate segments include a matrix, with or without a back layer, a protective layer on the adhesive side of the matrix, provided with a cut as a peel-off aid, and a cover film partially coated with adhesive, applied to the protective film, which overlaps the cut in the protective film using the adhesive-free part thereof The cover film prevents a leakage of the adhesive through the cut, and therefore a gluing together of the laminate segments to the packaging material thereof, without having an adverse effect on the function of the cut as a peel-off aid. Such laminate segments can be produced without the use of any intermediate carriers.07-15-2010
20090117188Methods of Augmenting or Repairing Soft Tissue - Methods of repairing or augmenting soft tissue in a subject are described. The methods include injecting into a subject composition comprising a biodegradable, polymerizable macromer, the macromer comprising a water soluble polymer modified with one or more biodegradable moieties; and polymerizing the macromer to provide a hydrogel, thus repairing or augmenting the soft tissue.05-07-2009
20090081293SUSTAINED RELEASE OF APO A-I MIMETIC PEPTIDES AND METHODS OF TREATMENT - A method including advancing a delivery device through a lumen of a blood vessel to a particular region in the blood vessel; and introducing a composition including a sustained-release carrier and an apolipoprotein A-I (apo A-I) synthetic mimetic peptide into a wall of the blood vessel at the particular region or a perivascular site, wherein the peptide has a property that renders the peptide effective in reverse cholesterol transport. A composition including an apolipoprotein A-I (apo A-I) synthetic peptide, or combination of an apo A-I synthetic mimetic peptide and an Acyl CoA cholesterol: acyltransferase (ACAT) inhibitor in a form suitable for delivery into a blood vessel, the peptide including an amino acid sequence in an order reverse to an order of various apo A-I mimetic peptides, or endogenous apo A-I analogs, or a chimera of helix 1 and helix 9 of endogenous apo A-I.03-26-2009
20100183719Surgical Applications for BMP Binding Protein - The present invention relates to the clinical application of BBP, alone or in combination with other growth factors, for use in bone healing applications, such as spinal surgery. Additional applications include use in orthopedic implantable prostheses and implantation into other surgical sites (e.g., surgical reconstruction, regional osteopenia, etc.) where bone is desired.07-22-2010
20100260846PARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND RELATED DEVICES AND METHODS - Embodiments of the invention include devices and methods for the release of nucleic acid complexes. In an embodiment the invention includes a nucleic acid delivery particle. The delivery particle can include a polymeric matrix including a polyethyleneglycol containing copolymer and a nucleic acid complex disposed within the polymeric matrix. The nucleic acid complex can include a nucleic acid and a carrier agent. In an embodiment the invention includes a medical device including a first polymeric matrix comprising a first polymer and a plurality of nucleic acid delivery particles disposed within the first polymeric matrix. The medical device can be configured to release the nucleic acid complex when the medical device is implanted within a subject. Other embodiments are included herein.10-14-2010
20100260843REGENERATION AND REPAIR OF NEURAL TISSUE USING POSTPARTUM-DERIVED CELLS - Cells derived from postpartum umbilicus and placenta are disclosed. Pharmaceutical compositions, devices and methods for the regeneration or repair of neural tissue using the postpartum-derived cells are also disclosed.10-14-2010
20100260847TISSUE MATRICES COMPRISING PLACENTAL STEM CELLS - A method of manufacturing a tissue matrix for implantation into a patient is disclosed. The method sets forth collecting embryonic stem cells from a placenta which has been treated to remove residual cord blood and seeding the collected stem cells onto or into a tissue matrix. The seeded tissue matrix is then implanted on or into a patient. The seeded tissue matrix made by the method of the present invention is also disclosed.10-14-2010
20090098204TISSUE IMPLANTS AND METHODS FOR MAKING AND USING SAME - The invention provides biocompatible, biodegradable calcium sulfate matrices containing calcium sulfate activated platelets for use in tissue formation. The matrices are particularly useful in stimulating hard tissue, for example, bone formation. The matrices may also further include a growth factor and/or a transfectable gene, the inclusion of which may be useful in stimulating the growth of tissue of interest.04-16-2009
20100183720Hetero-assembled hydrogels - A two-component, molecular-recognition gelation strategy that enables cell encapsulation without the need for environmental triggers is provided. The two components, which in one example contain WW and polyproline-rich peptide domains that interact via hydrogen bonds, undergo a sol-gel phase transition upon simple mixing. Hence, physical gelation is induced by the mixing of two components at constant environmental conditions, analogous to the formation of chemically crosslinked epoxies by the mixing of two components. Variations in the molecular-level design of the two components are used to predictably tune the association energy and hydrogel viscoelasticity. These hetero-assembly physical hydrogels encapsulate neural progenitor cells at constant physiological conditions within 10 seconds to create uniform 3D cell suspensions that continue to proliferate, differentiate, and adopt well-spread morphologies.07-22-2010
20100221341Alanine-Based Peptide Hydrogels - The present invention includes a method of preparing a hydrogel of a selected viscosity. The present invention further includes a method of promoting controlled release of a biomolecule into a medium using a hydrogel of a selected viscosity.09-02-2010
20110059174PKCdelta REGULATES NEUROINFLAMMATORY EVENTS - This invention relates to methods and pharmaceutical compositions for regulating the levels of proinflammatory substances released from activated microglia using a protein kinase C delta (PKCd) inhibitor. In particular, it relates to decreasing the levels of proinflammatory substances produced within the microglial cells or released from activated microglical cells or both. Accordingly, the invention provides for the treatment of diseases, disorders, and conditions where neuroinflammation is implicated. The invention also relates to methods of using PKCd inhibitors and pharmaceutical compositions to treat diseases, disorders, and conditions associated with activated microglia.03-10-2011
20110059173COMPOSITIONS AND METHODS FOR PROMOTING WOUND HEALING AND TISSUE REGENERATION - Provided herein are compositions and methods for use in promoting wound healing and tissue regeneration following tissue injury in a subject.03-10-2011
20110059172THERAPEUTIC COMPOSITIONS - Therapeutic compositions containing therapeutic agents and poly(beta-amino esters) or polymers thereof are described. These tertiary amine-containing polymers are preferably biodegradable and biocompatible. Nanoparticles and microparticles containing polymer/therapeutic agent complexes are also described.03-10-2011
20100215746PREVENTION OF CISPLATIN INDUCED DEAFNESS - The present invention relates to compositions and methods for the protection and restoration of hearing. In particular, the present invention relates to methods and compositions for the prevention of chemical (e.g., cisplatin) induced deafness. The present invention thus provides methods of improving the outcome of subjects treated with cisplatin.08-26-2010
20100226982Stabilized Active Ingredient Composition - The invention relates to a stabilized active ingredient composition comprising at least one carrier material and at least one active ingredient present in stabilized form, and at least one agent for forming the active ingredient from the stabilized form upon addition of an aqueous phase to the composition, wherein the composition is obtained by freeze drying, a process for producing the composition as well as the use of the composition.09-09-2010
20130216620EXTENDED-RELEASE FORMULATION FOR REDUCING THE FREQUENCY OF URINATION AND METHOD OF USE THEREOF - Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of a pharmaceutical composition comprising an analgesic agent formulated for extended-release.08-22-2013
20100239670Topical Composition Method for Treating Urinary Stress Incontinence - There is provided a method and composition for treating urinary stress incontinence based upon the topical administration of an alpha-adrenoceptor agonist, such as phenylephrine. A daily dosage of 20 mg to 2000 mg is suitable, and the composition may conveniently be applied as a cream or gel to the vaginal or peri-urethral area.09-23-2010
20100151026NOVEL STRAIN OF LACTOBACILLUS CRISPATUS - The invention provides a naturally occurring strain of 06-17-2010
20100247651PLATELET-DERIVED GROWTH FACTOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OSTEOCHONDRAL DEFECTS - The present invention provides compositions and methods for treating an osteochondral defect. In one embodiment, provided is a composition for treating an osteochondral defect comprising a biphasic biocompatible matrix and platelet derived growth factor (PDGF), wherein the biphasic biocompatible matrix comprises a scaffolding material and wherein the scaffolding material forms a porous structure comprising an osseous phase and a cartilage phase. In another embodiment, also provided is a method for treating an osteochondral defect in an individual comprising administering to the individual an effective amount of a composition comprising a biphasic biocompatible matrix and PDGF to at least one site of the osteochondral defect, wherein the biphasic biocompatible matrix comprises a scaffolding material and wherein the scaffolding material forms a porous structure comprising an osseous phase and a cartilage phase.09-30-2010
20100221343COMPOSITIONS AND METHODS OF MAKING BRITTLE-MATRIX PARTICLES THROUGH BLISTER PACK FREEZING - The present invention includes compositions and methods for treating and delivering medicinal formulations using an inhaler. The composition includes a space filled flocculated suspension having one or more flocculated particles of one or more active agents and a hydrofluoroalkane propellant. A portion of the one or more flocculated particles is templated by the formation of hydrofluoroalkane droplets upon atomization and the templated floc compacts upon the evaporation of the hydrofluoroalkane propellant to form a porous particle for deep lung delivery.09-02-2010
20100221340METHOD AND COMPOSITIONS FOR TREATMENT OR PREVENTION OF INFLAMMATORY CONDITIONS - Pharmaceutical compositions and methods for treating or preventing an inflammatory condition in a patient are disclosed. The pharmaceutical compositions and methods include the use of vincamine or a vincamine derivative, either alone or in combination with one or more additional therapeutic agents, including a steroid (preferably a corticosteroid), an angiotensin II receptor (type 1) antagonist, an angiotensin-converting enzyme (ACE) inhibitor, and a non-steroidal anti-inflammatory drug.09-02-2010
20100221342COMPOSITION AND METHOD OF TREATING A SORE THROAT - A composition comprising an antacid, and a local, topical anesthetic. The composition is used to relieve pain or discomfort associated with a sore throat, and therefore, the invention is also directed to a method of alleviating the pain or discomfort associated with a sore throat comprising instructing a human to orally administer the composition.09-02-2010
20120141587COMPOSITIONS AND METHODS FOR TREATMENT OR PREVENTION OF POST-OPERATIVE ORGAN OR TISSUE INFLAMMATION - Compositions, methods and kits for treatment or prevention of post operative organ or tissue inflammation are provided. The compositions contain an effective amount for local delivery, of an anti-inflammatory agent, alone or in combination with other pharmacologic agents, embedded within a polymeric matrix or gel. The polymeric matrix or gel may be a formed from natural or synthetic precursor components. The compositions are applied locally to an organ or tissue for the treatment or prevention of post inflammation resulting from surgical intervention.06-07-2012
20110129534REDUCTION OF DERMAL SCARRING - Methods and compositions for reducing or inhibiting dermal scarring by expressing p2106-02-2011
20100203139NANOEMULSION THERAPEUTIC COMPOSITIONS AND METHODS OF USING THE SAME - The present invention relates to therapeutic nanoemulsion compositions and to methods of utilizing the same. In particular, nanoemulsion compositions are described herein that find use in the treatment and/or prevention of infection (e.g., respiratory infection (e.g., associated with cystic fibrosis)), in burn wound management, and in immunogenic compositions (e.g., comprising a 08-12-2010
20090169625Electrostatically Controlled Hydrogels - The compositions and methods disclosed herein pertain to the manufacture and use of hydrogels. The disclosed compositions and methods pertain to hydrogels capable of induction by a variety of methodologies, such as by pH, salt and/or mixing. Such hydrogels are capable of self- or co-assembly and while doing so, may entrap a variety of bioactive agents in their native form, such as proteins, DNA, RNA and the like. The hydrogels of the present invention also demonstrate rapid sheer-responsiveness. The hydrogels of the present invention are biodegradable, biocompatible and useful as a biomaterial or drug-delivery device.07-02-2009
20090162437Modified self-assembling peptides - The present invention provides a self-assembling peptide comprising: (a) a first amino acid domain that mediates self-assembly, wherein the domain comprises alternating hydrophobic and hydrophilic amino acids that are complementary and structurally compatible and self-assemble into a macroscopic structure when present in unmodified form; and (b) a second amino acid domain that does not mediate self-assembly in isolated form, wherein the second amino acid domain comprises at least one minimal biologically active sequence. Such self-assembling peptides are described herein as “modified self-assembling peptides.” The present invention also provides pharmaceutical compositions, kits and matrices comprising a modified self-assembling peptide, and methods of using and making such compositions, kits and matrices.06-25-2009
20090110730Loadable Polymeric Particles for Marking or Masking Individuals and Methods of Preparing and Using the Same - The present invention relates to the use of certain microspheres, nanospheres, and other structures to provide a method of marking or masking identifying marks in individual biological hosts. Biological hosts for the present invention may include humans, other animals, or plants. Such methods may be used to sense, signal, track, mark, or identify individual biological hosts. Microspheres, nanospheres, and other structures of the present invention may be implanted, injected, ingested, or attached to individual biological hosts. Microspheres, nanospheres, and other structures of the present invention comprise poly[bis(trifluoroethoxy)phosphazene] and/or a derivative thereof which may be present throughout the particles or within an outer coating of the particles. The microspheres, nanospheres, and other structures may also comprise a core having a hydrogel which may further comprise one or more dyes or other chromophoric agents covalently bound permanently to the hydrogel core material. The microspheres, nanospheres, and other structures and/or the hydrogel core may further comprise radio frequency or other electronic chips or nanochips, capable of transmitting and/or receiving electronic signals from external transmitters and/or receivers.04-30-2009
20110129531Dermal Fillers Comprising Silk Fibroin Hydrogels and Uses Thereof - The present specification provides compositions useful as dermal fillers and methods using such compositions to treat a condition of skin.06-02-2011
20110129532METHOD AND MEANS FOR TREATING VIRAL DISEASE, IN PARTICULAR HIV/AIDS - A method of treating viral disease, in particular HIV/AIDS, comprises concomitant administration of GnRH or GnRH analog including pharmaceutically acceptable salts thereof in an amount sufficient to maintain in the patient an elevated unphysiological plasma level, in particular a castrating plasma level, of GnRH or GnRH analog, and of one or several natural, semi-synthetic or synthetic sexual hormones in a amount sufficient to compensate for the castration effect of GnRH or GnRH analog. Also disclosed is a corresponding pharmaceutical composition and a composition kit, and uses thereof.06-02-2011
20100297234METHOD OF USING AN EXTRACELLULAR MATRIX TO ENHANCE CELL TRANSPLANT SURVIVAL AND DIFFERENTIATION - Provided is a matrix for promoting survival and differentiation of cells transplanted thereon, comprising a base matrix and a cell-made matrix thereon. Methods and means for making and using same are also provided.11-25-2010
20110117195METHOD FOR IMPROVING MYOCARDIAL INFARCTION BY INTRAMYOCARDIAL OR TRANSENDOCARDIAL INJECTION OF PEPTIDE NANOFIBERS - A method for improving myocardial infarction by intramyocardial or transendocardial injection of peptide nanofibers is disclosed. The method firstly provides a pharmaceutical composition having a biologically compatible peptide hydrogel formed by a plurality of self-assembling peptide nanofibers and selectively having at least one type of autologous stem cells mixed with the self-assembling peptide nanofibers, and then the pharmaceutical composition is administered to an entire infarcted area of myocardium tissue with myocardial infarction by intramyocardial or transendocardial injection. Thus, adverse cardiac remodeling and dysfunction after acute infraction can be attenuated, while the therapeutic myocardial angiogenesis, the myocardial capillary density and potential myogenesis can be enhanced.05-19-2011
20100303909PREPARATION FOR TREATING HEART DISEASE USED IN CELL THERAPY - An object of the present invention is to establish a cell transplantation method which can markedly improve the survival of grafted pluripotent stem cells and the efficiency of cardiomyocyte regeneration in cell therapy using pluripotent stem cells derived from heart tissue and can treat heart disease further effectively. Specifically, according to the present invention, enhancement in the survival of grafted pluripotent stem cells and significant improvement in the efficiency of cardiomyocyte regeneration are achieved by using, in combination, pluripotent stem cells derived from heart tissue and a hydrogel containing a basic fibroblast growth factor (bFGF) in cell therapy for heart disease.12-02-2010
20130136796Acellular Bioabsorbable Tissue Regeneration Matrices - The present invention provides methods and compositions useful in the regeneration of damaged, lost and/or degenerated tissue in humans and animals. In certain embodiments, the present invention provides an acellular bioabsorbable tissue regeneration matrix, methods of making such a matrix, and methods of using such a matrix for the regeneration of damaged, lost and/or degenerated tissue. In certain embodiments, methods and compositions of the present invention are useful in the treatment of damaged, lost and/or degenerated nerve tissue.05-30-2013
20100310658Electroprocessed Fibrin-Based Matrices and Tissues - The invention is directed to formation and use of electroprocessed fibrin as an extracellular matrix and, together with cells, its use in forming engineered tissue. The engineered tissue can include the synthetic manufacture of specific organs or tissues which may be implanted into a recipient. The electroprocessed fibrin may also be combined with other molecules in order to deliver the molecules to the site of application or implantation of the electroprocessed fibrin. The fibrin or fibrin/cell suspension is electrodeposited onto a substrite to form the tissues and organs.12-09-2010
20100310656Immunotherapy and prevention of autoimmune hepatitis - The invention is within the field of immunology and microbiology, more specifically the field of virology and is related to immunotherapy and prophylaxis of hepatitis and autoimmune diseases. The composition useful for these purposes is disclosed, including the methods of making and using said composition.12-09-2010
20090246278USE OF ESSENTIAL OILS TO REDUCE BENZODIAZEPINE REQUIREMENTS DURING MEDICAL PROCEDURES - A method to reduce or eliminate the need for medicaments such as benzodiazepine and narcotics in noxious medical procedures, such as intravenous needle insertion, mechanical ventilation and intubation procedures, includes topically administering to the patient an effective amount of an essential oil composition including at least one essential oil selected from Roman Chamomile (10-01-2009
20110111032MANUFACTURING METHOD OF COLLAGEN GEL COMPOSITION FOR BONE REGENERATION - Disclosed herein is a method for preparing a collagen gel composition for bone regeneration comprising collecting bone marrow from animal tissues and isolating nucleated cells from the bone marrow; and mixing the nucleated cells and a bio-matrix composed of type I collagen and apatite.05-12-2011
20110111031Drug Delivery Platforms Comprising Silk Fibroin Hydrogels and Uses Thereof - The present specification provides drug delivery platforms useful for the controlled release of a compound over time in an individual.05-12-2011
20110111030Method of Producing Progenitor Cells from Differentiated Cells - The present invention provides a method of producing progenitor cells, such as cells capable of being differentiated into a plurality of different cell types, from differentiated cells. Methods of using progenitor cells in differentiation and/or tissue or organ repair and/or regeneration and/or building are also provides. Methods of using progenitor cells in treatment and prophylaxis of conditions alleviated by administering stem cells or tissue or organ derived from stem cells to a subject or by grafting stem cells or tissue or organ derived from stem cells into a subject or by transplanting stem cells or tissue or organ derived from stem cells into a subject are also provided. Also included are progenitor cells and differentiated cells and/or tissues and/or organs derived therefrom, and kits comprising same.05-12-2011
20110111028Composition and Methods For Repair of Connective Tissue - Compositions and methods for repairing a ruptured connective tissue are disclosed. The composition may include a first biocompatible material to provide a scaffold for connective tissue cell growth and tissue repair. This first biocompatible material may withstand a tensile load of up to 250 N. The composition may also include a second biocompatible material including at least one bioactive agent that can stimulate connective tissue cell growth and tissue repair. The method may include positioning a first end of the first biocompatible material adjacent a first end of a ruptured connective tissue, positioning a second end of the first biocompatible material adjacent a second end of the ruptured connective tissue, and anchoring the first biocompatible material to the first and second tendon ends. The method may alternatively comprise or further include positioning a second biocompatible material between the first and second ends of the ruptured connective tissue.05-12-2011
20090068270Treatment of degenerated disc with autologous cells - The present invention relates to administering autologous uncultured cells into a diseased intervertebral disc.03-12-2009
20110008435Nanoparticulate and Controlled Release Compositions Comprising Aryl-Heterocyclic Compounds - The present invention provides a composition comprising ziprasidone useful in the treatment and prevention of schizophrenia and similar psychiatric disorders. In one embodiment, the composition comprises nanoparticulate particles comprising ziprasidone and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. In another embodiment, the composition comprises a modified release composition that, upon administration to a patient, delivers ziprasidone in a bimodal, multimodal or continuous manner. The invention also relates to dosage forms containing such compositions, and to methods for the treatment and prevention of schizophrenia and similar psychiatric disorders.01-13-2011
20110008437Silk Fibroin Hydrogels and Uses Thereof - The present specification provides for methods for purifying fibroins, purified fibroins, methods of conjugating biological and synthetic molecules to fibroins, fibroins conjugated to such molecules, methods of making fibroin hydrogels, fibroin hydrogels and fibroin hydrogel formulations useful for a variety of medical uses, including, without limitation uses as bulking agents, tissue space fillers, templates for tissue reconstruction or regeneration, cell culture scaffolds for tissue engineering and for disease models, surface coating to improve medical device function, or drug delivery devices.01-13-2011
20110244042STABILIZED FORMULATIONS OF CNS COMPOUNDS - Formulations of molindone having superior stability and methods of administering same are provided. The formulations may be immediate, modified, or otherwise delayed release formulations of molindone.10-06-2011
20110008438Bone Repair Composition and a Method of Making the Same - Bone repair composition and method of making the same, the bone repair composition being formed by firstly mixing a first aqueous calcium phosphate suspension with bone graft granules to form an intermediate mixture. The intermediate mixture is then mixed with a second aqueous calcium phosphate suspension, wherein the first aqueous calcium phosphate suspension contains a lower weight concentration of calcium phosphate than the second aqueous calcium phosphate suspension.01-13-2011
20100183722MODULATION OF PROTEASES. PARTICULARLY IN THE TREATMENT OF CHRONIC ULCEROUS SKIN LESIONS - The invention provides a method of modulating proteases, particularly when treating a wound (for example, a chronic ulcerous skin lesion) in a human or non-human mammal (particularly a human). The medium containing the proteases (e.g. the wound) is contacted with a topical hydrogel composition comprising a hydrophilic polymer carrying multiple pendant sulphonyl groups, optionally with multiple pendant carboxylic groups, on each polymer molecule.07-22-2010
20090035375Pharmaceutical compositions for acute glucocorticoid therapy - The present invention relates to glucocorticoid-containing pharmaceutical compositions or kits for use in acute emergency situations where acute glucocorticoid therapy is required. Notably, the invention relates to pharmaceutical compositions and kits that are designed to be administered by non-medically trained persons outside a hospital or another medical or clinical setting. The invention also relates to a method for treating a disorder requiring acute glucocorticoid therapy by providing a fast onset of action of a glucocorticoid02-05-2009
20110020448PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF GLAUCOMA - Provided is a pharmaceutical composition for the treatment and prevention of glaucoma, containing (a) a therapeutically effective amount of a compound represented by Formula 1 or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and (b) a pharmaceutically acceptable carrier, diluent or excipient or any combination thereof.01-27-2011
20110033541SUBLINGUAL AND BUCCAL FILM COMPOSITIONS - The present invention relates to products and methods for treatment of narcotic dependence in a user. The invention more particularly relates to self-supporting dosage forms which provide an active agent for treating narcotic dependence while providing sufficient buccal adhesion of the dosage form.02-10-2011
20110033542SUBLINGUAL AND BUCCAL FILM COMPOSITIONS - The present invention relates to products and methods for treatment of various symptoms in a patient, including treatment of pain suffered by a patient. The invention more particularly relates to self-supporting dosage forms which provide an active agent while providing sufficient buccal adhesion of the dosage form. Further, the present invention provides a dosage form which is useful in reducing the likelihood of diversion abuse of the active agent.02-10-2011
20100172989ABUSE RESISTANT MELT EXTRUDED FORMULATION HAVING REDUCED ALCOHOL INTERACTION - The present invention relates to compositions for oral administration. The invention preferably comprises at least one abuse-resistant drug delivery composition for delivering a drug having potential for dose dumping in alcohol, related methods of preparing these dosage forms, and methods of treating a patient in need thereof comprising administering the inventive compositions to the patient. Most preferably, the dosage form includes verapamil. These formulations have reduced potential for abuse. In another formulation, preferably the abuse relevant drug is an opioid and the non-abuse relevant drug is acetaminophen or ibuprofen. More preferably, the opioid is hydrocodone, and the non-abuse relevant analgesic is acetaminophen. In certain preferred embodiments, the dosage forms are characterized by resistance to solvent extraction; tampering, crushing or grinding. Certain embodiments of the inventions provide dosage forms that provide an initial burst of release of drug followed by a prolonged period of controllable drug release.07-08-2010
20100047351TREATMENT OF STROKE USING ISOLATED PLACENTAL CELLS - Provided herein are methods for the treatment of stroke comprising administering to a stroke victim placental stem cells, populations of cells comprising placental stem cells, and/or compositions comprising placental stem cells.02-25-2010
20110244044COMPOUND, MEDICAMENT, VACCINE COMPOSITION AND NANOCAPSULES - The present invention relates to a compound comprising a polyelectrolyte and, covalently linked thereto, an immunological adjuvant and/or cell targeting ligand, wherein the covalently linked entity can have both adjuvant and cell targeting characteristics. The compound is used in the preparation of hydrophilic vaccine nanoparticles, which preferably have an antigenic compound or therapeutic agent, or genetic information encoding such compounds or agents entrapped in their matrix, or covalently linked to their surfaces. Vaccine compositions comprising the particles of the invention are advantageous, because a strong and long-lasting immune response is obtained following administration of a single dose. In a preferred embodiment, the polyelectrolyte of the compound is an anionic polymer, and the particle comprises a matrix comprising chitosan.10-06-2011
20100136113PHYTASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM - This invention relates to phytases, polynucleotides encoding them, uses of the polynucleotides and polypeptides of the invention, as well as the production and isolation of such polynucleotides and polypeptides. In particular, the invention provides polypeptides having phytase activity under high temperature conditions, and phytases that retain activity after exposure to high temperatures. The phytases of the invention can be thermotolerant and/or thermostable at low temperatures, in addition to higher temperatures. The phytases of the invention can be used in foodstuffs to improve the feeding value of phytate rich ingredients. The phytases of the invention can be formulated as foods or feeds or supplements for either to, e.g., aid in the digestion of phytate. The foods or feeds of the invention can be in the form of pellets, liquids, powders and the like. In one aspect, phytases of the invention are stabile against thermal denaturation during pelleting; and this decreases the cost of the phytase product while maintaining in vivo efficacy and detection of activity in feed.06-03-2010
20100028430MATERIAL AND MANUFACTURING METHOD OF BIOACTIVE PROTEIN-CALCIUM PHOSPHATE COMPOSITE - Disclosed are a bioactive protein-calcium phosphate ceramic composite for surface modification of a substrate for use as a substitute in the treatment of musculoskeletal disorders, and a preparation method thereof. The bioactive protein-calcium phosphate ceramic composite is prepared by mixing an aqueous solution of calcium phosphate and a protein, and impregnating the calcium phosphate and the protein in the resulting aqueous solution to co-precipitate them on a substrate, such as metals, ceramics and polymers, wherein the substrate is patterned, and different proteins are impregnated in at least two regions of the patterned regions.02-04-2010
20100239671Tissue-Engineered Endothelial and Epithelial Implants Differentially and Synergistically Regulate Tissue Repair - Endothelial implants restore vascular homeostasis after injury without reconstituting vascular architecture. Endothelial cells line the vascular epithelium and underlying vasa vasorum precluding distinction between cellular controls. Unlike blood vessels, the airway epithelium is highly differentiated and distinct from endothelial cells that line the bronchial vasa allowing investigation of the differential control tissue engineered cells may provide in airways and blood vessels. Through airway injury and cell culture models, tissue engineered implants of the bronchial epithelium and endothelium were found to promote synergistic repair of the airway through biochemical regulation of the airway microenvironment. While epithelial cells modulate local tissue composition and reaction, endothelial cells preserve the epithelium; together their relative impact was enhanced suggesting both cell types act synergistically for airway repair.09-23-2010
20100226984MOLECULAR RECOGNITION MATRIX AND METHOD FOR MAKING SAME - A molecular recognition matrix which utilizes the interaction between molecular building blocks and the surface of a substrate to develop specific molecular recognition cavities.09-09-2010
20110244043Controlled releasing composition - A controlled releasing composition comprising a plurality of microparticles and a matrix as well as the preparation method thereof is disclosed. The plurality of microparticles comprise a first material and the matrix comprises a second material. The melting temperature of the first material is higher than the melting temperature of the second material.10-06-2011
20100040688HYDROGEL MICROPARTICLE FORMATION IN AQUEOUS SOLVENT FOR BIOMEDICAL APPLICATIONS - The field of the disclosure relates to microparticles comprising a cross-linked water-soluble polymer or cross-linked water-soluble polymers and a process for forming thereof. Further, the field of the disclosure relates to coatings and scaffolds comprising microparticles and the processes for forming thereof.02-18-2010
20100008989PROCESS FOR MANUFACTURE OF GELATIN SOLUTIONS AND PRODUCTS THEREOF - A process for the preparation of gelatin solutions which is less than a physiologically relevant temperature, which is preferably less than about 37° C., the process comprising adding one or more transition point reducing agents, such as hydrogen bond breakers, reducing agents, plasticizers, surfactants, metal ions or denaturants (denaturing agents), to the gelatin solution. The reduced temperature processing can reduce damage to thermo sensitive pharmaceuticals ingredients or vitamins, or other heat sensitive ingredients.01-14-2010
20100015227DRIED ELECTRIFIED HYDROCOLLOID GELS HAVING UNIQUE STRUCTURE AND POROSITY - This invention discloses electrified freeze-dried hydrocolloid gels, having modified structures with improved properties, as well as methods for the preparation of these modified gels and their uses. Specifically gels modified by electrification and freeze-drying undergo changes including creation of concentric layers of gel and intervening spaces.01-21-2010
20100055184HYDROGELS FOR VOCAL CORD AND SOFT TISSUE AUGMENTATION AND REPAIR - The present invention provides hydrogels and compositions thereof for vocal cord repair or augmentation, as well as other soft tissue repair or augmentation (e.g., bladder neck augmentation, dermal fillers, breast implants, intervertebral disks, muscle-mass). The hydrogels or compositions thereof are injected into the superficial lamina propria or phonatory epithelium to restore the phonatory mucosa of the vocal cords, thereby restoring a patient's voice. In particular, it has been discovered that hydrogels with an elastic shear modulus of approximately 25 Pa are useful in restoring the pliability of the phonatory mucosa. The invention also provides methods of preparing and using the inventive hydrogels.03-04-2010
20110086099CRYSTALLINE MESOPOROUS OXIDE BASED MATERIALS USEFUL FOR THE FIXATION AND CONTROLLED RELEASE OF DRUGS - The invention describes a new class of crystalline silica material having two levels of porosity and structural order. At the first level, building units are nanoslabs of uniform size having zeolite framework. At the second structural level, nanoslabs are assembled, e.g. linked through their corners, edges or faces following patterns imposed by interaction with cationic surfactant or triblock copolymer molecules. After evacuation of these molecules, microporosity is obtained inside the nanoslabs, and a precise mesoporosity between the nanoslabs depending on the tiling pattern of the zeolite nanoslabs, as evidenced by X-ray diffraction. These materials are useful for the fixation of biologically active species, such as poorly soluble drugs.04-14-2011
20110104278Bone tissue substitute, a solidifiable bone precursor and method of making same - The present concerns a solidifiable bone precursor composition which can be used to produce a mineralized substitute bone tissue material and the method of making the substitute bone tissue material. The substitute bone tissue material includes a collagen matrix comprising pores, and an apatitic mineral within the pores of general formula:05-05-2011
20090214649Scaffolds with oxygen carriers, and their use in tissue regeneration - Provided are fibrin or silk matrices comprising an oxygen carrier, and matrices, which comprise an oxygen carrier and mesenchymal stem cells. Also provided are methods of generating and using same for ex vivo or in vivo tissue regeneration and/or repair such as for treating a non-union bone fracture and a condition requiring spinal fusion.08-27-2009
20110086100Polyethylene Glycol Aerogels for Targeted Delivery of Pharmaceutical Drubs - A polyethylene glycol (PEG) aerogel particles having an average particle diameter not substantially above about 2μ, a volumetric porosity of greater than about 50%, and pore sizes capable of retaining drug molecules. A method for preparing such polyethylene glycol (PEG) aerogel particles includes initiating a catalyzed reaction using a catalyst of PEG forming ingredients to form PEG particles; partially drying the formed PEG particles under conditions to control pore size; and subjecting the partially dried formed PEG particles to CO04-14-2011
20110151002SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING QUETIAPINE - A sustained release dosage form comprising Quetiapine or a pharmaceutically acceptable salt, polymorphs, solvates, hydrates thereof and one or more non-gellable release controlling polymer and one or more pharmaceutically acceptable excipient(s). A sustained release dosage form comprising first granulation comprising Quetiapine or its pharmaceutically acceptable salts, polymorphs, solvates, hydrates thereof and one or more release controlling material; and second granulation comprising one or more release controlling material which is the same or different than the one or more release controlling material of the first granulation and optionally quetiapine or its pharmaceutically acceptable salts, polymorphs, solvates, hydrates thereof. A method of preparing the sustained release dosage form by first and second granulation followed by milling; blending the said milled granules after second granulation with lubricant followed by compression to form a sustained release dosage form. A sustained release dosage form comprising immediate release core comprising Quetiapine or a pharmaceutically acceptable salt, polymorphs, solvates, hydrates thereof and one or more pharmaceutically acceptable excipients; and sustained release coating comprising one or more non-gellable release controlling material.06-23-2011
20110150998Methods For Producing ECM-Based Biomaterials - A method for forming an extracellular matrix material (ECM) material includes providing at least an ECM composition containing ECM particles varying in their capacity for migration through a fluid medium, including at least one population of expanded ECM particles. The ECM composition is combined in a fluid medium to form a flowable ECM composition. The flowable ECM composition is subjected to a centrifugal force in a mold for a period of time sufficient to distribute the ECM particles according to differences in their physical characteristics. The ECM composition is dried to form a dried ECM material having a density gradient extending from a less dense region to a more dense region. The dried ECM material may formed as a porous, substantially acellular ECM material expandable in an aqueous fluid environment by at least 100% in volume.06-23-2011
20100255097POLYSACCHARIDE DERIVATIVES OF LIPOIC ACID, AND THEIR PREPARATION AND USE AS SKIN COSMETICS AND MEDICAL DEVICES - Disclosed are polysaccharides containing residues of glucosamine or galactosamine in the repetitive unit, characterised by the presence of esters on the hydroxyls or amides on the amine functions, with lipoic acid or with mixtures of lipoic acid and formic acid.10-07-2010
20100297231PRESERVATION OF BIOACTIVE MATERIALS BY FREEZE DRIED FOAM - This invention provides methods, systems and compositions to preserve bioactive materials in a dried foam matrix. Methods provide non-boiling foam generation and penetration of preservative agents at temperatures near the phase transition temperature of the membranes. Bioactive materials can be preserved with high initial viability in a freeze-foam process employing low temperature secondary drying.11-25-2010
20100297233OSCILLATING CELL CULTURE BIOREACTOR - Methods and devices for cell or tissue culture are provided. One aspect provides a bioreactor having a gas permeable, closed-loop chamber for cell or tissue culture, and an oscillating means for moving the gas permeable, closed-loop chamber bidirectionally along an axis horizontal to an axis normal to the closed-loop chamber to force convection of cells and fluid in the gas permeable, closed-loop chamber. The bioreactor optionally includes a tissue engineering scaffold, an inlet means, an outlet means, and integrated sensors. Another aspect provides a bioreactor having a plurality of gas permeable, closed-loop chambers for cell or tissue culture. Methods of culturing cells and producing tissue constructs are also provided.11-25-2010
20110256223GASTRIC RETAINED GABAPENTIN DOSAGE FORM - A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.10-20-2011
20110045075TISSUE COATING FOR PREVENTING UNDESIRED TISSUE-TO-TISSUE ADHESIONS - Disclosed herein are a kit and a method for forming a tissue coating that prevents undesired tissue-to-tissue adhesions resulting from trauma, surgery, infection, or other stimulus. The tissue coating is a hydrogel formed by reacting an aminocarboxymethyldextran containing primary amine groups with an oxidized carboxymethylcellulose containing aldehyde groups.02-24-2011
20110250274ESTRIOL FORMULATIONS - Disclosed herein are oral dosage forms and methods of their use, in particular oral dosage systems for the delivery of estriol compounds. Embodiments described herein relate to rapidly disintegrating oral dosage formulations that disintegrate in the saliva of the buccal and/or sublingual and/or esophageal cavity. Oral dosage forms described herein relate to stabilized amorphous and nanocrystalline forms of the active ingredients of the formulations.10-13-2011
20100098760POLYPEPTIDE FOR TREATING OR PREVENTING ADHESIONS - The described invention provides compositions and methods for treating or preventing adhesions in a subject in need thereof, the method comprising the step of (a) administering an adhesion-reducing amount of a composition comprising a polypeptide having the amino acid sequence YARAAARQARAKALARQLGVAA [SEQ ID NO: 1] or a functional equivalent thereof and a carrier. The methods are clinically useful for reducing formation of adhesions initially and for therapeutic treatment of existing scars.04-22-2010
20130122094SIALIC ACID ANALOGS - The present invention provides sialic acid analogs and their compositions useful for the treatment of sialic acid deficiencies.05-16-2013
20100003324VINPOCETINE AND EBURN AMONINE DERIVATIVES FOR PROMOTING BONE GROWTH - The present invention provides a method of promoting bone growth in a subject in need thereof, by administering to the subject a therapeutically effective amount of a compound of Formula I. The compounds include the salts, hydrates and isomers thereof. The present invention also provides methods for the treatment of renal disease and cancer.01-07-2010
20080248116COMPOSITION FOR STIMULATING DE NOVO BONE INDUCTION - This invention relates to a composition for stimulating de novo bone induction in a mammal, to the use of this composition in stimulating de novo bone induction in a mammal and to a method of treating a mammal to stimulate de novo bone induction. The use and method involve introducing the composition, preferably by local injection, into the mammal at a site where de novo bone induction is desired. The composition consists of a combination of a bone morphogenetic protein and a reconstituted basement membrane which, in a preferred embodiment of the invention is Matrigel®. The Matrigel® serves, at least partly, to retain the bone morphogenetic protein at the site of introduction for a period sufficient to trigger a bone differentiation cascade.10-09-2008
20110212177CONFIGURABLE MICROSCOPIC MEDICAL PAYLOAD DELIVERY DEVICE TO DELIVER MEDICALLY THERAPEUTIC PAYLOADS TO SPECIFICALLY TARGETED CELL TYPES - The innovative strategy of treatment described here utilizes configurable microscopic medical payload delivery devices to act as a transport mechanism to deliver medically therapeutic payloads to specific cell types in the body. Utilizing probes on the exterior of the configurable microscopic medical payload delivery devices, these transport devices locate specific types of target cells in the body. Once a specific target cell is encountered and engaged, the configurable microscopic medical payload delivery device inserts its payload into the target cell. These medically therapeutic payloads are intended to improve cell function or the longevity of the cell or eliminate cells that pose a hazard to the general health of the body. By utilizing configurable microscopic medical payload delivery devices as a delivery system, the efficacy of medications and biologic tools are dramatically improved and there is a resultant significant reduction in the occurrence of unwanted side effects.09-01-2011
20080241244Preservation of bioactive materials by freeze dried foam - This invention provides methods and compositions to preserve bioactive materials in a dried foam matrix. Methods provide non-boiling foam generation and penetration of preservative agents at temperatures near the phase transition temperature of the membranes.10-02-2008
20110256222Recombinant Protein Enriched in a Heparin Binding Site and/or in a Heparan Sulfate Binding Site - The invention relates to a recombinant protein enriched in a heparin binding site and/or a heparan sulfate binding site. Such recombinant protein is used as an in vivo controlled release system of a protein of interest.10-20-2011
20080268055Use of an aqueous micro-emulsion for the preparation of a formulation for the treatment of adipose diseases - A method for treating a patient suffering from an adipose tissue disease and/or a condition associated with adipose tissue disease, comprising administering a micro-emulsion comprising at least one surfactant having a HLB value between 5 and 15, at least one lipophilic substance, and water in an amount effective for treatment of the disease and/or condition.10-30-2008
20120121706PAR-1 Activation by Metalloproteinase-1 (MMP-1) - Matrix metalloproteases (MMPs) play many important roles in normal and pathological remodeling processes including atherothrombotic disease, inflammation, angiogenesis and cancer. This invention relates to the activation of protease-activated receptor-1 (PAR-1) by endogenous platelet MMP-1 collagenase on the surface of platelets. Exposure of platelets to fibrillar collagen converts the surface-bound pro-MMP-1 zymogen to active MMP-1, which promotes aggregation through PAR-1, MMP-1 is shown to cleave the PAR-1 extracellular domain at a novel site, which then strongly activates Rho-GTP signaling pathways, cell shape change and motility, and MAPK signaling. Blockade of MMP-PAR 1 suppresses thrombogenesis under arterial flow conditions and inhibited thrombosis in animals. These studies provide a link between matrix-dependent activation of metalloproteases and platelet-G protein signaling and identify MMP-1/PAR-1 as a new target for the treatment and prevention of arterial thrombosis and other thrombotic diseases.05-17-2012
20120201890METHODS AND COMPOSITIONS TO SUPPORT TRANSPLANTED TISSUE INTEGRATION AND INNOSCULATION WITH ADIPOSE STROMAL CELLS - The present invention generally relates to methods, compositions and uses thereof for enhancing vascularization of a tissue or cell transplant for transplantation into a subject. In particular, one aspect of the present invention provides methods and compositions comprising the use of a population of stromal vascular fraction (SVF) cells to encapsulate or surround a tissue or cell transplant to enhance vascularization of the tissue or cell transplant. Another aspect of the present invention provides methods and compositions for enhancing vascularization of a tissue or cell transplant by combining a population of SVF cells with a tissue or cell transplant to form a transplant mixed with SVF cells. In some embodiments, the SVF cells can be on the surface or embedded within a three-dimensional matrix. In some embodiments, the SVF cells can be generically engineered to secrete therapeutic proteins or pro-angiogenic factors.08-09-2012
20110165242IN SITU GELLING DRUG DELIVERY SYSTEM - The invention provides liquid controlled-release drug delivery compositions which gel upon injection into the body to form, in situ, controlled-release drug implants. The compositions of the invention feature a gel-forming polymer that is insoluble in water, a polyethylene glycol solvent in which the polymer is dissolved, and the drug substance to be delivered.07-07-2011
20110165245COMPOSITIONS AND METHODS FOR DISTRACTION OSTEOGENESIS - The present invention relates to compositions and methods for use in osteodistraction procedures. In one embodiment, a method of stimulating osteogenesis during and/or following bone distraction comprises providing a composition comprising a PDGF solution disposed in a biocompatible matrix and applying the composition to at least one site of bone distraction.07-07-2011
20110165244BIORESPONSIVE POLYMER FORMULATIONS FOR DELIVERY OF BIOACTIVE AGENTS - Elutable coatings and materials comprising protein resistant polymer components and bioactive agent on medical devices are disclosed. The elutable coatings comprise labile linkers that can be cleaved in response to a targeted physiologic stimulus. Medical devices formed from elutable materials comprised of protein resistant polymer components and bioactive agents are also disclosed. The elutable materials comprise labile linkers that can be cleaved in response to a targeted physiologic stimulus.07-07-2011
20110165243Concurrent delivery of multiple therapeutic agents via hydrogels for biomedical applications - A process for concurrent delivery of multiple therapeutic agents via hydrogels. The process includes polymerizing a hydrogel and combining said hydrogel with at least two biologically therapeutic agents. Encapsulation of whole viable cells into polymerized hydrogel for transplantation is also disclosed.07-07-2011
20110262541FOAM-FORMED COLLAGEN STRAND - Foam-formed collagen strands and methods for forming strands involve depositing a dispersed solution of an isolated cleaned, de-fatted, enzymatically-treated (or non-enzyme treated) human-derived collagen product having a preserved amount of its natural constituents into grooves of a grooved plate, and processing the dispersed collagen product to provide a foam-formed collagen strand. Foam-formed collagen strands may be processed into threads having a matrix of reticulated pores to conduct biological materials in and through the strand, the collagen of the collagen strand comprising isolated, enzymatically-treated human derived collagen having a preserved amount of its natural collagen constituents.10-27-2011
20110020450TITRATABLE DOSAGE TRANSDERMAL DELIVERY SYSTEM - The present invention relates to a titratable dosage transdermal delivery system for systemic delivery of a therapeutic agent or drug. The system comprises a plurality of patch units that are connected along one or more borders. The plurality of patch units are divisible into units along the one or more borders having one or more lines of separation. Each patch unit is surrounded by a border. The therapeutic patch has at least a backing layer and a therapeutic agent comprising layer. The dosage of therapeutic agent delivered to a patient is proportional to the number of patch unit applied per treatment. The system enables systemic administration of a titratable dosage of therapeutic agent, adjustable by the patient under the direction of a physician, through the skin or mucosa. Moreover, the invention relates to a method of making the titratable dosage transdermal delivery system. Furthermore, the invention relates to a method of providing a titratable amount of therapeutic agent to a patient using the transdermal delivery system of the invention.01-27-2011
20110027367ADMINISTRATION OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTHOIC ACID FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS - Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.02-03-2011
20110027366SKIN EQUIVALENT CULTURE - Disclosed is a method of preparing a collagenous construct comprising casting a support matrix comprising fibrin and viable collagen-producing cells onto a support material, wherein said cells include human dermal fibroblasts, incubating in situ said support matrix in a collagen-inducing medium thereby, inducing or enhancing collagen production by said cells to form a collagenous construct, and degrading said fibrin, and rendering said collagenous construct free of said viable collagen-producing cells.02-03-2011
20110027363Nouvelle forme d'administration de proteines osteogeniques - Osteogenic compositions are formed from a coprecipitate that contains at least one insoluble calcium salt and at least one osteogenic protein, the coprecipitate being in divided form. A process for preparing the coprecipitate in divided form contains at least one insoluble calcium salt and at least one complex between an osteogenic protein and a polysaccharide. The invention also relates to the formulations, pharmaceutical products, kits and medical devices comprising the coprecipitate.02-03-2011
20110027364BIOACTIVE AND RESORBABLE SOYBEAN-BASED BIOMATERIALS - A method of producing a soybean-based biomaterial which is suitable for use in a biomedical product, the method comprising: defatting soy flour; either prior to or at the same time as, performing a solvent extraction; to produce a biomaterial comprising variable levels of soy proteins, carbohydrates and isoflavones. The resulting biomaterials have a range of biomedical uses and are particularly desirable because of their isoflavone content. Examples of biomedical products containing the biomaterials include wound dressings; scaffolds for tissue engineering; fillers or implants for use in surgery; temporary barriers for use in dental or surgical procedures or to prevent post-surgical tissue adherence; carriers for the delivery of drugs, bioactive peptides or plasmids; anti-inflammatory agents; coatings for wound dressings or for dental, medical, surgical or veterinary devices or implants; and compositions for soothing skin or gum irritation.02-03-2011
20110027365Patch Formulation For External Use - A patch formulation for external use where a basic drug, an organic acid and an organic acid salt are combined as essential components is disclosed. The basic drug is preferably in the form of its acid addition salt. The organic acid is preferably a carboxylic acid having carbon atoms of 2 to 7, and more preferably at least one acid selected from the group consisting of acetic, lactic, tartaric, citric, malic, benzoic and salicylic acids. The organic acid salt is preferably a metal salt of a carboxylic acid, and more preferably sodium acetate.02-03-2011
20100285130COATING OF COMPLEXED ACTIVES IN FILM FORMULATIONS - The present invention relates to products and methods of making products having a dual taste masked active component. In particular, the present invention relates to film dosage forms including at least one dual taste masked active, where the dual taste masked active includes a coated complexed active composition.11-11-2010
20100285128SPACE FILLED DRUG RELEASE STRUCTURE AND METHOD OF MANUFACTURING THE SAME - A space filled drug release structure and a method of manufacturing the same are disclosed. The structure is composed of a highly water-absorbing polymeric matrix and drug particles dispersed in the matrix. The matrix has pores and passages interconnecting the pores together. Because some water is present in the matrix, gastric acid can easily penetrate into the matrix to reach each drug particle. The surface of each drug particle is therefore possible to contact with the gastric acid. The drug releasing rate is therefore fast. Such structure is helpful for those drugs with low dissolution ability in the gastric acid.11-11-2010
20100330181Biphasic implant device providing gradient - Tissue implants prepared for the repair of tissues, especially avascular tissues such as cartilage. One embodiment presents an electric potential capable of receiving and accumulating desirable factors or molecules from surrounding fluid when exposed to dynamic loading. In another embodiment the implant promotes tissue conduction by retarding, restricting and controlling cellular invasion through use of gradients until competent tissue forms. Further embodiments of the tissue implants may be formed into a multi-phasic device that provides deep tissue mechanical stimulus by conduction of mechanical and fluid forces experienced at the surface of the implant.12-30-2010
20100166863BIODEGRADABLE COPOLYMER HYDROGELS - Biodegradable copolymer hydrogels are provided. The biodegradable copolymer hydrogels have a structure of Formula (I) or Formula (II)07-01-2010
20110135726HYDROGEL COMPOSITES AND WOUND DRESSINGS - The present invention provides an absorbent hydrogel composite for use in the manufacture of an article for application to a fluid-emitting surface, e.g. a wound, the composite having a laminar structure comprising first and second layers, the first layer being a surface contacting layer comprising a porous net structure having a surface contacting face and an outwardly directed face, the second layer comprising a low-crosslinked absorbent hydrogel disposed over the outwardly directed face of the first layer and arranged so that in use it is in fluid flow communication with the surface through apertures of the net structure.06-09-2011
20110052696DENDRIMERS WITH INTERIOR AND EXTERIOR FUNCTIONALITIES COMPRISING OF AZIDE OR ALKYNE GROUPS FOR POST-FUNCTIONALIZATION BY THE HUISGEN CLICK CYCLOADDITION - A dendritic structure includes a core and repeating units, wherein the repeating units comprise units of the type AB03-03-2011
20110052695DRUG DELIVERY PLATFORMS COMPRISING SILK FIBROIN HYDROGELS AND USES THEREOF - The present specification provides drug delivery platforms useful for the controlled release of a compound over time in an individual.03-03-2011
20110052693METHOD FOR PRODUCING ARTIFICIAL SKIN - An object of the invention is to provide artificial skin that does not contain any animal-derived material or pathogen and has excellent biocompatibility. The invention provides, as a solution means, a method for producing artificial skin comprising the steps of: (A) forming a dermal layer by solidifying a mixture of dermal fibroblasts and a peptide hydrogel having a fibrous structure; and (B) forming an epidermal layer by seeding skin keratinocytes onto the dermal layer obtained in Step (A), and culturing the epidermal keratinocytes.03-03-2011
20110135731ABUSE-RESISTANT OPIOID DOSAGE FORM - We provide a pharmaceutical dosage form including an opioid antagonist surrounded by a controlled release matrix and an opioid agonist in a surrounding matrix.06-09-2011
20110135729Methods for Controlling Heat Generation of Magnetic Nanoparticles and Heat Generating Nanomaterials - The present invention relates to a method for controlling heat generation of a magnetic nanomaterial, comprising the steps of: (a) mixing (i) a nanomaterial precursor comprising a metal precursor material and a predetermined amount of a zinc precursor with (ii) a reaction solvent; and (b) preparing a zinc-containing magnetic nanomaterial from the mixture of step (a) comprising a zinc doped metal oxide nanomaterial matrix; and wherein a specific loss power of the zinc-containing magnetic nanomaterial is varied depending an amount of zinc to be doped, whereby the heat generation of the magnetic nanomaterial is controlled. In addition, the present invention relates to a heat-generating nanoparticle and a composition for hyperthermia. The present invention suggests a novel approach to improve a heat generation of a magnetic nanomaterial. According to the present invention, the specific loss power can be controlled by changing a zinc-content to be introduced into nanomaterials and therefore a composition for hyperthermia showing controlled heat generation potential can be successfully provided.06-09-2011
20110135728GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR EXTENDED RELEASE OF POLYPEPTIDES - Gastric retentive dosage forms for controlled release of polypeptides are described. Methods of treatment using the dosage forms and methods of making the dosage forms are also described.06-09-2011
20110135725Lipid Construct for Delivery of Insulin to a Mammal - The instant invention is drawn to a hepatocyte targeted composition comprising insulin associated with a lipid construct comprising an amphipathic lipid and an extended amphipathic lipid that targets the construct to a receptor displayed by an hepatocyte. The composition can comprise a mixture of free insulin and insulin associated with the complex. The composition can be modified to protect insulin and the complex from degradation. The invention also includes methods for the manufacture of the composition and loading insulin into the composition and recycling various components of the composition. Methods of treating individuals inflicted with diabetes.06-09-2011
20110052692NOVEL HYDROGELS AND USES THEREOF - The present invention provides novel hydrogels and methods of making and using such hydrogels. The present invention provides hydrogels that may be formed by the self-assembly of peptides in solution. Such self-assembly may be brought about by a change in one or more characteristics of the solution. Characteristics of the solution that may be changed include pH, ionic strength, temperature, and concentration of one or more specific ions. In addition, hydrogels of the invention may be disassembled by changing one or more characteristic of the hydrogel such as pH, ionic strength, temperature, and concentration of one or more specific ions.03-03-2011
20110052691Sustained Release Systems and Preparation Method Thereof - The present invention relates to a hydrophilic drug and β-tricalcium phosphate (β-TCP) coating on a surface area of biopolymer matrix to form a sustained release system. The present invention also provides a method for preparing a sustained release system, comprising providing a surface are of biopolymer matrix coated with a hydrophilic drug and β-TCP.03-03-2011
20100330183SOLID DISPERSING VACCINE COMPOSITION FOR ORAL DELIVERY - The invention disclosed herein relate to an oral vaccine in which the vaccine composition and adjuvant(s) are carried on a solid fast-dispersing dosage form. The vaccines are targeted toward mucosal tissue and the adjuvant serves to ensure sufficient residence time for the vaccine composition on the mucosal tissue to facilitate its absorption thereby. The fast-dispersing oral solid vaccine dosage form of the invention is particularly useful to administer the vaccine to patients that have difficulty swallowing medications. In one embodiment, the invention provides a fast disintegrating oral solid vaccine dosage form comprising: an immunogenic amount of an antigenic preparation, the antigenic preparation comprising a microsphere-antigen complex; an adjuvant, wherein the adjuvant enhances the absorption of the antigen or potentiates the immunogenic response; a mucoadhesive substance; and a low density dosage form matrix.12-30-2010
20110097404TAMPER-RESISTANT ORAL OPIOID AGONIST FORMULATIONS - Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is not released when the dosage form is administered orally intact.04-28-2011
20110097403EXTRACELLULAR MATRIX COMPOSITIONS FOR THE TREATMENT OF CANCER - The present invention is directed to methods of inhibiting cancer cell growth or proliferation by contacting the cancer cell with an extracellular matrix (ECM) composition. Also provided are methods of delivering a chemotherapeutic agent to a cancer cell by contacting a cancer cell with an extracellular matrix composition containing a chemotherapeutic agent. Also provided are compositions containing ECM and a chemotherapeutic agent.04-28-2011
20110097402NON-ADHESIVE ELASTIC GELATIN MATRICES - The present invention is a substantially non-adhesive elastic gelatin matrix. The matrix is both non-adhesive to wounds, tissues and organs and is also elastic such that it is flexible. The matrix is a lyophilized mixture of protein(s), polymer(s), cross-linking agent(s) and optional plasticizer(s). The invention also provides methods for making the non-adhesive elastic gelatin matrix.04-28-2011
20100166862Local Complement Inhibition for Treatment of Complement-Mediated Disorders - The present invention features the local administration of complement inhibitors for treatment of complement-mediated disorders. In certain embodiments the invention features inhibiting activation of one or more locally produced complement proteins. The invention provides sustained release formulations and devices comprising a complement inhibitor and methods of use thereof.07-01-2010
20080274186NELL-1 enhanced bone mineralization - Provided herein are methods for enhancing bone mineralization for bone repair or regeneration and compositions and grafts therefor. Methods for screening agents that enhance or modulate NELL-1 gene expression or NELL-1 protein production in a cell are also provided.11-06-2008
20100159009CONTROLLED-RELEASE FORMULATIONS - Disclosed herein are extended-release levetiracetam formulations having a matrix comprising levetiracetam and a hydrophobic excipient or an acrylic polymer excipient.06-24-2010
20100159008HYDROGELS, METHODS OF MAKING HYDROGELS, METHODS OF USING HYDROGELS, AND METHODS OF ISOLATING, TRAPPING, ATTRACTING, AND/OR KILLING CANCER CELLS - Embodiments of the present disclosure provide for hydrogels, methods of making hydrogels, methods of using hydrogels, methods of isolating, trapping, attracting, and/or killing cancer cells, and the like.06-24-2010
20100196480GRAFT MATERIALS CONTAINING BIOACTIVE EXTRACELLULAR MATRICES AND CELLS - Described are packaged, sterile medical graft products containing controlled levels of a growth factor such as Fibroblast Growth Factor-2 (FGF-2). Also described are methods of manufacturing medical graft products wherein processing, including sterilization, is controlled and monitored to provide medical graft products having modulated, known levels of a extracellular matrix factor, such as a growth factor, e.g. FGF-2. Preferred graft materials are extracellular matrix materials isolated from human or animal donors, particularly submucosa-containing extracellular matrix materials. Further described are ECM compositions that are or are useful for preparing gels, and related methods for preparation and use.08-05-2010
20100196477Dry Mouldable drug formulation - Solid pharmaceutical compositions and methods of making and administering for parenteral injection comprising a binder and at least one therapeutic agent. The pharmaceutical composition has the strength to be injected directly with the need of using cannulas or the like.08-05-2010
20100196479METHODS AND COMPOSITIONS COMPRISING AT LEAST ONE ALPHA3 BETA4 nAChR ANTAGONIST OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF - The present invention is directed to methods and formulations for treating, modifying, and/or managing gastrointestinal secretion, and intestinal conditions that cause the same. Methods of using at least one α3 β4 nAChR antagonist and formulations comprising at least one α3 β4 nAChR antagonist, or pharmaceutically acceptable salt thereof, are included.08-05-2010
20100068278Ex vivo modifiable medicament release-associations - Described embodiments include a final dosage form, an article of manufacture, and method. A described final dosage form includes a medicament, and a substance associated with the medicament in a first release-control state. In the first release-control state, the medicament has a first bioavailability to the animal. The substance is modifiable ex vivo by an exposure to a stimulus to associate with the medicament in a second release-control state, wherein the medicament has a second bioavailability to the animal. The final dosage form also includes another medicament, and another substance associated with the another medicament in another first release-control state. In the another first release-control state, the another medicament has another first bioavailability to the animal. The another substance is modifiable ex vivo by an exposure to another stimulus to associate with the another medicament in another second release-control state, wherein the another medicament has another second bioavailability.03-18-2010
20100068276MULTIPARTICULATES OF SPRAY-COATED DRUG AND POLYMER ON A MELTABLE CORE - A pharmaceutical composition comprises multiparticulates comprising a melt-congeal core and a solid amorphous dispersion layer of a poorly water soluble drug and polymer. The multiparticulates are suitable for improving bioavailability of poorly water soluble drugs. The melt-congeal cores facilitate application of the solid amorphous dispersion layer, and allow incorporation of additional optional components to the core so as to adjust the release of drug from the multiparticulate.03-18-2010
20100068275Personalizable dosage form - Provided embodiments include a final dosage form, an article of manufacture, and a method. A method of fulfilling a request specifying a dose of a medicament for an individual animal includes choosing pursuant to the request an instance of a final dosage form that includes the medicament. The method also includes selecting a stimulus effective to change a medicament-release state of a release element of the final dosage form. The method further includes initiating an ex vivo exposure of the release element of the chosen instance of the final dosage form to the selected stimulus. The method further includes the release element configured in a first medicament-release state and changeable to a second medicament-release state upon an ex vivo exposure to a stimulus.03-18-2010
20110182991METHOD FOR IMPROVED FIBRIN SEALING - The present invention relates to a fibrin matrix, its preparation and use for effectively sealing a defect in a mucosa or other moist tissue.07-28-2011
20080317859Stabilization of Testosterone Within Transdermal Devices - The present invention relates to the chemical stabilization of testosterone contained in self-adhesive transdermal devices by way of the association of a desiccant agent with said device within a sealing packaging. The use of a desiccant agent makes it possible to limit the chemical degradation of the testosterone to androstenedione and other impurities and accordingly ensures storage of said device over periods of up to thirty-six months.12-25-2008
20110262542Controlled Delivery of Tetracycline Compounds and Tetracycline Derivatives - A composition is provided for delivering a tetracycline compound to a mammal. The composition includes an antibiotic tetracycline compound and a controlled-release agent having at least one controlled-release agent. The tetracycline compound is associated with the controlled-release matrix to provide a release profile whereby the mammal is treated substantially without antibiotic activity. Methods for treating a mammal with a tetracycline compound and a dosage unit are also provided utilizing the controlled-release tetracycline composition.10-27-2011
20090175945Systems, Methods, and Formulations for Topically Treating Nail Fungal Infections and Nail Psoriasis - The present invention is drawn to systems, methods, and formulations for treating nail disorders. The system comprises an active agent formulation and a first barrier film. The active agent formulation includes an active agent and an aqueous liquid component. The first barrier film is configured to form a sheath over at least a portion of a finger or toe on which the nail is located. An optional second barrier film, with lower moisture vapor transmission rate than the first barrier film, is placed between the first barrier film and the active agent formulation (or between the active agent formulation and the external environment) to reduce the water evaporation from the active agent formulation. The sheath is configured to be capable of securing and retaining the active agent formulation within the sheath on a finger nail or toe nail while reducing evaporation of the liquid component of the aqueous liquid component of the active agent formulation. The active agent formulation can be a “slow-molding” hydrogel formulation that can slowly flow into the exact shape of the diseased nail to assure intimate contact and continuous delivery of the drug, while cannot be squeezed out of the position during the application.07-09-2009
20090175944Gel suitable for implantation and delivery system - The invention concerns a dried form of a porous polymer gel material which may be rehydrated and placed under pressure or compression to induce salvation, thereby forming a high concentration gel, in the form of an injectable viscous putty or dough, which may be implantated in the body.07-09-2009
20090175943Transdiscal administration of specific inhibitors of pro-inflammatory cytokines - The present invention relates to injecting a high specificity cytokine antagonist into a diseased intervertebral disc.07-09-2009
20110189286Pulsatile Release of Valsartan - The present invention provides gastroretentive pulsatile pharmaceutical delivery systems that improve the bioavailability of Valsartan wherein the medicament has improved solubility, improved residence time in the gastrointestinal tract and a pulsatile release profile.08-04-2011
20100189792IN VIVO GENE TRANSFER METHODS FOR WOUND HEALING - The present invention relates to an in vivo method for specific targeting and transfer of DNA into mammalian repair cells. The transferred DNA may include any DNA encoding a therapeutic protein of interest. The invention is based on the discovery that mammalian repair cells proliferate and migrate into a wound site where they actively take up and express DNA. The invention further relates to pharmaceutical compositions that may be used in the practice of the invention to transfer the DNA of interest. Such compositions include any suitable matrix in combination with the DNA of interest.07-29-2010
20110189285HYDROGEL CAPABLE OF CONTAINING AND CONVEYING CELLS - An interpenetrating biodegradable polymeric matrix hydrogel and the use thereof to support, encapsulate, convey and release several types of cells under conditions which allow the cells to be kept alive, grow and interconnect. The hydrogel may be used to prepare implants for integrally or partially regenerating, reconstructing and/or replacing damaged, dead or no longer functional tissues, in particular at the central nervous system or spinal marrow level. In such use, the biodegradability of the hydrogel allows a progressive release of the conveyed cells in order to promote their integration, even functional, with the surrounding tissue. The hydrogel may also be employed to support cells, for example, neural cells such as neuronal cells, on measuring devices, specifically realised for monitoring several parameters of cell activity, also during pharmacological and bio-mechanical tests.08-04-2011
20110189284Peptide Fibres - This invention relates to protein fibrils, to methods and kits of producing those protein fibrils comprising a plurality of first peptide monomer units arranged in a first strand and a plurality of second peptide monomer units arranged in a second strand in which said first and second strands form an overlapping staggered heterodimer coiled coil structure, and wherein the amino acid residues on the exposed surface of said first and second strands enable said protein fibril to interact with another protein fibril in a plurality of non-parallel orientations. This invention also relates to bundles of protein fibrils and matrices, in particular, hydrogels produced using those protein fibrils.08-04-2011
20110189290Compositions Comprising Capture Peptides for A B-Amyloid Peptide - Disclosed herein is a composition for the treatment and/or prevention of Alzheimer's disease and the delivery thereof. The composition comprises a PEG hydrogel having bound thereto a capture peptide, wherein the capture peptide is capable of binding beta-amyloid. In another embodiment, the capture peptide is attached to a solid support.08-04-2011
20110189289Cell-Based Method and Means for Rebuilding Bone - The invention relates to the use of in vitro isolated or in vitro differentiated osteoclasts for bone rebuilding, in particular by in vivo application, to trigger bone rebuilding by attracting osteoblasts and preferably also vascular cells to sites of bone defect. It has been found by the inventors that osteoclasts can control bone rebuilding by secreting chemotactic factors and attracting osteoblasts and vascular cells to a site of bone defect. The invention further relates to the use of osteoclasts for the manufacture of a pharmaceutical preparation or medical product containing osteoclasts for the use for bone rebuilding.08-04-2011
20110151001PHARMACEUTICAL COMPOSITION FOR EXTERNAL APPLICATION CONTAINING PROCHLORPERAZINE - Disclosed is a novel pharmaceutical composition for external application for increasing the permeation of prochlorperazine or a pharmaceutically acceptable salt thereof through the skin to allow prochlorperazine or the pharmaceutically acceptable salt thereof to exhibit its excellent pharmacological activity. Specifically disclosed is a novel pharmaceutical composition for external application, which contains prochlorperazine or a pharmaceutically acceptable salt thereof as an active ingredient and further contains menthol. The composition contains, as an active ingredient, prochlorperazine which has been widely used clinically as the first-line drug of a therapeutic agent for nausea or vomiting before or after a surgery or the like, and is extremely highly useful as a transdermally absorbable antiemetic agent that has excellent efficacy and can be used safely over a long period.06-23-2011
20110189287METHODS AND COMPOSITIONS FOR WOUND HEALING - The present invention relates to methods and compositions for wound healing. In particular, the present invention relates to promoting and enhancing wound healing by utilizing cross-linker covalent modification molecules to attach and deliver wound active agents to a wound. In addition, the present invention provides methods and compositions utilizing oppositely charged polyelectrolytes to form a polyelectrolyte layer on a wound surface. The invention further relates to incorporating wound active agents into a polyelectrolyte layer for delivery to a wound.08-04-2011
20100028433IMMUNOGENIC COMPOSITIONS COMPRISING NANOEMULSION AND HEPATITIS B VIRUS IMMUNOGEN AND METHODS OF USING THE SAME - The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides immunogenic compositions and methods of using the same to induce immune responses (e.g., immunity (e.g., protective immunity)) against Hepatitis B virus (HBV)). Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.02-04-2010
20100028431COMPOSITIONS AND METHODS FOR THERAPEUTIC USE - A method and pharmaceutical composition for the enhancement of transfer of a therapeutic agent to a cell wherein the therapeutic agent is formulated in a buffer comprising a compound of Formula I:02-04-2010
20100260845Biocompatible and Biodegradable Biopolymer Matrix - The present invention provides a biodegradable biopolymer matrix for surgical and/or therapeutic use comprising chitosan hydrochloride and dextran dialdehyde is in the ratio of 1:1 to 1:2. The invention further provides a process for preparing the biopolymer matrix and a kit for a surgical and/or therapeutic use comprising the biopolymer matrix.10-14-2010
20120034304Prolonged Release Pharmaceutical Composition Containing 3-(3-Dimethylamino-1-Ethyl-2-Methyl-Propyl)Phenol - A pharmaceutical formulation for prolonged release of the active ingredient 3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol or a pharmaceutically acceptable salt thereof in a matrix containing between 1 and 80 wt. % of at least one pharmaceutically acceptable hydrophilic or hydrophobic polymer as a matrix forming agent and exhibiting in vivo the following release rate: 3 to 35% by weight (based on 100% by weight active ingredient) 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 0.5 hours; 5 to 50% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 1 hour; 10 to 75% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 2 hours; 15 to 82% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 3 hours; 30 to 97% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 6 hours; more than 50% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 12 hours; more than 70% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 18 hours, and more than 80% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 24 hours.02-09-2012
20090232890COMPOSITIONS AND METHODS FOR DISTRACTION OSTEOGENESIS - The present invention relates to compositions and methods for use in osteodistraction procedures. In one embodiment, a method of stimulating osteogenesis during and/or following bone distraction comprises providing a composition comprising a PDGF solution disposed in a biocompatible matrix and applying the composition to at least one site of bone distraction.09-17-2009
20100303910TOPICAL SKIN CARE COMPOSITIONS - The present invention relates to a composition in the form of a phase-stable oil-in-water emulsion useful for topical skin care products, where the composition includes a quaternary ammonium salt, from about 0.5 to about 4.5 percent by weight of a starch; and at least 20 percent by weight of a hydrophobic agent, where the concentration of the quaternary ammonium salt plus the starch is from about 1.75 to about 5.5 weight percent, based on total weight of the composition.12-02-2010
20090252796NUTRITIONAL SUPPLEMENT FOR THE PREVENTION OF CARDIOVASCULAR DISEASE, ALZHEIMER'S DISEASE, DIABETES, AND REGULATION AND REDUCTION OF BLOOD SUGAR AND INSULIN RESISTANCE - A mixture (which may be utilized as a food or a drink or a supplement or a drug or a cosmetic or a hygienic product) that is formulated and is capable of improving a person's well being, lowering the risks of cardiovascular and/or Alzheimer's diseases and/or lowering blood sugar using natural and synthetic ingredients. Numerous ratios of ingredients may be formulated to balance synergy resonance of antioxidants, flow (viscosity), sediment/uniformity, color, taste, sugar content, flavor and aroma. Moreover, ingredients for natural preservatives and sugar substitutes and methods of nano-dispersion, nano-encapsulation, time-released delivery and apparatus for personalized nutrition are also described herein.10-08-2009
20100159010Active Agent Formulations, Methods of Making, and Methods of Use - An active agent composition includes particles containing a water-insoluble active agent or an active agent with a significant food effect; and a ternary amine polymer having both hydrophobic (meth)acrylate units and acid-soluble (meth)acrylate units, and an acidifying agent; wherein upon ingestion by a human subject, the acidifying agent facilitates the dissolution of the ternary amine polymer in the gastrointestinal tract.06-24-2010
20100272806Compositions and Methods for Treating and Preventing Urolithiasis and Conditions Associated Therewith - Compositions and methods for the treatment of urinary calculi and fragments thereof are provided. Compositions and methods for the prevention and/or treatment of renal and urinary colic caused by urinary calculi or fragments are also provided. Such compositions and methods provide locally effective amounts of diazepam sufficient to prevent formation of and/or expel ureteral calculi and fragments thereof and thus prevent and/or treat pain associated with calculi and fragments thereof.10-28-2010
20100278916TOPICAL APPLICATION AND FORMULATION OF ERYTHROPOIETIN FOR SKIN WOUND HEALING - The invention relates to the use of erythropoietin (EPO), in particular EPO in a polymer-based pharmaceutical preparation which stabilises the active compound, for the treatment of traumatised skin, in particular for wound healing in the case of mechanical or pathological injuries or in the case of burns.11-04-2010
20100068277Ex vivo modifiable multiple medicament final dosage form - Described embodiments include a final dosage form for administering a medicament to an animal, an article of manufacture, and method. A described final dosage form includes a dosage portion having a medicament and a release element in a first medicament-release state. The medicament has a first bioavailability to the animal. The release element is modifiable ex vivo to a second medicament-release state by an exposure to a stimulus, wherein the medicament has a second bioavailability to the animal. The final dosage form includes another dosage portion having another medicament and another release element in another first medicament-release state. In the another first medicament-release state, the another medicament has another first bioavailability to the animal. The another release element is modifiable ex vivo to another second medicament-release state by an exposure to another stimulus, wherein the another medicament has another second bioavailability to the animal.03-18-2010
20100189793ELECTROPHORETIC TRANSDERMAL DELIVERY SYSTEM - A transdermal delivery system (TDS) for administering at least one active agent through the skin. The system has a first electrode, a second electrode, and a matrix located between the first and second electrodes. The TDS contains at least one active agent which is either alkaline or acidic. The system is configured such that when applying a voltage to the electrodes, the pH of the matrix, in the case of an alkaline active agent, does not exceed the pH of the active agent and, in case of an acidic active agent, does not fall below the pH of the active agent.07-29-2010
20100215745COMPOSITIONS OF SPORES OF NON PATHOGENIC BACTERIA - Liquid-based phamaceutical and/or veterinary and/or nutraceutical compositions comprising non pathogenic sporogenic bacteria, component SP), and the following components: 08-26-2010
20110135730Oral Formulations of Glycyl-2-Methylprolyl-Glutamate - Oral formulations of G-2MePE including microemulsions, coarse emulsions, liquid crystals, tablets and encapsulated forms of G-2MePE have improved bioavailability than conventional aqueous formulations. In particular, microparticles, nanoparticles and microemulsions can exhibit great neuroprotective effects after oral administration. In a microemulsion formulation, G-2MePE can nearly completely inhibit cerebral infarction in an animal model of stroke even after the stroke had been initiated. Thus, improved oral formulations can be desirably used to treat a variety of neurodegenerative conditions with improved convenience and improved efficacy.06-09-2011
20090175946USE OF GELATIN AND A CROSS-LINKING AGENT FOR PRODUCING CROSS-LINKING MEDICAL GLUES - The invention relates to the use of gelatin and a cross-linking agent to provide a medical glue which forms a cross-linked gelatin gel in an area of application of the human or animal body. According to the invention, (i) the gelatin and the cross-linking agent are mixed with each other to form the cross-linking medical glue which is then administered to the area of application; or (ii) the gelatin and the cross-linking agent are made available in separate form and are administered, simultaneously or one after the other, to the area of application while forming the cross-linking medical glue.07-09-2009
20090068269ORALLY ADMINSTRABLE OPIOID FORMULATIONS HAVING EXTENDED DURATION OF EFFECT - Sustained release oral solid dosage forms of opioid analgesics are provided as multiparticulate systems which are bioavailable and which provide effective blood levels of the opioid analgesic for at least about 24 hours. A unit dose of the opioid analgesic contains a plurality of substrates including the opioid analgesic in sustained release form. The substrates have a diameter from about 0.1 mm to about 3 mm.03-12-2009
20080292703Antitumoral Bioconjugates of Hyaluronic Acid or Its Derivatives Obtained by Indirect Chemical Conjugation, and Their Use in the Pharmaceutical Field - The present invention describes a new group of bioconjugates which can be obtained by means of indirect synthesis, via a molecular spacer, between hyaluronic acid and/or its derivatives and drugs with an antitumoral activity belonging to different groups, their preparation process and use in the oncological field. The new derivatives, in relation to the type of bond and Substitution degree, have different physico-chemical properties which improve their tolerability and efficiency and allow a more accurate modulation of the dosage, exploiting an active targeting mechanism.11-27-2008
20100183723Fetal Skin Cell Protein Compositions for the Treatment of Skin Conditions, Disorders or Diseases and Methods of Making and Using the Same - The present invention provides methods and compositions designed for treating a subject suffering from skin conditions, disorders or diseases. The compositions include fetal skin cell proteins obtained from fetal skin cells after induced cell lysis.07-22-2010
20100112061Monophosphates as Mutual Prodrugs of Muscarinic Receptor Antagonists and Beta-Agonists for the Treatment of COPD And Chronic Bronchitis - A mutual prodrug of a MRA and a (β-agonist for formulation for delivery by aerosolization to inhibit pulmonary bronchoconstriction is described. The mutual prodrug is preferably formulated in a small volume solution (10-500 μL) dissolved in a quarter normal saline having pH between 5.0 and 7.0 for the treatment of respiratory tract bronchoconstriction by an aerosol having mass median average diameter predominantly between 1 to 5μ, produced by nebulization or by dry powder inhaler.05-06-2010
20110305760TISSUE REGENERATION SYSTEM - A system for growing tissue based upon layers of an inorganic extracellular matrix, wherein each layer of the inorganic matrix is designed to dissolve at a separate rate and result in sequential growth factor delivery upon its dissolution.12-15-2011
20110111029COMPOSITION FOR TRANSDERMAL DELIVERY OF CATIONIC ACTIVE AGENTS - A composition for transdermal delivery, particularly iontophoretic transdermal delivery, having at least one cationic active agent or a salt thereof. The composition comprises at least one cationic active agent or a salt thereof, at least one polyamine and/or polyamine salt, water or an aqueous solvent mixture, and optionally one or more additives. Use of the composition as a component of a transdermal patch or of an iontophoretic transdermal patch is also provided, as well as the use of the composition in a method for transdermally or iontophoretically administering cationic active agents. A method for determining the in vitro skin permeation properties of an active agent-containing iontophoretic composition is also provided.05-12-2011
20120040001DISINTEGRATING PARTICLE COMPOSITION AND RAPIDLY DISINTEGRATING COMPRESSION-MOLDED MATERIAL USED THE SAME - [Subject Matter]02-16-2012
20100266690STABILIZER CONCENTRATE FOR MATRIX COMPOSITIONS PROCESSED AT ELEVATED TEMPERATURES - A stabilizer concentrate of, by wt. (a) 5 to 50% of N-(trichloromethylthio)phthalimide, (b) 5-20% antioxidant, and optionally (c) a carrier component. The concentrate can be incorporated into a matrix composition, e.g., a plastic, and processed at temperatures up to 2800 C without degrading the biocide or discoloring the plastic.10-21-2010
20080220062Sustained release of agents for localized pain management - The invention relates to the treatment of localized pain by providing sustained release of an agent suitable for treating pain, methods for preparing and administering the agent, and methods of formulating and administering the agent as a pharmaceutical preparation. The agent can be locally administered to reduce systemic concentrations of the agent.09-11-2008
20090274760Use of An Alkyl Glycoside Or Of A Mixture Of Alkyl Glycosides Having Anti-Ageing And/Or Calming Properties As Active Agents In Cosmetic Compositions, And Methods Of Cosmetic Care Using Said Compositions - The present invention relates to a novel use of alkyl glycosides and of mixtures of alkyl glycosides having anti-ageing and/or calming properties as active agents in cosmetic compositions, and to methods of cosmetic care using the said compositions.11-05-2009
20110052694USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES - Described herein are microneedle drug delivery systems comprising a pharmaceutical compositions comprising pharmaceutically active agents (e.g., cannabidiol and prodrugs of cannabidiol) and microneedle arrays suitable for local and systemic delivery of the active agent to a mammal. Also described herein are methods of using a microneedle transdermal or topical drug delivery systems comprising pharmaceutical compositions, comprising cannabidiol and prodrugs of cannabidiol, and microneedle arrays in the treatment disease, including pancreatitis and pancreatic cancer.03-03-2011
20090136573Methods for Making and Delivering Rho-Antagonist Tissue Adhesive Formulations to the Injured Mammalian Central and Peripheral Nervous Systems and uses Thereof - The present invention provides methods for making, delivering and using formulations that combine a therapeutically active agent(s) (such as for example a Rho antagonist(s)) and a flowable carrier component capable of forming a therapeutically acceptable matrix in vivo (such as for example tissue adhesives), to injured nerves to promote repair and regeneration and regrowth of injured (mammalian) neuronal cells, e.g. for facilitating axon growth at a desired lesion site. Preferred active agents are known Rho antagonists such as for example C3, chimeric C3 proteins, etc. or substances selected from among known trans-4-amino(alkyl)-1-pyridylcarbamoylcyclohexane compounds or Rho kinase inhibitors. The system for example may deliver an antagonist(s) in a tissue adhesive such as, for example, a fibrin glue or a collagen gel to create a delivery matrix in situ. A kit and methods of stimulating neuronal regeneration are also included.05-28-2009
20110064809SCAFFOLDS - The invention relates to methods of preparing tissue implants for use in the augmentation, repair and regeneration of tissues.03-17-2011
20110318414REGENERATIVE TISSUE GRAFTS AND METHODS OF MAKING SAME - A graft containing a scaffold that includes a matrix in which are positioned mesenchymal progenitor cells (MPCs) has the capacity to substantially improve wound healing, including wounds resulting from injury to nerve, bone and vascular tissue. MPCs can be harvested from debrided muscle tissue following orthopaedic trauma. The traumatized muscle-derived progenitor cells are a readily available autologous cell source that can be utilized to effect or improve wound healing in a variety of therapeutic settings and vehicles.12-29-2011
20120003315Flowable Carrier Matrix - A carrier matrix may be delivered to a target position within a patient in a minimally invasive manner by first cutting a collagen sponge sheet into a plurality of relatively small pieces. These pieces are sized so that, when wet, they are capable of flowing through a cannula and/or reduced-diameter syringe tip. The pieces are placed into a syringe and wetted, say with a morphogenic solution, and optionally mixed with a bulking material, which is similarly sized to fit through the cannula. The thoroughly mixed and wetted product forms a viscous aggregate which may then be injected into the patient at the target site.01-05-2012
20100055183TRIMEPRAZINE AND ETHOPROPAZINE DERIVATIVES FOR PROMOTING BONE GROWTH - The present invention provides a method of promoting bone growth in a subject in need thereof, by administering to the subject a therapeutically effective amount of a compound of Formula I. The present invention also provides methods for the treatment of renal disease and cancer.03-04-2010
20100221339Use of a combination of morphine and at least one opiate antagonist to treat opiate dependency and prevent non-oral opiate abuse among opiate addicts - The present invention relates to the use of an inseparable combination of morphine and at least one opiate antagonist with a bioavailability of less than 5% on oral administration for producing a medicament to be administered orally for treatment of opiate dependency in humans and to the use of an inseparable combination of an opiate and at least one opiate antagonists with a bioavailability of less than 5% on oral administration for producing a medicament to be administered orally for prevention of non-oral opiate abuse in opiate addicts.09-02-2010
20120009260NANOPARTICLE FILM DELIVERY SYSTEMS - A therapeutic or bioeffecting film delivery system which includes nanoparticles having actives bound to or associated with the nanoparticles and which when administered allow the active to perform a therapeutic or bioeffecting function.01-12-2012
20120009261NOVEL GASTRO-RETENTIVE DOSAGE FORMS - A gastro-retentive pharmaceutical dosage form of a therapeutically effective amount of at least one GABA Analog, at least one opioid, and at least one pharmaceutically acceptable excipient wherein the said dosage form is retained in the stomach for at least four hours and is suitable for formulating for once daily or twice daily administration. Further provided is a method of treating a disorder by administering to a patient in need thereof, a gastro-retentive pharmaceutical dosage form of a therapeutically effective amount of at least one GABA Analog, at least one opioid, and at least one pharmaceutically acceptable excipient wherein the said dosage form is retained in the stomach for at least four hours and is suitable for once daily or twice daily administration. The opioid is either in slow release form or in immediate release form.01-12-2012
20100151027METHOD OF TREATING PAIN UTILIZING CONTROLLED RELEASE OXYMORPHONE PHARMACEUTICAL COMPOSITIONS AND INSTRUCTION ON DOSING FOR RENAL IMPAIRMENT - The invention pertains to a method of using oxymorphone in the treatment of pain by providing a patient with an oxymorphone dosage form and informing the patient or prescribing physician that the bioavailability of oxymorphone is increased in patients with renal impairment.06-17-2010
20120045511THERMOSENSITIVE HEPATITIS B VACCINE - A thermosensitive hepatitis B vaccine is provided. The thermosensitive hepatitis B vaccine includes an aqueous phase solution comprising a biodegradable thermosensitive hydrogel copolymer; a surface antigen of hepatitis B virus (HBsAg); and a bioactive substance. The thermosensitive hepatitis B vaccine of the disclosure is particularly suitable for being applied in the patients, which are low responsive or non-responsive to conventional hepatitis B vaccine, for enhancing the induction of cell-mediated immune responses and overcoming the HBsAg non-responsiveness.02-23-2012
20100226983Compositions for treatment and prevention of acne, methods of making the compositions, and methods of use thereof - The present invention relates to methods for treating and preventing acne or 09-09-2010
20120207835BROAD-SPECTRUM BIOCIDE COMPOSITIONS AND A METHOD FOR THEIR PREPARATION - The present invention provides biocide compositions, containing DBNPA encapsulated or absorbed in ceramic powders or xerogels, for preventing the formation of biofilms and for incorporating into paints, coatings, plasters, and plastics.08-16-2012
20120064163ANTI-TUMOR/CANCER HETEROLOGOUS ACELLULAR COLLAGENOUS PREPARATIONS AND USES THEREOF - Disclosed are mammalian tumor and/or cancer cell conditioned substrate preparations having tumor inhibiting activity. In some embodiments, the mammalian tumor and/or cancer cell conditioned substrate preparations are essentially free of cellular components. These preparations comprise a conditioned heterologous acellular collagenous tissue preparation, and may be prepared using a mammalian extracellular matrix substrate. The conditioned substrates include many different anti-tumor and/or anti-cancer biomolecules, such as that population of anti-tumor biomolecules that are secreted and/or produced by mammalian tumor and/or cancer cells as they grow on a substrate, thus imparting the anti-tumor and/or anti-cancer properties to the conditioned substrates of the invention. The present disclosure also provides methods for preparing the mammalian tumor and/or cancer cell conditioned substrates, as well as methods for using the preparations to inhibit tumor growth, such as in a vaccine or wound dressing. Methods for inhibiting prostate tumors and melanoma with the described conditioned substrates are also described. The conditioned mammalian tumor and/or cancer cell substrate preparations are essentially free of viable and/or carcinogenic or invasive tumor and/or cancer cells. The conditioned substrates and substrate preparations include anti-tumor and anti-cancer properties that may be used in preparations and formulations for the treatment of cancer.03-15-2012
20110033540POLYMER FORMULATIONS FOR DELIVERY OF BIOACTIVE AGENTS - Disclosed in the present application are compositions comprising a bioresorbable polymer matrix and a bio active agent, wherein the bioactive agent is dispersed within polymer matrix as a solid. Also provided herein are methods for preparing a bioactive agent formulation, wherein the agent is present in a solid form and, wherein the agent is occluded into a polymeric matrix by polymerization of polymer matrix precursors or by self assembly of the polymer.02-10-2011
20090274759SOLID PHARMACEUTICAL COMPOSITION WITH A FIRST FRACTION OF A DISPERSION MEDIUM AND A SECOND FRACTION OF A MATRIX, THE LATTER BEING AT LEAST PARTIALLY FIRST EXPOSED TO GASTROINTESTINAL FLUIDS - A solid pharmaceutical composition in the form of a single dosage unit for oral use, the composition comprising a first and a second fraction, the first fraction comprises a therapeutically and/or prophylactically active substance dispersed in a dispersion medium that is sufficiently fluid at body temperature and the second fraction comprises a matrix comprising a substantially water soluble and/or crystalline polymer or a mixture of substantially water soluble and/or crystalline polymers, the first fraction being included in the composition in such a manner that at least a part of the second fraction is firstly exposed to the gastrointestinal fluids upon administration before the first fraction becomes exposed. The system is designed to release the active substance after a predetermined period of time after administration, and the release of the active substance at that point in time is relatively fast.11-05-2009
20120058187WATER-IN-OIL TYPE EMULSION FOR TREATING A DISEASE OF THE EYE - A composition is described herein for administering with a sustained release kinetic a therapeutically effective amount of a therapeutic agent to a subject in need thereof for treating diseases or conditions of the eye, wherein the composition is an water-in-oil type emulsion comprising an oil phase, a lipophilic surfactant dissolved in the oil phase, an aqueous phase dispersed in the oil phase, a hydrophilic therapeutic agent dissolved in the aqueous dispersed phase, and wherein the composition is intraocularly injectable, wherein the composition has a density lower than 1. Some embodiments also relate to a pharmaceutical composition or to a medicament comprising a composition described herein, and to a method for treating a condition or disease of the eye comprising administering a therapeutic amount of a composition described herein.03-08-2012
20090169626TAMPER RESISTANT DOSAGE FORMS - Tamper resistant controlled release formulations.07-02-2009
20100189794NUCLEIC ACID HYDROGEL VIA ROLLING CIRCLE AMPLIFICATION - Methods and compositions are provided for producing nucleic acid-based compositions. Methods include enzyme catalyzed or nucleic acid polymer conjugation. Compositions include nucleic acid-containing hydrogels which can be elongated via rolling circle amplification. The hydrogels can encapsulate bioactive agents for drug delivery.07-29-2010
20120156299COMPOSITIONS COMPRISING LILIUM MARTAGON EXTRACTS AND USES THEREOF - Provided are compositions comprising an extract of 06-21-2012
20120156298COMPOSITIONS COMPRISING LILIUM SIBERIA EXTRACTS AND USES THEREOF - Provided are compositions comprising an extract of 06-21-2012
20120156297COMPOSITIONS COMPRISING LILIUM CANDIDUM EXTRACTS AND USES THEREOF - Provided are compositions comprising certain extracts of 06-21-2012
20080199523Particles Comprising A Releasable Dopant Therein - A process for making particles comprising a hydrophobic dopant for subsequent release therefrom is disclosed. The process comprises providing an emulsion comprising a hydrophilic phase and a hydrophobic phase dispersed in the hydrophilic phase, and reacting the precursor material to form the particles comprising the dopant therein. The hydrophobic phase comprises a precursor material and the dopant.08-21-2008
20110091553METHOD FOR PRODUCING MICROCAPSULES USING SOLID FAT - An object of the present invention is to provide a method for production of fine microcapsules which encapsulate a hydrophilic bioactive substance at a high content and can be used in wide range of applications such as foods and medical drugs, which method enabling efficient industrial production. The present invention is directed to a method for production of S/O type microcapsules in which a hydrophilic bioactive substance is polydispersed in a solid fat matrix, including steps of: dispersing a complex of the hydrophilic bioactive substance with a surfactant (A) in a solid fat at a temperature not lower than the melting point of the solid fat to obtain an S/O suspension, followed by permitting liquid droplet dispersion of the S/O suspension, and hardening the solid fat by cooling the S/O suspension liquid droplets to lower than the melting point of the solid fat to obtain solid particles; and an S/O type microcapsule wherein a milk protein-derived ingredient such as lactoferrin is polydispersed in a solid fat matrix.04-21-2011
20110091552Use of Bcl Inhibitors for the Treatment of Scarring Caused By Cutaneous Wounds, Burns and Abrasions - The present invention relates to use of Bcl inhibitors for the prevention of fibroproliferation resulting in the growth of visible or disfiguring scar tissue on human skin, including without limitation keloids and hypertrophic scars. In particular, the present invention relates to the new use of small molecule inhibitors of the Bcl-2/Bcl-XL family of anti-apoptotic proteins for the treatment of cutaneous wounds, burns and abrasions during the healing phase.04-21-2011
20110091551WOUND COVERING COMPRISING OCTENIDINE DIHYDROCHLORIDE FOR USE IN THE ANTISEPSIS OF CATHETER INSERTION POINTS - A wound covering includes a) a transparent film and b) applied to the film, a transparent hydrogel which includes octenidine dihydrochloride. The wound covering is suitable in particular for use in the antisepsis of catheter insertion points. The active ingredient octenidine dihydrochloride is released from the hydrogel quickly, but in a long-lasting manner. A wound covering set and a hydrogel including octenidine dihydrochloride for use for the antisepsis of catheter insertion points are also described.04-21-2011
20110091550Methods for Promoting the Revascularization and Reenervation of CNS Lesions - The present invention provides methods of promoting the revascularization and/or reenervation of central nervous system lesions using an in-situ crosslinkable hydrogel.04-21-2011
20110091549Modulating Drug Release Rate By Controlling The Kinetics Of The pH Transition In Hydrogels - Methods and compositions relate to modulating the release profile of drug molecules from a hydrogel by controlling the kinetics of the pH transition of the hydrogel. The hydrogel is formed by in situ polymerization and includes a drug molecule having a pKa between the pH of the formed hydrogel and the physiologic environment in which the hydrogel is placed.04-21-2011
20100291213COMPOSITE NON-WOVEN FIBROUS WEBS HAVING CONTINUOUS PARTICULATE PHASE AND METHODS OF MAKING AND USING THE SAME - The disclosure relates to composite nonwoven fibrous web including an embedded phase having a population of particulates forming a substantially continuous three-dimensional network, and a matrix phase comprising a population of fibers forming a three-dimensional network around the particulates. The disclosure also relates to methods of making a composite nonwoven fibrous web including forming an embedded phase having a population of particulates in a substantially continuous three-dimensional network, and forming a matrix phase comprising a population of fibers forming a three-dimensional network around the particulates. Articles made from a composite nonwoven fibrous web prepared according to the methods as described above are also disclosed. In exemplary embodiments, the articles may include gas filtration articles, liquid filtration articles, sound absorption articles, surface cleaning articles, cellular growth support articles, drug delivery articles, personal hygiene articles, and wound dressing articles.11-18-2010
20100291210NOVEL LIPID PEPTIDE AND HYDROGEL - There is provided a lipid peptide that is capable of forming a hydrogel with an extremely small amount thereof over a liquid property range from acidic to alkaline, and a hydrogel having high environmental suitability, biocompatibility and biodegradability. A lipid peptide represented by Formula (1):11-18-2010
20110104279HEALING POWDER AND METHOD OF USE THEREOF - A method for treating wounds, comprising providing a dry powder mixture, which when partially hydrated, forms a gel having an osmotic pressure sufficient to achieve and maintain antiseptic conditions in hydrated portions of the gel, the gelled portion comprising a biocompatible polymer, the dry powder being readily wettable by wound secretions; and applying the dry powder to a wound having wound secretions in sufficient excess to produce a self-adherent gel cake having a dry powder surface. The administration may be repeated by administration of the dry powder while wound healing progresses.05-05-2011
20120219628FAST DISSOLVING SOLID DOSAGE FORM - There is provided a fast dissolving solid dosage form adapted for the release of a biologically active material in the oral cavity wherein the dosage form comprises at least one biologically active material, and at least one matrix forming agent, wherein the dosage form substantially dissolves in the oral cavity. A method of producing the same and a kit comprising the same are also provided.08-30-2012
20100092558Method for Producing a Product Having a Polymer Matrix, Implants Made Thereof and Use Thereof - The invention concerns a method for the production of a product having a polymer matrix, products which can be produced in accordance therewith and the use thereof.04-15-2010
20100092560REDUCED COENZYME Q10-CONTAINING PARTICULATE COMPOSITION AND METHOD FOR PRODUCING THE SAME - The present invention aims to propose a particulate composition containing reduced coenzyme Q10, which simultaneously shows high oxidative stability and high absorbability in the body and a production method thereof, as well as a stabilizing method thereof, to be used in the fields of foods, foods with nutrient function claims, foods for specified health uses, nutritional supplements, nutritional products, animal drugs, beverages, feeds, cosmetics, pharmaceuticals, therapeutic drugs, prophylactic drugs and the like. The present inventors have conducted intensive studies in an attempt to solve the aforementioned problems and found that a particulate composition containing reduced coenzyme Q10, wherein an oil component containing the reduced coenzyme Q10 is polydispersed forming a domain in a matrix containing a water-soluble excipient as a main component and a water-soluble ascorbic acid is a composition simultaneously having high oxidative stability and high absorbability in the body, and completed the present invention.04-15-2010
20100247650TREATMENT FOR PRE-ECLAMPSIA IN PREGNANT WOMEN USING TARGETED APHERESIS - This invention uses “targeted apheresis” to treat pregnant women who are at risk of developing eclampsia. “Targeted Apheresis” is a process whereby the sFlt-1 receptors responsible for causing the disease symptoms are selectively removed from the blood by passing the blood through a cartridge containing either immobilized PIGF, and/or through a cartridge containing immobilized anti-sFlt-1 antibody. The sFlt-1 receptor is bound out and the cleaned blood is returned to the patient Removal of circulating sFlt-1 receptors will diminish the risk of developing eclampsia during pregnancy.09-30-2010
20090130212COMPOSITION AND IMPROVED METHOD FOR PREPARATION OF SMALL PARTICLES - The present invention relates to a novel method of loading drug molecules into small pores, along with the composition so produced. In a preferred embodiment, the drug is dissolved in a suitable solvent (which may or may not be biocompatible), and the solution is allowed to move into the pores of solid matrixes by, e.g., capillary action, optionally under the influence of pressure or vacuum. The drug is then precipitated in the pores by evaporating the solvent faster than the drug can diffuse out of the pores, which leaves solid drug particles that are not larger than the pore. Since the pore radii in solid pharmaceutical matrixes can be as small as several nanometers, the drug particle size range includes particles that are much smaller than those produced using current methods. The solvent may be a pure material, a combination of solvents, a combination of liquids and surfactants, or a supercritical fluid with or without surfactants.05-21-2009
20090130211Gelled colloidal emulsion for appetite suppression - Disclosed is a composition and method for producing individual dosages of chewable snack of gelled-colloidal-emulsion containing a large dose of hydrophilic and lipophilic neutraceutical and pharmaceutical preparations and in particular to the administration of edible composition having appetite reduction benefits with desirable eating characteristics for mammals.05-21-2009
20100183721ENHANCED DELIVERY OF IMMUNOSUPPRESSIVE DRUG COMPOSITIONS FOR PULMONARY DELIVERY - The present invention includes compositions and methods for making and using a rapid dissolving, high potency, substantially amorphous nanostructured aggregate for pulmonary delivery of tacrolimus and a stabilizer matrix comprising, optionally, a polymeric or non-polymeric surfactant, a polymeric or non-polymeric saccharide or both, wherein the aggregate comprises a surface area greater than 5 m07-22-2010
20120128774MAXILLOFACIAL BONE AUGMENTATION USING RHPDGF-BB AND A BIOCOMPATIBLE MATRIX - The present invention provides effective new methods and materials for maxillofacial bone augmentation, particularly alveolar ridge augmentation, that are free of problems associated with prior art methods. In one embodiment, these materials include human recombinant platelet derived growth factor (rhPDGF-BB) and a biocompatible matrix. In another embodiment, these materials include rhPDGF-BB, a deproteinized bone block or calcium phosphate, and a bioresorbable membrane. The use of these materials in the present method is effective in regenerating maxillofacial bones and facilitating achievement of stable osseointegrated implants. The mandible and maxilla are preferred bones for augmentation, and enhancement of the alveolar ridge is a preferred embodiment of the present invention.05-24-2012
20100028432FORMULATIONS OF ACTIVE PRINCIPLES INCORPORATED IN SLNS SUITABLE FOR TRANSDERMAL ADMINISTRATION - The present invention relates to formulations suitable for transdermal administration characterized by containing SLNs which contain active principles with a very short half-life and/or drugs with high activity.02-04-2010
20120164225BONE GRAFT MATERIALS AND METHODS - Compositions, materials, methods and kits for bone grafting are described. In some embodiments, a bone graft composition includes about 15% to about 20% by weight collagen, about 55% to about 70% by weight bioactive glass, and about 15% to about 30% by weight a calcium phosphate. The bioactive glass and the calcium phosphate together are about 80% to about 85% by weight of the bone graft composition. In some embodiments, a bone graft composition includes a collagen matrix and a plurality of bioactive glass particulates dispersed throughout the collagen matrix. The collagen matrix is about 20% to about 60% by weight of the bone graft composition, and the bioactive glass is about 40% to about 80% of the bone graft composition. In some embodiments, a majority of the bioactive glass particulates are about 53 μm to about 425 μm in size.06-28-2012
20120164224Hemostatic Preparation Containing an Extract of Golden Moss - The present invention relates generally to agents and devices for promoting hemostasis and, more particularly, to an extract of a plant-based “Traditional Chinese Medicinal” product and devices incorporating such agents for the delivery thereof to bleeding wounds.06-28-2012
20110182990NANOCOMPOSITE HYDROGEL AND METHOD FOR PREPARING IT, FOR INDUSTRIAL AND MEDICAL APPLICATIONS - Nanocrystalline cellulose (NCC) is employed as the cross-linker and reinforcement domain for developing nanocomposite hydrogels possessing high strength and improved diffusion property; the resulting nanocomposite hydrogels are shown to have high mechanical properties, reversible swelling ability, and are biodegradable and biocompatible; the approach relies on free radical polymerization to form the hydrogels using a variety of hydrophilic vinyl monomers. These hydrogels are suitable for developing highly absorbent hygiene products, as well as for applications in medicine, engineering materials and sensors.07-28-2011
20110182989COMPOSITIONS AND METHODS FOR INHIBITING CELLULAR ADHESION OR DIRECTING DIAGNOSTIC OR THERAPEUTIC AGENTS TO RGD BINDING SITES - Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH—CH(CH07-28-2011
20120135079Modified Release Tranexamic Acid Formulation - A modified release dosage form for the oral administration of tranexamic acid.05-31-2012
20100172988SUSTAINED RELEASE PREPARATION AND METHOD FOR PRODUCTION THEREOF - Disclosed is a sustained release preparation which comprises an active ingredient having a higher release rate at pH 4 compared to that in pH 1.2 or pH 6.8 and exerts a controlled release of the active ingredient in a pH-independent manner. The sustained release preparation comprises ethyl (−)-2-[4-[2-[[(1S,2R)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl]-2,5-dimethyl-phenoxy]acetate hydrochloride as the active ingredient and a pH-independent gel-forming polymer and contains substantially no pH-controlling agent other than the polymer. The sustained release preparation can release the active ingredient in a pH-independent manner in the range from 1.2 to 6.8 and shows a constant release rate for a prolonged period of time. Therefore, the preparation is useful as a therapeutic agent for frequent urination/incontinence of urine which has a long-lasting effect.07-08-2010
20100272805HYDROGELS FOR COMBINATORIAL DELIVERY OF IMMUNE-MODULATING BIOMOLECULES - One embodiment of the current disclosure relates to an immune-modulating composition comprising a hydrogel-forming polymer, an immune-modulating biomolecule operable to recruit or retain an immune cell, and an antigen-related biomolecule. Another embodiment of the current disclosure relates to a method of providing an antigen to an antigen presenting cell in an animal by administering to the animal at an administration site an immune-modulating composition as described above. Next, one forms a hydrogel in-situ from the hydrogel-forming polymer, then recruits at least one antigen presenting cell to the administration site using the immune-modulating biomolecule, and finally inducing phagocytosis of the at least one antigen-related biomolecule by the antigen presenting cell.10-28-2010
20100272804OXIDIZED CATIONIC POLYSACCHARIDE-BASED POLYMER TISSUE ADHESIVE FOR MEDICAL USE - A tissue adhesive formed by reacting an oxidized cationic polysaccharide containing aldehyde groups and amine groups with a multi-arm amine is described. The oxidized cationic polysaccharide-based polymer tissue adhesive may be useful for medical applications including wound closure, supplementing or replacing sutures or staples in internal surgical procedures such as intestinal anastomosis and vascular anastomosis, ophthalmic procedures, drug delivery, anti-adhesive applications and as a bulking agent to treat urinary incontinence. Additionally, due to the presence of the positively charged amine groups on the oxidized polysaccharide, the polymer tissue adhesive disclosed herein may promote wound healing and blood coagulation, and may possess antimicrobial properties.10-28-2010
20100272803REPAIR AND REGENERATION OF OCULAR TISSUE USING POSTPARTUM-DERIVED CELLS - Cells derived from postpartum umbilicus and placenta are disclosed. Pharmaceutical compositions, devices and methods for the regeneration or repair of ocular tissue using the postpartum-derived cells are also disclosed.10-28-2010
20100008990CRYSTALLINE MESOPOROUS OXIDE BASED MATERIALS USEFUL FOR THE FIXATION AND CONTROLLED RELEASE OF DRUGS - The invention describes a new class of crystalline silica material having two levels of porosity and structural order. At the first level, building units are nanoslabs of uniform size having zeolite framework. At the second structural level, nanoslabs are assembled, e.g. linked through their corners, edges or faces following patterns imposed by interaction with cationic surfactant or triblock copolymer molecules. After evacuation of these molecules, microporosity is obtained inside the nanoslabs, and a precise mesoporosity between the nanoslabs depending on the tiling pattern of the zeolite nanoslabs, as evidenced by X-ray diffraction. These materials are useful for the fixation of biologically active species, such as poorly soluble drugs.01-14-2010
20120219627COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS - The specification discloses compositions and methods for treating a soft tissue defect of an individual.08-30-2012
20090060998LIPID-BASED DISPERSIONS USEFUL FOR DRUG DELIVERY - The invention provides lipid-based dispersion comprising, a) phosphatidyl choline; b) an anionic phospholipid; optionally c) up to 1% cholesterol by weight of total lipids; and optionally d) a therapeutic agent; wherein the mean particle size measured by dynamic light scattering is less than 100 nm. The invention also provides pharmaceutical compositions comprising such a dispersion as well as methods of producing a therapeutic effect in a mammal comprising administering an effective amount of such a dispersion.03-05-2009
20120315333DIRECT INKJET FABRICATION OF DRUG DELIVERY DEVICES - In some aspects of the present application, a method of forming one or more layers of at least a portion of a drug delivery device (DDD) is described. The method can include providing a substrate; providing one or more DDD components that are dissolved or dispersed in one or more pharmaceutically compatible phase change inks; ejecting, by one or more nozzles, a first portion of the one or more pharmaceutically compatible phase change inks to form a first layer on the substrate; and ejecting, by the one or more nozzles, a second portion of the pharmaceutically compatible phase change inks to form a second layer over the first layer.12-13-2012
20120258174Methods for Treating Bacterial Infection - This invention relates to methods for treating bacterial infection, which methods find utility in the treatment of, for example, infected ulcers, optionally infected diabetic ulcers. In particular, this invention relates to treating bacterial infection, for example, infected diabetic ulcers by topical administration of at least one aminoglycoside antibiotic at the site of infection, in combination with at least one antibacterial agent, which antibacterial agent is administered remote from the site of infection, preferably administered systemically. In a particular embodiment, the present invention relates to a composition for use in treating bacterial infection, the composition comprising gentamicin sulphate (a water-soluble broad-spectrum aminoglycoside antibiotic) uniformly dispersed in a type-I collagen matrix; in combination with at least one systemically-administered antibacterial agent. The present invention provides bactericidal activity against most strains of aerobic gram-negative and gram-positive and facultative anaerobic gram-negative pathogens, including methicillin-resistant 10-11-2012
20120082724DRY MOULDABLE DRUG FORMULATION - Solid pharmaceutical compositions for parenteral injection comprising a binder and at least one therapeutic agent. The pharmaceutical composition has the strength to be injected directly with the need of using cannulas or the like.04-05-2012
20090017119MODIFICATIONS OF SOLID 3-SN-PHOSPHOGLYCERIDES - Methods for hydrolyzing solid ungranulated lysophosphatidylcholine with phospholipase A01-15-2009
20110123620SILICON DIOXIDE NANOPARTICLES AND THE USE THEREOF FOR VACCINATION - The invention relates to ultrasmall, monodisperse nanoparticles comprising silicon dioxide to the surface of which at least one antigen is attached. The nanoparticles can be used for the immunoprophylaxis or immunotherapy of cancer. The invention also relates to a method for the targeting of antigens at antigen-presenting cells and for the activation of the immune system, where the efficiency of targeting and/or immunoactivation are set via the particle characteristics. The invention also relates to a method for the active and passive immunisation of a mammal.05-26-2011
20110123619BUCCAL DELIVERY SYSTEM - A buccal delivery system capable of being blended in a normal dry powder process and compressed using a standard tabletting machine, said buccal delivery system comprising a matrix of: (a) an effective amount of one or more active ingredients; (b) an amount of one or more polyethylene glycols or derivatives thereof having a molecular weight between 1000 to 8000 sufficient to provide the required hardness and time for dissolution of the matrix; (c) 0.05-2% by weight of the total matrix of one or more suspending agents; (d) 0.05-2% by weight of the total matrix of one or more flowing agents; and (e) 0.05-2% by weight of the total matrix of one or more sweeteners.05-26-2011
20080299201DEVICES, METHODS, AND SYSTEMS FOR ACCESSING NATIVE NEURONS THROUGH ARTIFICIAL NEURAL MEDIATORS (ANMS) - The present invention relates to devices, methods, and systems for accessing native neurons in the nervous system of an animal. Specifically, one or more artificial neural mediators (ANMs) each comprising a neural cell are first formed, and neural connection is then established between the ANMs and one or more native neurons or collections of native neurons located in the nervous system. In this manner, the native neurons or collections of native neurons can be assessed through the ANMs. The neural connection between the ANMs and the native neurons is preferably established by guided axonal growth in the present invention, i.e., either an axon from one of the ANMs is grown into contact with one of the native neurons or collections of native neurons, or an axon from one of the native neurons or collections of native neurons is grown into contact with one of the ANMs.12-04-2008
20080299200Oil-in-Water Emulsion for Creating New Product Consistencies - The invention concerns an oil-in-water emulsion wherein the oil droplets of a diameter in the range of 5 nm to hundreds of micrometers exhibit a nano-sized self-assembled structure with hydrophilic domains having a diameter size in the range of 0.5 to 200 nm, due to the presence of a lipophilic additive, and the oil-in-water emulsion contains a thickener or gelling agent in order to create new product consistencies and textures.12-04-2008
20080299199Swellable Dosage Form Comprising Gellan Gum - A novel dosage form. The dosage form is presented in particulate form and before oral ingestion the particulate material is subjected to an aqueous medium, whereby it is converted to a semi-solid form by swelling or gelling of one or more of the components, especially of a gellan gum, of the particulate matter. The invention also relates to a vehicle for oral administration of one or more active substances, the vehicle comprising a gellan gum arranged in a configuration allowing optimal water diffusion so that upon addition of a predetermined amount of an aqueous medium, without the necessity of applying shear forces or other mixing forces, within a time period of 5 minutes or less swells and/or gels and the texture of the swelled vehicle being similar to that of a soft pudding and having a viscosity of at least about 10,000 cps as measured by a Brookfield Viscometer with a #4 LV spindle at 6 rpm and at 20-25° C. In one embodiment of the invention, the particulate matter can be moulded into a desired shape or pressed onto a dispensing unit such as a spoon.12-04-2008
20110002996ACELLULAR TISSUE MATRICES MADE FROM ALPHA-1,3-GALACTOSE-DEFICIENT TISSUE - The invention provides acellular tissue matrices made from collagen-containing tissues of animals genetically modified so as to be deficient in the galactose 1,3-galactose epitope and methods of making and using such acellular tissue matrices.01-06-2011
20110002995PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CARDIAC DISEASE - Provided is a pharmaceutical composition for the treatment and prevention of cardiac diseases, containing (a) a therapeutically effective amount of a compound represented by Formula 1 or 2 or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and (b) a pharmaceutically acceptable carrier, diluent or excipient or any combination thereof.01-06-2011
20110002994METHOD OF REGULATING THE TH17 PATHWAY AND ITS ASSOCIATED METABOLIC IMPACT - It is disclosed a method of immunomodulating an immune response in a subject comprising administering to a subject a malleable protein matrix (MPM), from fermented whey, in an amount effective to modulate the biological activity of Th17 cells, and its associated metabolic pathway, for a preventative or a therapeutic purpose of a variety of health applications in the field of immunity or obesity related diseases.01-06-2011
20100233263METHODS AND COMPOSITIONS FOR TREATMENT OF LESIONED SITES OF BODY VESSELS - Methods and compositions for inducing apoptosis of cells, such as macrophages, at a lesioned site of a body vessel are disclosed herein. Nitric oxide can be directly or indirectly delivered to a treatment site to increase macrophage apoptosis. Delivery can include site specific delivery of nitric oxide gas, nitric oxide in aqueous solution or a substance(s) which releases nitric oxide or causes nitric oxide to be generated from an endogenous source. Delivery can be achieved by a delivery system such as a catheter assembly, stent or other suitable device.09-16-2010
20100034881MACROMOLECULAR DIFFUSION AND RELEASE FROM SELF-ASSEMBLED BETA-HAIRPIN PEPTIDE HYDROGELS - A hydrogel for delayed release of an anionic macromolecule, wherein the hydrogel comprises the anionic macromolecule, 150 mM NaCl, and a peptide selected from the group consisting of SEQ ID NO:1 through SEQ ID NO:33 in an aqueous medium at a pH of 7.4; wherein the anionic macromolecule has an isoelectric point of at most 6.8; and wherein the hydrogel is capable of retaining at least 25% of the anionic macromolecule after 28-day extraction at 37° C. with a pH=7.4 BTP buffer containing 150 mM NaCl.02-11-2010
20110038935ANTIBODIES AGAINST INFLUENZA VIRUS AND METHODS OF USE THEREOF - The invention provides human scFv antibodies and monoclonal antibodies that neutralize influenza virus. Also provided are methods of treating and/or preventing a influenza related disease or disorder such bird flu The invention also provides methods of vaccinating a patient against influenza. Also provided are methods of diagnosing influenza-related diseases or disorders and methods of detecting the presence of a influenza in a sample.02-17-2011
20110045074MATRIX TYPE SUSTAINED-RELEASE PREPARATION CONTAINING BASIC DRUG OR SALT THEREOF AND, METHOD FOR MANUFACTURING THE SAME - A matrix type sustained-release preparation and a manufacturing method therefor are provided wherein dissolution with low pH dependence of a basic drug or a salt thereof at the early stage of dissolution can be ensured in a dissolution test, and wherein as the dissolution test proceeds, a ratio of a dissolution rate of the basic drug or the salt thereof in an acidic test solution to a dissolution rate of the basic drug or the salt thereof in a neutral test solution (dissolution rate in the acidic test solution/dissolution rate in the neutral test solution) decreases with dissolution time at the late stage of dissolution, as compared to the early stage of dissolution. According to the present invention, the matrix type sustained-release preparation contains a basic drug or a salt thereof and at least one enteric polymer, in which solubility of the basic drug or the salt thereof in a 0.1 N hydrochloric acid solution and a neutral aqueous solution, pH 6.0 is higher than in a basic aqueous solution, pH 8.0.02-24-2011
20110045073METHODS AND COMPOSITIONS OF SPHINGOLIPID FOR PREVENTING AND TREATING MICROBIAL INFECTIONS - The present invention relates to controlled release composition for preventing and/or treating microbial infections in the oral cavity of a subject, said composition comprising a controlled delivery matrix which matrix has releasably associated therewith an amount of between 0.000009 and 5 wt % of a sphingolipid, wherein the composition provides a sphingolipid-release-profile in the oral cavity of a subject, wherein said release-profile is maintained for between 15 seconds and 24 hours and wherein said release-profile provides for a concentration of said sphingolipid in the saliva of said subject of between 20 μmole/L and 250 μmole/L.02-24-2011
20110045071GENERATION OF A NOVEL TYPE OF ANTI-INFLAMMATORY MACROPHAGES FOR CLINICAL USE - The invention relates to a purified, novel anti-inflammatory population of macrophage and methods of making and using such macrophage.02-24-2011
20120148674SELF-ASSEMBLING HYDROGELS BASED ON DICEPHALIC PEPTIDE AMPHIPHILES - We have disclosed dicephalic amphiphiles having peptide sequences as the head groups. We have also disclosed self-assembly hydrogels prepared from the dicephalic peptide amphiphiles. These hydrogels are useful for the encapsulation and delivery of bioactives to a patient.06-14-2012
20110217375Dendrimeric peptides, pharmaceutical compositions and methods of using the same - Novel dendrimeric peptide compounds are disclosed that have a formula represented by the following formula I:09-08-2011
20110236484Genus-Wide Chlamydial Peptide Vaccine Antigens - Peptides generated from a random library that are bound by a monoclonal antibody to Chlamydial glycolipid exoantigen (GLXA) and thus mimic this antigen are disclosed. Peptides that correspond to antigen-binding regions of an anti-idiotypic antibody (mAb2) specific for anti-GLXA antibody (Ab1) which act as molecular mimics of GLXA are also disclosed used as immunogens to induce broadly reactive genus-specific anti-chlamydial antibodies. These peptides and immunogenic DNA encoding the mAb2-like peptides, microparticle or nanoparticle formulations and other formulations of these peptides are disclosed as are methods for immunizing subjects to obtain genus-specific anti-chlamydial antibodies and to treat or prevent 09-29-2011
20110236483RNA VECTOR THERAPY - The innovative treatment strategy described here utilizes configurable microscopic medical payload delivery devices to act as a transport vector to deliver a wide variety of cellular ribonucleic acid molecules to specific types of cells in the body. Utilizing probes on the exterior of the transport devices, the transport devices locate a specific type of cell in the body. Once a specific target cell type has been encountered, the configurable microscopic medical payload delivery devices insert their payload of cellular ribonucleic acid molecules into the target cells. By delivering cellular ribonucleic acid molecules into specific cells a wide variety of protein deficiencies are correctable, gene expression is capable of being modulated, and telomere synthesis is enhanced.09-29-2011
20120100216MATRIX CARRIER COMPOSITIONS, METHODS AND USES - Provided is a matrix carrier composition for use in pharmaceutical delivery system, the composition comprising an intermolecular association of at least a first solid phase comprising nanoparticles having hydrophobic surface, wherein the size of the nanoparticles is in the range of about 5-1000 nm, a second solid phase, comprising a biopolymer having hydrophilic and hydrophobic parts, and a continuous phase comprising oil associated with the first and said second solid phases.04-26-2012
20120100215MULLER STEM CELLS - A method for the production of retinal cells, useful in transplantation therapy, comprises: (i) obtaining one or more mammalian adult Müller cells; and (ii) culturing the cells in the presence of an extracellular matrix protein and a growth factor to thereby induce dedifferentiation of the Müller cells into a progenitor phenotype.04-26-2012
20100203137FORMULATION OF MENINGITIS VACCINES - A liquid Hib component is used to reconstitute a lyophilised meningococcal component, thereby producing a combined meningitis vaccine. A lyophilised meningococcal component can also be reconstituted with an oil-in-water emulsion.08-12-2010
20100203136METHOD FOR DELIVERING A HUMAN CHORIONIC GONADOTROPIN (Hcg) VACCINE FOR LONG-ACTING ANTIBODY PROTECTION - This invention comprises a method of immunization in which human chorionic gonadotropin (hCG) vaccine antigens are incorporated into an inorganic salt/biopolymer complex using a simple manufacturing process. The resulting solid matrix is administered to human subjects in the form of microparticles. The method comprises suspending microparticles in an emulsion of a natural oil and water containing an adjuvant compound acceptable for human use and injecting a pharmaceutical dose of the suspension intramuscularly. The vaccine antigens are conjugates of peptide fragments of the beta subunit of hCG with a carrier protein, diphtheria toxoid. Vaccine antigens delivered in this formulation are effective for eliciting antibodies in recipients for the treatment of cancer or hormone-related diseases.08-12-2010
20100203135Skin Equivalent Culture - Methods of forming soft connective tissue compositions such as skin equivalents, compositions made by the methods and their uses. In particular, a method of forming a connective tissue equivalent, comprising the steps of: (i) incubating collagen-producing cells in or on a support matrix; (ii) inducing and/or enhancing collagen production by the collagen-producing cells to form a collagenous construct and degradation and replacement of the support matrix; (iii) freeze-drying the construct; and (iv) re-populating the freeze-dried construct with collagen-producing cells and/or epithelial cells and/or endothelial cells and/or mesenchymal cells, thereby forming a connective tissue equivalent, wherein: (a) the collagen-producing cells are substantially fibroblasts; for example human neonatal dermal fibroblasts; (b) the support matrix is a provisional support matrix in which the support matrix is a fibrin matrix, for example formed by thrombin-mediated polymerisation of fibrinogen; and (c) as a result of the collagen production by the collagen-producing cells the provisional fibrin support matrix is digested by the cells and is replaced by collagen, thereby essentially replacing the provisional fibrin matrix with a collagen matrix synthesised in situ by the cells.08-12-2010
20100196478PROTEIN MATRIX MATERIALS, DEVICES AND METHODS OF MAKING AND USING THEREOF - The present invention relates to protein matrix materials and devices and the methods of making and using protein matrix materials and devices. More specifically the present invention relates to protein matrix materials and devices that may be utilized for various medical applications including, but not limited to, drug delivery devices for the controlled release of pharmacologically active agents, encapsulated or coated stent devices, vessels, tubular grafts, vascular grafts, wound healing devices including protein matrix suture material and meshes, skin/bone/tissue grafts, biocompatible electricity conducting matrices, clear protein matrices, protein matrix adhesion prevention barriers, cell scaffolding and other biocompatible protein matrix devices. Furthermore, the present invention relates to protein matrix materials and devices made by forming a film comprising one or more biodegradable protein materials, one or more biocompatible solvents and optionally one or more pharmacologically active agents. The film is then partially dried, rolled or otherwise shaped, and then compressed to form the desired protein matrix device.08-05-2010
20130017263GASTRIC ACID SECRETION INHIBITING COMPOSITION - An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid-susceptible proton pump inhibitor and an H2 receptor antagonist in combination with at least on pharmacologically acceptable excipient which causes a delayed release and/or an extended release of the proton pump inhibitor. The H2 receptor antagonist is included in the dosage form in such a way that it is rapidly released after administration. This dosage form is suitable for the treatment of conditions associated with an excessive secretion of gastric acid and provides a suitable combination of a rapid onset and a long-lasting duration of the effect. The invention also relates to a method for manufacturing such a dosage form and to a method for the treatment of conditions associated with the secretion of gastric acid.01-17-2013
20110135727Hepatocyte Delivery Vehicle for Delivery of a Combination of Recombinant Human Regular Insulin and Recombinant Human Insulin Isophane to a Mammal - The instant invention is drawn to a hepatocyte targeted composition comprising a mixture of free recombinant human insulin isophane and free Recombinant human regular insulin insulin and a mixture of recombinant human insulin isophane and Recombinant human regular insulin insulin associated with a water insoluble target molecule complex, wherein the complex comprises multiple linked individual units and a supra-molecular lipid construct matrix. Recombinant human insulin isophane and Recombinant human regular insulin insulin are present within the complex in at least one form wherein the recombinant human insulin isophane and Recombinant human regular insulin insulin have regions of positive charge which interacts with a negative charge on the complex. The invention also includes methods for the manufacture of the composition and methods of managing blood glucose levels in individuals with Type I and Type II diabetes.06-09-2011
20110151000NITRIC OXIDE-RELEASING COMPOSITIONS, DEVICES AND METHODS - Nitric oxide releasing compositions, which comprise nanoparticles having an exterior surface comprising solid amorphous silica, the exterior surface having nitrosothiol-containing groups attached thereto, the nanoparticles being dispersible in an aqueous system, devices including the compositions, and methods of making and using the compositions and devices are disclosed.06-23-2011
20110159099BONE-FILLING TYPE AGENT FOR INDUCING CARTILAGE REGENERATION - Provided is a medical material which enables a novel treatment method for cartilage regeneration being different from a treatment method through transplantation of autologous cartilage, a cartilage alternative or undifferentiated cells. Provided is a bone-filling type agent for inducing cartilage regeneration comprising a hydrogel which contains, as a monomer unit, an acid having an acidic group and/or a salt obtained by adding a metal to an acidic group and does not contain an interpenetrating network structure or a semi-interpenetrating network structure composed of two or more polymers. The bone-filling type agent for inducing cartilage regeneration can induce natural cartilage regeneration in the body by filling it in a hole or a groove provided in subchondral bone beneath cartilage defect.06-30-2011
20110159098STABILIZATION AND DELIVERY OF NUCLEIC ACID COMPLEXES - Compositions and methods for delivering nucleic acid, including siRNA, to a target cell are provided. In one embodiment, the composition includes the nucleic acid and a stabilizing protein. In another embodiment, the nucleic acid is complexed with a carrier, for example, a peptide carrier. In yet another embodiment, the nucleic acid combined with a protein which is cross-linked to form a proteinaceous controlled release matrix. Methods for making the compositions are also described.06-30-2011
20110159097EXTRACT OF THE PLANT RAVENALA MADAGASCARIENSIS AND USE AS COSMETIC HYDRATING AGENT - An extract is from the plant 06-30-2011
20080241242Porous Polyelectrolyte Materials - The present invention relates to porous polyelectrolyte materials, particularly nanoporous polyelectrolyte materials and to methods of making such materials. In a preferred embodiment, the invention relates to nanoporous polyelectrolyte spheres. In a preferred form of the invention, the materials are manufactured with the use of mesoporous silica spheres as templates. The invention also relates to a method of manufacturing such materials, and in particular, to a method of manufacturing such materials by a layer-by-layer process.10-02-2008
20080233194Dispersion for pulmonary delivery of a bioactive agent - Stabilized dispersions are provided for the delivery of a bioactive agent. The dispersions preferably comprise a plurality of perforated microstructures dispersed in a suspension medium that typically comprises a liquid fluorochemical. As density variations between the suspended particles and suspension medium are minimized and attractive forces between microstructures are attenuated, the disclosed dispersions are particularly resistant to degradation, such as by settling or flocculation. In particularly preferred embodiments the stabilized dispersions may be directly administered to the lung of a patient using an endotracheal tube or bronchoscope.09-25-2008
20080233193ORAL ANTIMICROBIAL PHARMACEUTICAL COMPOSITIONS - The present invention relates to oral pharmaceutical compositions with controlled and/or programmed release containing at least one active ingredient having antimicrobial and/or anti-infectious activity for the treatment of infections of the large intestine, in particular the colon.09-25-2008
20080226720Wound Healing Composition - The present invention relates to compositions and methods for tissue regeneration, particularly for treating skin lesions such as wounds. In one aspect, the invention provides a wound healing composition comprising living cells such as fibroblasts within a support matrix such as fibrin, in which the cells have a wound healing phenotype, and in which the composition is single layered and has been incubated for up to about 8 days to allow development of the wound healing phenotype. The compositions and methods of the invention are useful especially for assisting the process of wound healing, particularly chronic open lesions that are slow to heal or resistant to healing.09-18-2008
20090181092Methods for Treating Joints and Discs with a Carrier Matrix and Cells - Methods for enhancing pain relief and accelerating repair of painful disruptions associated with damaged and/or degenerated synovial joints and spinal discs are disclosed. These methods include injecting an effective amount of a biocompatible matrix or biocompatible polymeric compound, as well as a plurality of cells, into and/or around the damaged and/or degenerated synovial joints or spinal discs. The plurality of cells may include fibroblast cells, chondrocytes, genetically altered cells, stem cells such as mesenchymal stem cells, or combinations thereof.07-16-2009
20090169627PARTICLES FOR INJECTION AND PROCESSES FOR FORMING THE SAME - In accordance with one aspect of the invention, injectable particles are provided which comprise (a) a first group of injectable particles comprising first polymeric particles loaded with a first therapeutic agent and (b) a second group of injectable particles comprising second polymeric particles loaded with a second therapeutic agent. The first and second polymeric particles may be the same or different, and the first and second therapeutic agents may be the same or different. Other aspects of the invention pertain to methods of making such particles, to kits that comprise such particles, and to methods of treatment that employ such injectable particles.07-02-2009
20080220063Biologic-Chemical Fungicide Compositions and Methods of Use - The present invention is directed to biologic-chemical fungicide compositions (BCFs) that include one or more chemical fungicides, and microorganisms including gram-positive and/or gram-negative bacteria and yeast. Any chemical fungicide or combination of fungicides can be used. The BCFs typically also include an optional nutrient component in an amount sufficient to support the growth and replication of the microorganisms. If the BCF is applied to soil rich in nutrients, or if the crops would support the growth of the microorganisms in the BCFs, then the nutrients can be left out. Compositions having a biologic component of microorganisms in addition to one or more chemical fungicides are significantly more effective than chemical fungicides applied without microorganisms. The invention is also directed to chemical-free biologic fungicides that contain microorganisms with suppressive activity against pathogenic fungi, and nutrients.09-11-2008
20130177648COLLAGEN/HYDROXYAPATITE COMPOSITE SCAFFOLD, AND PROCESS FOR THE PRODUCTION THEREOF - A process for producing a collagen/hydroxyapatite (HA) composite scaffold comprises the steps of forming a homogenous suspension of collagen and HA in an acidic solution, lyophilising the suspension until a desired final freezing temperature is reached to produce the composite scaffold, and optionally cross-linking the composite scaffold, wherein the ratio of HA to collagen is at least 1:10 (w/w). Also provided is a collagen/hydroxyapatite (HA) composite scaffold comprising a homogenous distribution of hydroxyapatite within a porous, crosslinked, collagen matrix, wherein the ratio of HA to collagen is at least 1:10 (w/w). Suitably, the composite scaffold has a porosity of at least 99% (v/v), and a compressive stiffness of at least 0.3 KPa. Composite scaffolds of the invention may be used to provide osteoconductive bone implants and tissue engineering implants.07-11-2013
20130101671POLYPEPTIDE FOR TREATING OR PREVENTING ADHESIONS - The described invention provides compositions and methods for treating or preventing adhesions in a subject in need thereof, the method comprising the step of (a) administering an adhesion-reducing amount of a composition comprising a polypeptide having the amino acid sequence YARAAARQARAKALARQLGVAA [SEQ ID NO: 1] or a functional equivalent thereof and a carrier. The methods are clinically useful for reducing formation of adhesions initially and for therapeutic treatment of existing scars.04-25-2013
20130142875METHODS AND COMPOSITIONS FOR TREATING PROSTATE CANCER - Treatment of prostate cancer by regional and prolonged release of one or more nucleotide-based RNAi agents is provided.06-06-2013
20130142876AMPHIPATHIC LIPID-BASED SUSTAINED RELEASE COMPOSITIONS - Chewable sustained release compositions and their methods of production are provided. The sustained release compositions contain amphipathic lipids, which are used to encapsulate various drugs and active ingredients.06-06-2013
20110223253PHYSICALLY STABILIZED BIODEGRADABLE OSTEOCHONDRAL IMPLANT AND METHODS FOR ITS MANUFACTURE AND IMPLANTATION - A physically stabilized biodegradable osteochondral implant includes a porous matrix element of a resilient material and blood coagulated in vitro in open pores of the element. Also disclosed is a method of manufacture of the implant and a method of restoring a damaged articular surface by use of the implant.09-15-2011
20080260829Bmp Gene and Fusion Protein - This invention relates to BMP fusion genes, BMP fusion proteins. The invention further relates to methods for treatment using BMP fusion genes and BMP fusion proteins. Additionally, the invention relates to BMP fusion gene and BMP fusion protein pharmaceutical compositions.10-23-2008
20130122096COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF MANUFACTURING AND USING SAME - Polymeric implants containing microparticles and nanoparticles, delivery of microparticles and nanoparticles from a polymeric implant is provided.05-16-2013
20120276204Bone Growth Compositions and Methods - The present invention provides an improved technique for spinal fusion involving the administration of an HMG-CoA reductase inhibitor to a fusion. The HMG-CoA reductase inhibitor is preferably delivered to the site by a carrier. More preferably, the HMG-CoA reductase inhibitor is delivered to the site by a non-compressible delivery vehicle. The invention is suitable for promoting non-anatomic or heterotopic bone growth between any bony surfaces where bone growth is desired but does not naturally occur.11-01-2012
20120276203COLLAGEN MATRIX FOR CELL THERAPY - The invention relates to the use of an active collagen matrix for culturing mammalian cells and the use of the active collagen matrix and cells for the treatment of disease.11-01-2012
20120276202COLLAGEN MATRIX FOR TISSUE ENGINEERING - The invention relates to the use of an active collagen matrix for culturing mammalian cells and the use of the active collagen matrix and cells for the treatment of disease.11-01-2012
20100285131FGF21 MUTANTS AND USES THEREOF - The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.11-11-2010
20100291211MATERIAL COMPOSITIONS WHICH COMPRISE ADULT STEM CELLS OBTAINED FROM EXOCRINE GLANDULAR TISSUE, IN PARTICULAR FOR USE IN REGENERATIVE MEDICINE, E.G. FOR RESTORING INJURED OR DAMAGED MYOCARDIAL TISSUE - The invention relates to material compositions comprising adult stem cells obtained from exocrine gland tissue and a supporting matrix having the shape of a thread structure and/or of a net. The supporting matrix preferably consists of a plastic material which is physiologically acceptable and degradable in the body. The material compositions of the invention are in particular suited for use in regenerative medicine, e.g. for regeneration of injured or damaged myocard tissue.11-18-2010
20100310657PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF KIDNEY DISEASES - Provided is a pharmaceutical composition for the treatment and prevention of kidney diseases, containing (a) a therapeutically effective amount of a compound represented by Formulae 1 or 2 or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and (b) a pharmaceutically acceptable carrier, diluent or excipient or any combination thereof.12-09-2010
20100316717INJECTABLE HYDROGEL MICROSPHERES FROM AQUEOUS TWO-PHASE SYSTEM - Injectable hydrogel microspheres are prepared by forming an emulsion where hydrogel precursors are in a disperse aqueous phase and polymerizing the hydrogel precursors. In a preferred case, the hydrogel precursors are poly(ethylene glycol) diacrylate and N-isopropylacrylamide and the continuous phase of the emulsion is an aqueous solution of dextran and a dextran solubility reducer. The microspheres will load protein, e.g., cytokines, from aqueous solution.12-16-2010
20100316716METHOD FOR TREATING HERPES ZOSTER LESIONS - The present invention relates to the treatment of herpes zoster lesions. Compositions comprising an effective amount of a compound selected from the group consisting of potassium aluminum sulfate, potassium aluminum sulfate dodecahydrate, ammonium aluminum sulfate, ammonium aluminum sulfate dodecahydrate, and ammonium chloride are described as well as methods of their use for treatment purposes.12-16-2010
20100316715CHITOSAN COMPOSITION - This invention relates to a cross-linkable chitosan composition comprising chitosan having a degree of deacetylation between 30 and 75%, wherein the chitosan is randomly deacetylated, and a cross-linking agent, wherein the molar ratio of the cross-linking agent to chitosan is 0.2:1 or less based on the number of functional groups in the cross-linking agent and the number of accessible amino groups in the chitosan. The invention also provides a chitosan hydrogel formed therefrom and uses thereof.12-16-2010
20100316714METHODS OF TREATING DISEASE WITH RANDOM COPOLYMERS - The invention relates to novel methods and kits for treating or preventing disease through the administration of random copolymers comprising amino acids tyrosine (Y), phenylalanine (F), alanine (A), and lysine (K). The invention also relates to the treatment of autoimmune diseases, such as multiple sclerosis, and to the administration of random copolymers in treatment regimen comprising formulations that are administered at intervals greater than 24 hours, or to sustained release formulations which administer the copolymer over a period greater than 24 hours. The invention further relates to methods for conducting a pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the formulations or dosing regimens of random copolymer described herein.12-16-2010
20130122095PLATELET-DERIVED GROWTH FACTOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OSTEOCHONDRAL DEFECTS - The present invention provides compositions and methods for treating an osteochondral defect. In one embodiment, provided is a composition for treating an osteochondral defect comprising a biphasic biocompatible matrix and platelet derived growth factor (PDGF), wherein the biphasic biocompatible matrix comprises a scaffolding material and wherein the scaffolding material forms a porous structure comprising an osseous phase and a cartilage phase. In another embodiment, also provided is a method for treating an osteochondral defect in an individual comprising administering to the individual an effective amount of a composition comprising a biphasic biocompatible matrix and PDGF to at least one site of the osteochondral defect, wherein the biphasic biocompatible matrix comprises a scaffolding material and wherein the scaffolding material forms a porous structure comprising an osseous phase and a cartilage phase.05-16-2013
20110311629NON-ADHESIVE ELASTIC GELATIN MATRICES - The present invention is a substantially non-adhesive elastic gelatin matrix. The matrix is both non-adhesive to wounds, tissues and organs and is also elastic such that it is flexible. The matrix is a lyophilized mixture of protein(s), polymer(s), cross-linking agent(s) and optional plasticizer(s). The invention also provides methods for making the non-adhesive elastic gelatin matrix.12-22-2011
20120027858Methods and Compositions for Managing Cancer Cell Growth - The invention relates to composition and a method of using the composition for modulating proliferation, invasiveness, the expression of a biomarker of an abnormal cell, of reducing the risk of a patient cell becoming abnormal, or of modulating proliferation of a carcinoma-associated fibroblast or of a tumor-associated macrophage. The invention also relates to a method of culturing the composition to produce molecules that modulate abnormal cell proliferation, invasiveness, or metastasis. The composition comprises a biocompatible matrix and cells engrafted thereon.02-02-2012
20120045512METHODS AND SUBSTRATES FOR DIFFERENTIATION OF NEURAL STEM CELLS - The present invention is directed to methods and substrates for promoting the differentiation of neural stem cells to neurons.02-23-2012
20130202704USE OF MEXIPROSTIL IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE AND/OR OF IRRITABLE BOWEL SYNDROME - The invention relates to the use of mexiprostil in the treatment and/or prevention of inflammatory bowel disease and of irritable bowel syndrome, to the combinations of mexiprostil with other drugs, and also to a novel method for the synthesis of mexiprostil.08-08-2013
20120087980STIMULATION OF NEUROREGENERATION BY FLAVONOID GLYCOSIDES - Flavonoid glycosides, such as isoquercitrin, are shown to stimulate the formation of neuritis and neuronal synapses in neurons and neuronal progenitor (stem) cells.04-12-2012
20120093928ORAL METAXALONE COMPOSITIONS - The present invention relates to a pharmaceutical composition comprising low-dose metaxalone and one or more pharmaceutically acceptable polymer, as well as methods of preparing them.04-19-2012

Patent applications in class Matrices

Patent applications in all subclasses Matrices